<SEC-DOCUMENT>0001104659-23-043909.txt : 20230411
<SEC-HEADER>0001104659-23-043909.hdr.sgml : 20230411
<ACCEPTANCE-DATETIME>20230411121046
ACCESSION NUMBER:		0001104659-23-043909
CONFORMED SUBMISSION TYPE:	DEF 14A
PUBLIC DOCUMENT COUNT:		21
FILED AS OF DATE:		20230411
DATE AS OF CHANGE:		20230411

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			TEKLA HEALTHCARE INVESTORS
		CENTRAL INDEX KEY:			0000805267
		IRS NUMBER:				046564285
		STATE OF INCORPORATION:			MA
		FISCAL YEAR END:			0930

	FILING VALUES:
		FORM TYPE:		DEF 14A
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	811-04889
		FILM NUMBER:		23812841

	BUSINESS ADDRESS:	
		STREET 1:		100 FEDERAL STREET
		STREET 2:		19TH FLOOR
		CITY:			BOSTON
		STATE:			MA
		ZIP:			02110
		BUSINESS PHONE:		6177728515

	MAIL ADDRESS:	
		STREET 1:		100 FEDERAL STREET
		STREET 2:		19TH FLOOR
		CITY:			BOSTON
		STATE:			MA
		ZIP:			02110

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	H&Q HEALTHCARE INVESTORS
		DATE OF NAME CHANGE:	19920703

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Tekla World Healthcare Fund
		CENTRAL INDEX KEY:			0001635977
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			MA

	FILING VALUES:
		FORM TYPE:		DEF 14A
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	811-23037
		FILM NUMBER:		23812842

	BUSINESS ADDRESS:	
		STREET 1:		100 FEDERAL STREET
		STREET 2:		19TH FLOOR
		CITY:			BOSTON
		STATE:			MA
		ZIP:			02110
		BUSINESS PHONE:		(617) 772-8515

	MAIL ADDRESS:	
		STREET 1:		100 FEDERAL STREET
		STREET 2:		19TH FLOOR
		CITY:			BOSTON
		STATE:			MA
		ZIP:			02110

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Tekla Healthcare Opportunities Fund
		CENTRAL INDEX KEY:			0001604522
		IRS NUMBER:				465317248
		STATE OF INCORPORATION:			MA
		FISCAL YEAR END:			0930

	FILING VALUES:
		FORM TYPE:		DEF 14A
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	811-22955
		FILM NUMBER:		23812843

	BUSINESS ADDRESS:	
		STREET 1:		100 FEDERAL STREET
		STREET 2:		19TH FLOOR
		CITY:			BOSTON
		STATE:			MA
		ZIP:			02110
		BUSINESS PHONE:		617-772-8500

	MAIL ADDRESS:	
		STREET 1:		100 FEDERAL STREET
		STREET 2:		19TH FLOOR
		CITY:			BOSTON
		STATE:			MA
		ZIP:			02110

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Tekla Healthcare Growth & Income Fund
		DATE OF NAME CHANGE:	20140402
</SEC-HEADER>
<DOCUMENT>
<TYPE>DEF 14A
<SEQUENCE>1
<FILENAME>tm233915d1_def14a.htm
<DESCRIPTION>DEF 14A
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>
<!--INTEGIX by Ez-XBRL--><!-- Assembled by CompSci Transform  (tm) - http://www.compsciresources.com - version 1.2 -->
<!-- Created: Mon Apr 10 16:52:38 UTC 2023 -->
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2022-02-16" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:cef="http://xbrl.sec.gov/cef/2022" xmlns:ck0001635977="http://www.teklacap.com/20230411" xmlns:dei="http://xbrl.sec.gov/dei/2022"><head><meta http-equiv="Content-Type" content="text/html; charset=UTF-8" /><title>Tekla World Healthcare Fund - 1635977 - 2023</title></head><body>
        <div style="display:none">
        <ix:header><ix:hidden><ix:nonNumeric name="dei:EntityCentralIndexKey" contextRef="C_20230411to20230411"  id="Fdei_EntityCentralIndexKey20230406134046386" >0001635977</ix:nonNumeric><ix:nonNumeric name="dei:AmendmentFlag" contextRef="C_20230411to20230411"  id="Fdei_AmendmentFlag20230406134104483" >false</ix:nonNumeric><ix:nonNumeric name="dei:DocumentType" contextRef="C_20230411to20230411"  id="Fdei_DocumentType20230406134124323" >DEF 14A</ix:nonNumeric></ix:hidden>
<ix:references>
        <link:schemaRef xlink:type="simple" xlink:href="ck0001635977-20230411.xsd"/>
        </ix:references><ix:resources><xbrli:context id="C_20230411to20230411"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635977</xbrli:identifier></xbrli:entity><xbrli:period>
        <xbrli:startDate>2023-04-11</xbrli:startDate>
        <xbrli:endDate>2023-04-11</xbrli:endDate>
        </xbrli:period></xbrli:context></ix:resources></ix:header></div><div>
  <p style="margin:12pt 0pt 0pt 0pt;text-align:center"><img alt="j2339152_aa001.jpg" src="j2339152_aa001.jpg" style="width:684px;height:9px" /></p>
  <p style="margin:10px 0pt 8px;text-align:center"><span style="font-size:18pt;font-family:Times New Roman, Times, serif"><strong>UNITED STATES<br />SECURITIES AND EXCHANGE COMMISSION</strong></span></p>
  <p style="margin:0pt 0pt 9pt 0pt;text-align:center"><span style="font-size:12pt;font-family:Times New Roman, Times, serif"><strong>Washington, D.C. 20549</strong></span></p>
  <p style="margin:6pt 0pt 8pt 0pt;text-align:center"><span style="font-size:18pt;font-family:Times New Roman, Times, serif"><strong>SCHEDULE 14A</strong></span></p>
  <p style="margin:0pt 0pt 9pt 0pt;text-align:center"><span style="font-size:12pt;font-family:Times New Roman, Times, serif"><strong>Proxy Statement Pursuant to Section 14(a) of<br />the Securities Exchange Act of 1934 (Amendment No. )</strong></span></p>
  <p style="margin:3pt 0pt 8px;text-align:left"><span style="font-size:9pt;font-family:Times New Roman, Times, serif">Filed by the Registrant </span><span style="font-size:9pt;font-family:Wingdings">x</span></p>
  <p style="margin:3pt 0pt 8px;text-align:left"><span style="font-size:9pt;font-family:Times New Roman, Times, serif">Filed by a Party other than the Registrant </span><span style="font-size:9pt;font-family:Wingdings">o</span></p>
  <p style="margin:4px 0pt 0pt;text-align:left"><span style="font-size:9pt;font-family:Times New Roman, Times, serif">Check the appropriate box:</span></p>
  <p style="margin:4px 0pt 0pt;text-align:left"><span style="font-size:9pt;font-family:Wingdings">o</span><span style="font-size:9pt;font-family:Times New Roman, Times, serif">&#160;&#160;Preliminary Proxy Statement</span></p>
  <p style="margin:4px 0pt 0pt;text-align:left"><span style="font-size:9pt;font-family:Wingdings">o</span><span style="font-size:9pt;font-family:Times New Roman, Times, serif">&#160;&#160;</span><span style="font-size:9pt;font-family:Times New Roman, Times, serif"><strong>Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))</strong></span></p>
  <p style="margin:4px 0pt 0pt;text-align:left"><span style="font-size:9pt;font-family:Wingdings">x</span><span style="font-size:9pt;font-family:Times New Roman, Times, serif">&#160;&#160;Definitive Proxy Statement</span></p>
  <p style="margin:4px 0pt 0pt;text-align:left"><span style="font-size:9pt;font-family:Wingdings">o</span><span style="font-size:9pt;font-family:Times New Roman, Times, serif">&#160;&#160;Definitive Additional Materials</span></p>
  <p style="margin:4px 0pt 0pt;text-align:left"><span style="font-size:9pt;font-family:Wingdings">o</span><span style="font-size:9pt;font-family:Times New Roman, Times, serif">&#160;&#160;Soliciting Material under &#167;240.14a-12</span></p>
  <p style="margin:6pt 0pt 1pt 0pt;text-align:center"><span style="font-size:12pt;font-family:Times New Roman, Times, serif"><strong>Tekla Healthcare Investors, Tekla Heathcare Opportunities Fund,<br /><ix:nonNumeric id="Fxbrl_20230407002516323" name="dei:EntityRegistrantName" contextRef="C_20230411to20230411">Tekla World Healthcare Fund</ix:nonNumeric></strong></span></p>
  <p style="margin-top:10pt;margin-bottom:5pt;text-align:center"><img alt="j2339152_aa002.jpg" src="j2339152_aa002.jpg" style="width:684px;height:2px" /></p>
  <p style="margin-top:0pt;margin-bottom:25pt;text-align:center"><span style="font-size:9pt;font-family:Times New Roman, Times, serif">(Name of Registrant as Specified In Its Charter)</span></p>
  <p style="margin-top:0pt;margin-bottom:0pt;text-align:center"><img alt="j2339152_aa003.jpg" src="j2339152_aa002.jpg" style="width:684px;height:2px" /></p>
  <p style="margin-top:5pt;margin-bottom:12pt;text-align:center"><span style="font-size:9pt;font-family:Times New Roman, Times, serif">(Name of Person(s) Filing Proxy Statement, if other than the Registrant)</span></p>
  <p style="margin:4px 0pt 0pt;text-align:left"><span style="font-size:9pt;font-family:Times New Roman, Times, serif">Payment of Filing Fee (Check the appropriate box):</span></p>
  <p style="margin:4px 0pt 0pt;text-align:left"><span style="font-size:9pt;font-family:Wingdings">x</span><span style="font-size:9pt;font-family:Times New Roman, Times, serif">&#160;&#160;No fee required.</span></p>
  <p style="margin:4px 0pt 0pt;text-align:left"><span style="font-size:9pt;font-family:Wingdings">o</span><span style="font-size:9pt;font-family:Times New Roman, Times, serif">&#160;&#160;Fee paid previously with preliminary materials.</span></p>
  <p style="margin:4px 0pt 0pt;text-align:left"><span style="font-size:9pt;font-family:Wingdings">o</span><span style="font-size:9pt;font-family:Times New Roman, Times, serif">&#160;&#160;Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a6(i)(1) and 0-11</span></p>
  <p style="margin:6pt 0pt 0pt 0pt;text-align:center"><img alt="j2339152_aa004.jpg" src="j2339152_aa004.jpg" style="width:684px;height:9px" /></p>
  <p style="margin:12pt 0pt 0pt 0pt;text-align:center"><img alt="j2339152_aa005.jpg" src="j2339152_aa002.jpg" style="width:684px;height:2px" /></p>
  <hr style="height:2px;text-align:center;width:100%;background-color:gray;page-break-after:always;margin-top:10pt" />
  <div style="margin:8pt 0pt 8pt 0pt">
    <p style="margin:0pt 0pt 0pt 0pt;text-align:center"><span style="font-size:10pt;font-family:Times New Roman, Times, serif"><strong>TEKLA HEALTHCARE INVESTORS<br />TEKLA HEALTHCARE OPPORTUNITIES FUND<br />TEKLA WORLD HEALTHCARE FUND</strong></span></p>
    <p style="margin:0pt 0pt 0pt 0pt;text-align:center"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">100 Federal Street, 19th Floor<br />Boston, Massachusetts 02110<br />(617) 772-8500</span></p>
    <p style="margin:24pt 0pt 18pt 0pt;text-align:center"><span style="font-size:10pt;font-family:Times New Roman, Times, serif"><strong>NOTICE OF JOINT ANNUAL MEETING OF SHAREHOLDERS</strong></span></p>
    <p style="margin:0pt 0pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">To the Shareholders of TEKLA HEALTHCARE INVESTORS, TEKLA HEALTHCARE OPPORTUNITIES FUND AND TEKLA WORLD HEALTHCARE FUND:</span></p>
    <p style="margin:6pt 0pt 0pt 0pt"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">An Annual Meeting of Shareholders of Tekla Healthcare Investors ("HQH"), Tekla Healthcare Opportunities Fund ("THQ") and Tekla World Healthcare Fund ("THW") (each a "Fund", together the "Funds") will be held on Thursday, June 8, 2023 at 12:00 p.m. at 100 Federal Street, 19th Floor, Boston, Massachusetts 02110, for the following purposes:</span></p>
    <p style="margin:6pt 0pt 0pt 0pt"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">(1)&#160;&#160;The election of Trustees of each Fund;</span></p>
    <p style="margin:6pt 0pt 0pt 0pt"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">(2)&#160;&#160;The ratification or rejection of the selection of Deloitte &#38; Touche LLP as the independent registered public accountants of each Fund for the fiscal year ending September 30, 2023; and</span></p>
    <p style="margin:6pt 0pt 0pt 0pt"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">(3)&#160;&#160;The transaction of such other business as may properly come before the Annual Meeting and any adjournment(s) or postponement(s) thereof.</span></p>
    <p style="margin:6pt 0pt 0pt 0pt"><span style="font-size:10pt;font-family:Times New Roman, Times, serif"><strong>The Board of Trustees of each Fund recommends that shareholders vote FOR the election of all nominees for election as Trustees and FOR the selection of Deloitte &#38; Touche LLP as the independent registered public accountants of each Fund.</strong></span></p>
    <p style="margin:6pt 0pt 0pt 0pt"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">Although the Annual Meetings are held together, each Fund's shareholders take action independently of the other. Shareholders of record at the close of business on April 12, 2023 will be entitled to vote at the Joint Annual Meeting or at any adjournment(s) or postponement(s) thereof.</span></p>
    <p style="margin:6pt 0pt 0pt 0pt"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">We encourage you to check our website, www.teklacap.com, prior to the Joint Annual Meeting if you plan to attend.</span></p>
    <p style="margin:6pt 0pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">By Order of the Board of Trustees of each Fund,</span></p>
    <p style="margin:54pt 0pt 3pt 0pt;text-align:left"><img alt="j2339152_ac006.jpg" src="j2339152_ac006.jpg" style="width:186px;height:39px" /></p>
    <p style="margin:0pt 0pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">Daniel R. Omstead, PhD<br />President</span></p>
    <p style="margin:6pt 0pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">April 17, 2023</span></p>
    <p style="margin:12pt 0pt 0pt 0pt"><span style="font-size:10pt;font-family:Times New Roman, Times, serif"><i>Please complete, date and sign the Proxy for the shares held by you and return the Proxy in the envelope provided so that your vote can be recorded. No postage is required if the envelope is mailed in the United States. It is important that you return your signed Proxy promptly, regardless of the size of your holdings, so that a quorum may be assured.</i></span></p>
  </div>
  <hr style="height:2px;text-align:center;width:100%;background-color:gray;page-break-after:always" />
<div><div style="margin:8pt 0pt 8pt 0pt"><p style="margin:0pt 0pt 0pt 0pt;text-align:center"><span style="font-size:10pt;font-family:Times New Roman, Times, serif"><strong>TEKLA HEALTHCARE INVESTORS<br />TEKLA HEALTHCARE OPPORTUNITIES FUND<br />TEKLA WORLD HEALTHCARE FUND</strong></span></p><p style="margin:33pt 0pt 0pt 0pt;text-align:center"><span style="font-size:10pt;font-family:Times New Roman, Times, serif"><strong>JOINT PROXY STATEMENT</strong></span></p><p style="margin:6pt 0pt 0pt 0pt"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">This Joint Proxy Statement is furnished in connection with the solicitation by the Board of Trustees (each a "Board," together the "Boards") of Tekla Healthcare Investors ("HQH"), Tekla Healthcare Opportunities Fund ("THQ") and Tekla World Healthcare Fund ("THW") (each a "Fund", together the "Funds") of proxies to be voted at the Joint Annual Meeting of Shareholders of the Funds to be held on June 8, 2023 (the "Annual Meeting"), and any adjournment(s) or postponement(s) thereof, for the purposes set forth in the accompanying Notice of Joint Annual Meeting, dated April 17, 2023. This Joint Proxy Statement, the Notice of Joint Annual Meeting and the Proxy Card(s) are first being mailed to shareholders on or about April 17, 2023.</span></p><p style="margin:6pt 0pt 0pt 0pt"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">Proposal 1 relates to the election of Trustees of each Fund and Proposal 2 relates to the ratification of the independent registered public accountants of each Fund.</span></p><p style="margin:6pt 0pt 0pt 0pt"><span style="font-size:10pt;font-family:Times New Roman, Times, serif"><strong>The Board of Trustees of each Fund recommends that shareholders vote FOR the election of all nominees for election as Trustees and FOR the selection of Deloitte &#38; Touche LLP as the independent registered public accountants of each Fund.</strong></span></p><p style="margin:6pt 0pt 0pt 0pt"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">Each Fund will furnish, without charge, a copy of its Annual Report, or the most recent Semi-Annual Report succeeding the Annual Report, if any, to a shareholder upon request. Requests may be sent to the Fund at 100 Federal Street, 19th Floor, Boston, MA 02110 or be made by calling (617) 772-8500.</span></p><p style="margin:10pt 0pt 0pt 0pt;text-align:center"><span style="font-size:10pt;font-family:Times New Roman, Times, serif"><strong>Proposal 1<br />ELECTION OF TRUSTEES</strong></span></p><p style="margin:6pt 0pt 0pt 0pt"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">Each Fund's Declaration of Trust, as amended to date (the "Declaration of Trust"), provides that its Board shall be divided into three classes with staggered terms. For HQH, the term of office of the Class A Trustees expires on the date of the 2023 Annual Meeting and the term of office of the Class B and Class C Trustees will expire one and two years, respectively, thereafter. For THQ, the term of office of the Class C Trustees expires on the date of the 2023 Annual Meeting and the term of office of the Class A and Class B Trustees will expire one and two years, respectively, thereafter. For THW, the term of office of the Class B Trustees expires on the date of the 2023 Annual Meeting and the term of office of the Class C and Class A Trustees will expire one and two years, respectively, thereafter. Trustees chosen to succeed the Class A, B or C Trustees whose terms are expiring will be elected for a three-year term.</span></p><p style="margin:6pt 0pt 0pt 0pt"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">Each Fund's Declaration of Trust provides that a majority of its Trustees shall fix the number of the entire Board of Trustees and that such number shall be at least three and no greater than fifteen. Each Fund's Board has fixed the number of Trustees at six. Proxies will be voted for the election of the following nominees for HQH, THQ and THW. Each nominee has consented to serve as a Trustee if elected at the Annual Meeting. In the event that a nominee is unable to serve for any reason when </span></p></div><p style="text-align:center"><br /><span style="font-size:13px;font-family:Times New Roman PS, Times New Roman, Times">1</span></p><hr style="height:2px;text-align:center;width:100%;background-color:gray;page-break-after:always" /><div style="margin:8pt 0pt 8pt 0pt"><p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">the election occurs, the accompanying Proxy will be voted for such other person or persons as the applicable Fund's Board may recommend. Each nominee is presently serving as a Trustee.</span></p><table border="0" cellpadding="0" cellspacing="0" width="100%"><tr><td colspan="3" style="padding:4pt .7pt 0pt 0pt;text-align:left;width:41;background-color:#cceeff" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">HQH</span></p></td><td colspan="1" style="background-color:#cceeff">&#160;</td><td colspan="3" style="padding:4pt .7pt 0pt 0pt;text-align:left;width:184;background-color:#cceeff" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">Class A Nominees to Serve until 2026</span></p></td><td colspan="1" style="background-color:#cceeff">&#160;</td><td colspan="3" style="padding:4pt .7pt 0pt 0pt;text-align:left;width:131;background-color:#cceeff" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">Jeffrey A. Bailey</span></p></td><td colspan="1" style="background-color:#cceeff">&#160;</td></tr><tr><td colspan="3" style="padding:4pt .7pt 0pt 0pt;text-align:left;width:41" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</span></p></td><td colspan="1">&#160;</td><td colspan="3" style="padding:4pt .7pt 0pt 0pt;text-align:left;width:184" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</span></p></td><td colspan="1">&#160;</td><td colspan="3" style="padding:4pt .7pt 0pt 0pt;text-align:left;width:131" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">Rakesh K. Jain, Ph.D.</span></p></td><td colspan="1">&#160;</td></tr><tr><td colspan="3" style="padding:4pt .7pt 0pt 0pt;text-align:left;width:41;background-color:#cceeff" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">THQ</span></p></td><td colspan="1" style="background-color:#cceeff">&#160;</td><td colspan="3" style="padding:4pt .7pt 0pt 0pt;text-align:left;width:184;background-color:#cceeff" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">Class C Nominees to Serve until 2026</span></p></td><td colspan="1" style="background-color:#cceeff">&#160;</td><td colspan="3" style="padding:4pt .7pt 0pt 0pt;text-align:left;width:131;background-color:#cceeff" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">Jeffrey A. Bailey</span></p></td><td colspan="1" style="background-color:#cceeff">&#160;</td></tr><tr><td colspan="3" style="padding:4pt .7pt 0pt 0pt;text-align:left;width:41" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</span></p></td><td colspan="1">&#160;</td><td colspan="3" style="padding:4pt .7pt 0pt 0pt;text-align:left;width:184" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</span></p></td><td colspan="1">&#160;</td><td colspan="3" style="padding:4pt .7pt 0pt 0pt;text-align:left;width:131" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">Thomas M. Kent, CPA</span></p></td><td colspan="1">&#160;</td></tr><tr><td colspan="3" style="padding:4pt .7pt 0pt 0pt;text-align:left;width:41;background-color:#cceeff" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">THW</span></p></td><td colspan="1" style="background-color:#cceeff">&#160;</td><td colspan="3" style="padding:4pt .7pt 0pt 0pt;text-align:left;width:184;background-color:#cceeff" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">Class B Nominees to Serve until 2026</span></p></td><td colspan="1" style="background-color:#cceeff">&#160;</td><td colspan="3" style="padding:4pt .7pt 0pt 0pt;text-align:left;width:131;background-color:#cceeff" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">Rakesh K. Jain, Ph.D.</span></p></td><td colspan="1" style="background-color:#cceeff">&#160;</td></tr><tr><td colspan="3" style="padding:4pt .7pt 0pt 0pt;text-align:left;width:41" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</span></p></td><td colspan="1">&#160;</td><td colspan="3" style="padding:4pt .7pt 0pt 0pt;text-align:left;width:184" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</span></p></td><td colspan="1">&#160;</td><td colspan="3" style="padding:4pt .7pt 0pt 0pt;text-align:left;width:131" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">Daniel R. Omstead, Ph.D.</span></p></td><td colspan="1">&#160;</td></tr></table><p style="margin:6pt 0pt 0pt 0pt"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">Each of the following persons is presently serving as a Trustee and has consented to so serve in the class and for the term specified below.</span></p><table border="0" cellpadding="0" cellspacing="0" width="100%"><tr><td colspan="3" style="padding:4pt .7pt 0pt 0pt;text-align:left;width:41;background-color:#cceeff" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">HQH</span></p></td><td colspan="1" style="background-color:#cceeff">&#160;</td><td colspan="3" style="padding:4pt .7pt 0pt 0pt;text-align:left;width:184;background-color:#cceeff" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">Class B Trustees to Serve until 2024</span></p></td><td colspan="1" style="background-color:#cceeff">&#160;</td><td colspan="3" style="padding:4pt .7pt 0pt 0pt;text-align:left;width:131;background-color:#cceeff" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">Thomas M. Kent, CPA</span></p></td><td colspan="1" style="background-color:#cceeff">&#160;</td></tr><tr><td colspan="3" style="padding:4pt .7pt 0pt 0pt;text-align:left;width:41" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</span></p></td><td colspan="1">&#160;</td><td colspan="3" style="padding:4pt .7pt 0pt 0pt;text-align:left;width:184" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</span></p></td><td colspan="1">&#160;</td><td colspan="3" style="padding:4pt .7pt 0pt 0pt;text-align:left;width:131" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">Daniel R. Omstead, Ph.D.</span></p></td><td colspan="1">&#160;</td></tr><tr><td colspan="3" style="padding:4pt .7pt 0pt 0pt;text-align:left;width:41;background-color:#cceeff" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</span></p></td><td colspan="1" style="background-color:#cceeff">&#160;</td><td colspan="3" style="padding:4pt .7pt 0pt 0pt;text-align:left;width:184;background-color:#cceeff" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">Class C Trustees to Serve until 2025</span></p></td><td colspan="1" style="background-color:#cceeff">&#160;</td><td colspan="3" style="padding:4pt .7pt 0pt 0pt;text-align:left;width:131;background-color:#cceeff" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">Kathleen L. Goetz</span></p></td><td colspan="1" style="background-color:#cceeff">&#160;</td></tr><tr><td colspan="3" style="padding:4pt .7pt 0pt 0pt;text-align:left;width:41" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</span></p></td><td colspan="1">&#160;</td><td colspan="3" style="padding:4pt .7pt 0pt 0pt;text-align:left;width:184" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</span></p></td><td colspan="1">&#160;</td><td colspan="3" style="padding:4pt .7pt 0pt 0pt;text-align:left;width:131" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">W. Mark Watson, CPA</span></p></td><td colspan="1">&#160;</td></tr><tr><td colspan="3" style="padding:4pt .7pt 0pt 0pt;text-align:left;width:41;background-color:#cceeff" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">THQ</span></p></td><td colspan="1" style="background-color:#cceeff">&#160;</td><td colspan="3" style="padding:4pt .7pt 0pt 0pt;text-align:left;width:184;background-color:#cceeff" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">Class A Trustees to Serve until 2024</span></p></td><td colspan="1" style="background-color:#cceeff">&#160;</td><td colspan="3" style="padding:4pt .7pt 0pt 0pt;text-align:left;width:131;background-color:#cceeff" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">Kathleen L. Goetz</span></p></td><td colspan="1" style="background-color:#cceeff">&#160;</td></tr><tr><td colspan="3" style="padding:4pt .7pt 0pt 0pt;text-align:left;width:41" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</span></p></td><td colspan="1">&#160;</td><td colspan="3" style="padding:4pt .7pt 0pt 0pt;text-align:left;width:184" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</span></p></td><td colspan="1">&#160;</td><td colspan="3" style="padding:4pt .7pt 0pt 0pt;text-align:left;width:131" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">W. Mark Watson, CPA</span></p></td><td colspan="1">&#160;</td></tr><tr><td colspan="3" style="padding:4pt .7pt 0pt 0pt;text-align:left;width:41;background-color:#cceeff" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</span></p></td><td colspan="1" style="background-color:#cceeff">&#160;</td><td colspan="3" style="padding:4pt .7pt 0pt 0pt;text-align:left;width:184;background-color:#cceeff" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">Class B Trustees to Serve until 2025</span></p></td><td colspan="1" style="background-color:#cceeff">&#160;</td><td colspan="3" style="padding:4pt .7pt 0pt 0pt;text-align:left;width:131;background-color:#cceeff" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">Rakesh K. Jain, Ph.D.</span></p></td><td colspan="1" style="background-color:#cceeff">&#160;</td></tr><tr><td colspan="3" style="padding:4pt .7pt 0pt 0pt;text-align:left;width:41" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</span></p></td><td colspan="1">&#160;</td><td colspan="3" style="padding:4pt .7pt 0pt 0pt;text-align:left;width:184" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</span></p></td><td colspan="1">&#160;</td><td colspan="3" style="padding:4pt .7pt 0pt 0pt;text-align:left;width:131" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">Daniel R. Omstead, Ph.D.</span></p></td><td colspan="1">&#160;</td></tr><tr><td colspan="3" style="padding:4pt .7pt 0pt 0pt;text-align:left;width:41;background-color:#cceeff" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">THW</span></p></td><td colspan="1" style="background-color:#cceeff">&#160;</td><td colspan="3" style="padding:4pt .7pt 0pt 0pt;text-align:left;width:184;background-color:#cceeff" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">Class C Trustees to Serve until 2024</span></p></td><td colspan="1" style="background-color:#cceeff">&#160;</td><td colspan="3" style="padding:4pt .7pt 0pt 0pt;text-align:left;width:131;background-color:#cceeff" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">Jeffrey A. Bailey</span></p></td><td colspan="1" style="background-color:#cceeff">&#160;</td></tr><tr><td colspan="3" style="padding:4pt .7pt 0pt 0pt;text-align:left;width:41" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</span></p></td><td colspan="1">&#160;</td><td colspan="3" style="padding:4pt .7pt 0pt 0pt;text-align:left;width:184" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</span></p></td><td colspan="1">&#160;</td><td colspan="3" style="padding:4pt .7pt 0pt 0pt;text-align:left;width:131" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">Thomas M. Kent, CPA</span></p></td><td colspan="1">&#160;</td></tr><tr><td colspan="3" style="padding:4pt .7pt 0pt 0pt;text-align:left;width:41;background-color:#cceeff" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</span></p></td><td colspan="1" style="background-color:#cceeff">&#160;</td><td colspan="3" style="padding:4pt .7pt 0pt 0pt;text-align:left;width:184;background-color:#cceeff" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">Class A Trustees to Serve until 2025</span></p></td><td colspan="1" style="background-color:#cceeff">&#160;</td><td colspan="3" style="padding:4pt .7pt 0pt 0pt;text-align:left;width:131;background-color:#cceeff" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">Kathleen L. Goetz</span></p></td><td colspan="1" style="background-color:#cceeff">&#160;</td></tr><tr><td colspan="3" style="padding:4pt .7pt 0pt 0pt;text-align:left;width:41" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</span></p></td><td colspan="1">&#160;</td><td colspan="3" style="padding:4pt .7pt 0pt 0pt;text-align:left;width:184" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</span></p></td><td colspan="1">&#160;</td><td colspan="3" style="padding:4pt .7pt 0pt 0pt;text-align:left;width:131" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">W. Mark Watson, CPA</span></p></td><td colspan="1">&#160;</td></tr></table><p style="margin:0pt 0pt 4pt 0pt">&#160;</p><p style="margin:6pt 0pt 0pt 0pt"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">The Boards believe that each Trustee's experience, qualifications, attributes and skills on an individual basis and in combination with those of other Trustees lead to the conclusion that each Trustee should serve in such capacity. Among the attributes or skills common to all Trustees are their ability to review critically and to evaluate, question and discuss information provided to them, to interact effectively with the other Trustees, the Fund's investment adviser, the administrator and other service providers, counsel and independent registered public accounting firm, and to exercise effective and independent business judgment in the performance of their duties as Trustees. Each Trustee's ability to perform the duties of a trustee effectively has been attained and enhanced through the Trustee's education, professional training and other life experiences, such as business, consulting or public service positions and through experience from service as a member of each Fund's Board, public companies, or non-profit entities or other organizations.</span></p></div><p style="text-align:center"><br /><span style="font-size:13px;font-family:Times New Roman PS, Times New Roman, Times">2</span></p><hr style="height:2px;text-align:center;width:100%;background-color:gray;page-break-after:always" /><div style="margin:8pt 0pt 8pt 0pt"><p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:10pt;font-family:Times New Roman, Times, serif"><i>Jeffrey A. Bailey:</i></span><span style="font-size:10pt;font-family:Times New Roman, Times, serif"> Mr. Bailey is a seasoned operational healthcare executive with over 30 years of leadership experience within the healthcare industry. Mr. Bailey has extensive business development and transactional expertise, with diverse leadership experiences in commercial and supply chain management, finance, business development and product development for various pharmaceutical medical device companies. He serves as Chairman of the Board of Trustees and also on the Valuation Committee and on the Governance and Nominating Committee of each Fund. Most recently, Mr. Bailey served as chief executive officer and director of BioDelivery Sciences, a biotechnology company, from 2020-2022. He served as president and chief executive officer of IlluminOss Medical, Inc., a medical device company, from 2018 to 2020. From 2015 until 2017, Mr. Bailey served as chief executive officer of Neurovance, Inc., a biotechnology company. Previously, from 2013 through 2015, Mr. Bailey served as president and chief executive officer and as a director of Lantheus Medical Imaging, Inc., a public medical diagnostic company. Prior to 2013, Mr. Bailey held various leadership positions with several public and private pharmaceutical and medical device companies, including president and general manager at Novartis Pharmaceuticals, a multinational pharmaceutical company, and a 22-year career with Johnson &#38; Johnson, a multinational medical devices, pharmaceutical and consumer packaged goods manufacturing company. Mr. Bailey also has extensive board member experience, having previously served on boards of directors for eight companies. Mr. Bailey currently serves as a director for Aileron Therapeutics, Inc. and Madison Vaccines, Inc. Mr. Bailey holds a BA in business administration from Rutgers University.</span></p><p style="margin:6pt 0pt 0pt 0pt"><span style="font-size:10pt;font-family:Times New Roman, Times, serif"><i>Kathleen Goetz:</i></span><span style="font-size:10pt;font-family:Times New Roman, Times, serif"> Ms. Goetz brings to the Fund over 30 years of healthcare business and leadership experience. She brings extensive knowledge of healthcare markets, with leadership experience across product development, operational effectiveness, organizational governance and design, and marketing and sales strategy. She currently acts as a consultant and an advisor within the pharmaceutical, biotech, and medical technology sectors. Ms. Goetz was Vice President Head of Sales at Novartis Pharmaceuticals, a global healthcare company until 2019. During her 28 years with Novartis, Ms. Goetz held positions of increasing responsibility, leading marketing, sales and reimbursement teams through various stages of commercialization from pre-launch planning through to loss of exclusivity across diverse therapeutic areas. Other key roles during her time at Novartis also include National Executive Director of Strategic Accounts, Integrated Market Planning and Marketing Director, providing her with valuable experience leading organizational transformation, resourcing, forecasting, and analytics. She continues to act as a mentor to future leaders and as a champion for diversity through her past work as an Executive Leadership Development mentor and a former Novartis Pharmaceuticals Women in Leadership Chair. Ms. Goetz has won numerous healthcare and business leadership awards and recognition throughout her career, including being recognized with the Healthcare Women's Business Association Rising Star Award. She serves on the Audit Committee and Valuation Committee of the Fund. Ms. Goetz holds a Business Finance degree from Iowa State University.</span></p><p style="margin:6pt 0pt 0pt 0pt"><span style="font-size:10pt;font-family:Times New Roman, Times, serif"><i>Rakesh K. Jain, Ph.D.:</i></span><span style="font-size:10pt;font-family:Times New Roman, Times, serif"> Dr. Jain is the A. W. Cook Professor of Radiation Oncology (Tumor Biology) at Harvard Medical School and the Director of the E. L. Steele Laboratories of Tumor Biology at Massachusetts General Hospital, providing each Fund with a valuable perspective on emerging life sciences technologies. Dr. Jain co-founded XTuit Pharmaceuticals, Inc. in 2012, where he also served as a board member until 2018. He serves as the Chairman of the Governance and Nominating Committee of each Fund. Prior to joining Harvard, he was professor of chemical engineering at Columbia University and Carnegie Mellon University. Dr. Jain is regarded as a pioneer in the fields of tumor biology, drug delivery, in vivo imaging and bioengineering. Dr. Jain has authored more than 750 publications. He serves on advisory panels to government, industry and academia, and has served </span></p></div><p style="text-align:center"><br /><span style="font-size:13px;font-family:Times New Roman PS, Times New Roman, Times">3</span></p><hr style="height:2px;text-align:center;width:100%;background-color:gray;page-break-after:always" /><div style="margin:8pt 0pt 8pt 0pt"><p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">or continues to serve on editorial advisory boards of twenty journals, including Journal of Clinical Oncology and Nature Reviews Clinical Oncology. He has received more than 90 major awards and lectureships, including the United States National Medal of Science, a Guggenheim Fellowship, the Humboldt Senior Scientist Award, the National Cancer Institute's Research Career Development Award and Outstanding Investigator Grant, the Academic Scientist of the Year Award from the Pharmaceutical Achievements Awards, the Distinguished Service Award from Nature Biotechnology and the Innovator Award from the DoD Breast Cancer Program. He is a member of all three branches of U.S. National Academies &#8211; the Institute of Medicine, the National Academy of Engineering and the National Academy of Sciences and is a member of both the National Academy of Investors and the American Academy of Arts and Sciences. In May 2016, Dr. Jain received the National Medal of Science from President Obama at the White House.</span></p><p style="margin:6pt 0pt 0pt 0pt"><span style="font-size:10pt;font-family:Times New Roman, Times, serif"><i>Thomas M. Kent, CPA:</i></span><span style="font-size:10pt;font-family:Times New Roman, Times, serif"> Mr. Kent was a Partner at PricewaterhouseCoopers LLP, where he served the Investment Management Industry for over 30 years, 24 years as a Partner. In so doing, he worked with and for more than 20 different and distinct Investment Company Boards, and along side several of those Boards' service providers, including Advisors, Custodians, Accounting Agents, Transfer Agents, Security Pricing Providers, Tax advisors and others. His clients included both large and small fund groups, with both open-end and closed-end fund structures. Therefore, he provides the Funds with deep expertise in audit, valuation, operational and governance matters. He serves on the Governance and Nominating Committee and as Chairman of the Audit Committee of each Fund. Mr. Kent also serves as a Director of Principal Global Investors Trust Co., and a Director of the New England Canada Business Council. Mr. Kent is a member of the American Institute of CPA's and the Massachusetts Society of CPA's where he serves on the Registered Investment Company Committee. He received his AB cum laude from Harvard College, where he majored in Economics and his MS in Accountancy from the Stern School of Business at New York University.</span></p><p style="margin:6pt 0pt 0pt 0pt"><span style="font-size:10pt;font-family:Times New Roman, Times, serif"><i>Daniel R. Omstead, Ph.D.:</i></span><span style="font-size:10pt;font-family:Times New Roman, Times, serif"> Dr. Omstead is President and Chief Executive Officer of Tekla Capital Management LLC (the "Adviser"), a registered investment adviser that serves as investment adviser to the Funds. Dr. Omstead is also President of the Funds and serves on their Valuation Committee. Dr. Omstead is portfolio manager for the public and restricted/venture portfolios within the Funds. Prior to joining the Adviser, Dr. Omstead was President and CEO of Reprogenesis, Inc., a private development stage biotech company which developed therapies in the field of tissue engineering and regenerative medicine. Before joining Reprogenesis, Dr. Omstead was Senior Vice President, Research and Development, at Cytotherapeutics, Inc, a public biotech company. Prior to entering the biotech industry, Dr. Omstead was employed for fourteen years in positions of increasing responsibility within the pharmaceutical industry at Ortho Pharmaceutical Corporation and at the R.W. Johnson Pharmaceutical Research Institute, both divisions of Johnson &#38; Johnson, and at Merck, Sharp and Dohme Research Laboratories, a division of Merck &#38; Co., Inc. Dr. Omstead provides each Fund with insights into both pharmaceutical and biotech companies. Dr. Omstead holds Ph.D. and Master's Degrees in Chemical Engineering and Applied Chemistry from Columbia University and a B.S. degree in Civil Engineering from Lehigh University. He is an emeritus member of the Board of Directors of a non-profit agency that provides emergency shelter, housing and supportive services to homeless and low-income individuals and families in the Boston area. Dr. Omstead was also a member of the Board of Trustees at the Joslin Diabetes Center.</span></p><p style="margin:6pt 0pt 0pt 0pt"><span style="font-size:10pt;font-family:Times New Roman, Times, serif"><i>W. Mark Watson, CPA:</i></span><span style="font-size:10pt;font-family:Times New Roman, Times, serif"> Mr. Watson is a Certified Public Accountant with over 40 years of experience in public accounting and auditing, having spent his entire career from January 1973 to June 2013 at Deloitte Touche Tohmatsu, the multinational professional services network, and its predecessor, most recently as Central Florida Marketplace Leader. Mr. Watson provides the Funds with a particular expertise in the health and life sciences sector, having played a significant role in the development of Deloitte's </span></p></div><p style="text-align:center"><br /><span style="font-size:13px;font-family:Times New Roman PS, Times New Roman, Times">4</span></p><hr style="height:2px;text-align:center;width:100%;background-color:gray;page-break-after:always" /><div style="margin:8pt 0pt 8pt 0pt"><p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">audit approach for health and life sciences companies and leading its national healthcare regulatory and compliance practice. He has served as lead audit partner and advisory partner on the accounts of many public companies ranging from middle market firms to Fortune 500 enterprises. Mr. Watson is a member of the American Institute of Certified Public Accountants and the Florida Institute of Certified Public Accountants. Mr. Watson is a member of the Board of Directors of Vaxart Inc., Global Health MCS and the Moffitt Cancer Center. He received his undergraduate degree in Accounting from Marquette University.</span></p><p style="margin:4pt 0pt 10pt"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">The Trustees and their principal occupation for at least the last five years are set forth in the table below.</span></p><table border="0" cellpadding="0" cellspacing="0" style="width:100%" width="100%"><tr><td colspan="3" style="padding:6pt 0.7pt 0pt 0pt;border-top:none;border-right:none;border-left:none;border-image:initial;border-bottom:1pt solid windowtext;text-align:center;margin-top:0pt;margin-bottom:0pt;width:33%" valign="bottom"><p style="margin-top:0pt;margin-bottom:0pt"><span style="font-size:8pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><strong style="margin-top:0pt;margin-bottom:0pt">Name, Address</strong><strong style="margin-top:0pt;margin-bottom:0pt"><sup style="margin-top:0pt;margin-bottom:0pt">1</sup></strong><strong style="margin-top:0pt;margin-bottom:0pt">, Date of Birth,</strong></span></p><p style="margin-top:0pt;margin-bottom:0pt"><span style="font-size:8pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><strong style="margin-top:0pt;margin-bottom:0pt">Length of Time Served, Principal Occupation(s)</strong></span></p><p style="margin-top:0pt;margin-bottom:0pt"><span style="font-size:8pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><strong style="margin-top:0pt;margin-bottom:0pt">During Past 5 Years and Other Directorship Held</strong></span></p></td><td colspan="1" style="width:1%">&#160;</td><td colspan="3" style="padding:6pt 0.7pt 0pt 0pt;border-top:none;border-right:none;border-left:none;border-image:initial;border-bottom:1pt solid windowtext;text-align:center;margin-top:0pt;margin-bottom:0pt;width:55%" valign="bottom"><p style="margin-top:0pt;margin-bottom:0pt"><span style="font-size:8pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><strong style="margin-top:0pt;margin-bottom:0pt">Position(s) Held with Funds,</strong></span></p><p style="margin-top:0pt;margin-bottom:0pt"><span style="font-size:8pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><strong style="margin-top:0pt;margin-bottom:0pt">Term of Office</strong><strong style="margin-top:0pt;margin-bottom:0pt"><sup style="margin-top:0pt;margin-bottom:0pt">2</sup></strong></span></p></td><td colspan="1" style="border-bottom:1pt solid windowtext;width:1%">&#160;</td><td colspan="1" style="width:1%">&#160;</td><td colspan="1" style="padding:6pt 0.7pt 0pt 0pt;border-top:none;border-right:none;border-left:none;border-image:initial;border-bottom:1pt solid windowtext;text-align:center;margin-top:0pt;margin-bottom:0pt;width:7%" valign="bottom"><p style="margin-top:0pt;margin-bottom:0pt"><span style="font-size:8pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><strong style="margin-top:0pt;margin-bottom:0pt">Number of Portfolios</strong></span></p><p style="margin-top:0pt;margin-bottom:0pt"><span style="font-size:8pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><strong style="margin-top:0pt;margin-bottom:0pt">in Fund Complex</strong></span></p><p style="margin-top:0pt;margin-bottom:0pt"><span style="font-size:8pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><strong style="margin-top:0pt;margin-bottom:0pt">Overseen by Trustee</strong></span></p></td><td colspan="1" style="width:1%">&#160;</td></tr><tr><td colspan="10" style="padding:6pt .7pt 1pt 0pt;text-align:center;width:641" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:9pt;font-family:Times New Roman, Times, serif"><strong>INDEPENDENT TRUSTEES AND NOMINEES</strong></span></p></td><td colspan="1">&#160;</td></tr><tr><td colspan="3" style="padding:1pt 0.7pt 6pt 0pt;text-align:left;width:33%" valign="top"><span style="font-size:9pt;font-family:Times New Roman, Times, serif"><strong>Jeffrey A. Bailey, </strong></span><span style="font-size:9pt;font-family:Times New Roman, Times, serif">Born: 4/1962</span></td><td colspan="1" style="width:1%">&#160;</td><td colspan="3" style="padding:1pt 0.7pt 6pt 0pt;text-align:left;width:55%" valign="top"><p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:9pt;font-family:Times New Roman, Times, serif">Trustee since 2020; Chairman since 2022; Vice Chairman 2021-2022</span></p></td><td colspan="1" style="width:1%">&#160;</td><td colspan="1" style="padding:1pt 0.7pt 6pt 0pt;width:1%" valign="top">&#160;</td><td colspan="1" style="padding:1pt 0.7pt 6pt 0pt;text-align:right;width:7%" valign="top"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">4</span></p></td><td colspan="1" style="width:1%">&#160;</td></tr></table><p style="margin:0pt 0pt 0pt 0pt;height:18pt">&#160;</p><table border="0" cellpadding="0" cellspacing="0" width="100%"><tr><td colspan="3" style="padding:0pt .7pt 6pt 0pt;width:1708" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:9pt;font-family:Times New Roman, Times, serif">CEO, IlluminOss Inc. (2018-2020); Board Chairman, Aileron Therapeutics Inc. (since 2017); Director, Madison Vaccines, Inc. (since 2018); Director and CEO, BioDelivery Systems, Inc. (2020-2022).</span></p></td><td colspan="1">&#160;</td></tr></table><p style="margin:0pt 0pt 0pt 0pt;height:18pt">&#160;</p><table border="0" cellpadding="0" cellspacing="0" width="100%"><tr><td colspan="3" style="padding:1pt .7pt 6pt 0pt;text-align:left;width:194" valign="top"><span style="font-size:9pt;font-family:Times New Roman, Times, serif"><strong>Kathleen L. Goetz, </strong></span><span style="font-size:9pt;font-family:Times New Roman, Times, serif">Born: 4/1966</span></td><td colspan="1">&#160;</td><td colspan="3" style="padding:1pt .7pt 6pt 0pt;text-align:left;width:337" valign="top"><p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:9pt;font-family:Times New Roman, Times, serif">Trustee since 2021</span></p></td><td colspan="1">&#160;</td><td colspan="1" style="padding:1pt .7pt 6pt 0pt;width:8" valign="top">&#160;</td><td colspan="1" style="padding:1pt .7pt 6pt 0pt;text-align:right;width:94" valign="top"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">4</span></p></td><td colspan="1" style="padding:1pt .7pt 6pt 0pt;width:8" valign="top">&#160;</td><td colspan="1" style="width:8">&#160;</td></tr></table><p style="margin:0pt 0pt 0pt 0pt;height:18pt">&#160;</p><table border="0" cellpadding="0" cellspacing="0" width="100%"><tr><td colspan="3" style="padding:0pt .7pt 6pt 0pt;width:1708" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:9pt;font-family:Times New Roman, Times, serif">Vice President and Head of Sales, Novartis Pharmaceuticals (2017-2019); Executive Director of Strategic Account Management, Novartis Pharmaceuticals (2015-2016); Independent Consultant (2020-current).</span></p></td><td colspan="1">&#160;</td></tr></table><p style="margin:0pt 0pt 0pt 0pt;height:18pt">&#160;</p><table border="0" cellpadding="0" cellspacing="0" width="100%"><tr><td colspan="3" style="padding:1pt .7pt 6pt 0pt;text-align:left;width:194" valign="top"><span style="font-size:9pt;font-family:Times New Roman, Times, serif"><strong>Rakesh K. Jain, Ph.D.,</strong></span><span style="font-size:9pt;font-family:Times New Roman, Times, serif"> Born: 12/1950</span></td><td colspan="1">&#160;</td><td colspan="3" style="padding:1pt .7pt 6pt 0pt;text-align:left;width:337" valign="top"><p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:9pt;font-family:Times New Roman, Times, serif">Trustee HQH since 2007; THQ since 2014; THW since 2015</span></p></td><td colspan="1">&#160;</td><td colspan="1" style="padding:1pt .7pt 6pt 0pt;width:8" valign="top">&#160;</td><td colspan="1" style="padding:1pt .7pt 6pt 0pt;text-align:right;width:94" valign="top"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">4</span></p></td><td colspan="1" style="padding:1pt .7pt 6pt 0pt;width:8" valign="top">&#160;</td><td colspan="1" style="width:8">&#160;</td></tr></table><p style="margin:0pt 0pt 0pt 0pt;height:18pt">&#160;</p><table border="0" cellpadding="0" cellspacing="0" width="100%"><tr><td colspan="3" style="padding:0pt .7pt 6pt 0pt;width:1708" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:9pt;font-family:Times New Roman, Times, serif">Director, Steele Lab of Tumor Biology at Massachusetts General Hospital (since 1991); A.W. Cook Professor of Radiation Oncology (Tumor Biology) at Harvard Medical School (since 1991); Ad hoc Consultant/Scientific Advisory Board Member for pharmaceutical/biotech companies (various times since 2002); Ad hoc Consultant, Gershon Lehman Group (since 2004); Director, Co-Founder, XTuit Pharmaceuticals, Inc. (2012-2018).</span></p></td><td colspan="1">&#160;</td></tr></table><p style="margin:0pt 0pt 0pt 0pt;height:18pt">&#160;</p><table border="0" cellpadding="0" cellspacing="0" width="100%"><tr><td colspan="3" style="padding:1pt .7pt 6pt 0pt;text-align:left;width:194" valign="top"><span style="font-size:9pt;font-family:Times New Roman, Times, serif"><strong>Thomas M. Kent, CPA,</strong></span><span style="font-size:9pt;font-family:Times New Roman, Times, serif"> Born: 6/1953</span></td><td colspan="1">&#160;</td><td colspan="3" style="padding:1pt .7pt 6pt 0pt;text-align:left;width:337" valign="top"><p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:9pt;font-family:Times New Roman, Times, serif">Trustee since 2017</span></p></td><td colspan="1">&#160;</td><td colspan="1" style="padding:1pt .7pt 6pt 0pt;width:8" valign="top">&#160;</td><td colspan="1" style="padding:1pt .7pt 6pt 0pt;text-align:right;width:94" valign="top"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">4</span></p></td><td colspan="1" style="padding:1pt .7pt 6pt 0pt;width:8" valign="top">&#160;</td><td colspan="1" style="width:8">&#160;</td></tr></table><p style="margin:0pt 0pt 0pt 0pt;height:18pt">&#160;</p><table border="0" cellpadding="0" cellspacing="0" width="100%"><tr><td colspan="3" style="padding:0pt .7pt 6pt 0pt;width:1708" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:9pt;font-family:Times New Roman, Times, serif">Director, Principal Global Investors Trust Co. (since 2014); Trustee, Thayer Academy (2009-2018); Director, New England Canada Business Council (since 2017); Partner, PricewaterhouseCoopers LLP (1989-2013).</span></p></td><td colspan="1">&#160;</td></tr></table><p style="margin:0pt 0pt 0pt 0pt;height:18pt">&#160;</p><table border="0" cellpadding="0" cellspacing="0" width="100%"><tr><td colspan="3" style="padding:1pt .7pt 6pt 0pt;text-align:left;width:194" valign="top"><span style="font-size:9pt;font-family:Times New Roman, Times, serif"><strong>W. Mark Watson, CPA,</strong></span><span style="font-size:9pt;font-family:Times New Roman, Times, serif"> Born: 7/1950</span></td><td colspan="1">&#160;</td><td colspan="3" style="padding:1pt .7pt 6pt 0pt;text-align:left;width:337" valign="top"><p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:9pt;font-family:Times New Roman, Times, serif">Trustee since 2022</span></p></td><td colspan="1">&#160;</td><td colspan="1" style="padding:1pt .7pt 6pt 0pt;width:8" valign="top">&#160;</td><td colspan="1" style="padding:1pt .7pt 6pt 0pt;text-align:right;width:94" valign="top"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">4</span></p></td><td colspan="1" style="padding:1pt .7pt 6pt 0pt;width:8" valign="top">&#160;</td><td colspan="1" style="width:8">&#160;</td></tr></table><p style="margin:0pt 0pt 0pt 0pt;height:18pt">&#160;</p><table border="0" cellpadding="0" cellspacing="0" width="100%"><tr><td colspan="3" style="padding:0pt .7pt 6pt 0pt;width:1708" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:9pt;font-family:Times New Roman, Times, serif">Director of Vaxart Inc. (since 2022); BioDelivery Sciences International, Inc. (2017-2022); Inhibitor Therapeutics, Inc. (2014-2022); Global Health MCS (since 2014); Sykes Enterprises, Inc. (2018-2021); the Moffitt Cancer Center (since 2009).</span></p></td><td colspan="1">&#160;</td></tr></table><p style="margin:0pt 0pt 0pt 0pt;height:18pt">&#160;</p><table border="0" cellpadding="0" cellspacing="0" width="100%"><tr><td colspan="11" style="padding:4pt .7pt 1pt 0pt;text-align:center;width:641" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:9pt;font-family:Times New Roman, Times, serif"><strong>INTERESTED TRUSTEE</strong></span></p></td><td colspan="1">&#160;</td></tr><tr><td colspan="3" style="padding:1pt .7pt 6pt 0pt;text-align:left;width:194" valign="top"><span style="font-size:9pt;font-family:Times New Roman, Times, serif"><strong>Daniel R. Omstead, Ph.D.,</strong></span><span style="font-size:9pt;font-family:Times New Roman, Times, serif"> Born: 7/1953<sup>3</sup></span></td><td colspan="1">&#160;</td><td colspan="3" style="padding:1pt .7pt 6pt 0pt;text-align:left;width:337" valign="top"><p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:9pt;font-family:Times New Roman, Times, serif">President since 2001, Trustee HQH since 2003; THQ since 2014; THW since 2015</span></p></td><td colspan="1">&#160;</td><td colspan="1" style="padding:1pt .7pt 6pt 0pt;width:8" valign="top">&#160;</td><td colspan="1" style="padding:1pt .7pt 6pt 0pt;text-align:right;width:94" valign="top"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">4</span></p></td><td colspan="1" style="padding:1pt .7pt 6pt 0pt;width:8" valign="top">&#160;</td><td colspan="1" style="width:8">&#160;</td></tr></table><p style="margin:0pt 0pt 0pt 0pt;height:18pt">&#160;</p><table border="0" cellpadding="0" cellspacing="0" width="100%"><tr><td colspan="3" style="padding:0pt .7pt 6pt 0pt;width:1708" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:9pt;font-family:Times New Roman, Times, serif">President of HQH (since 2001), of Tekla Life Sciences Investors ("HQL") (since 2001), of THQ (since 2014), of THW (since 2015); President, Chief Executive Officer and Managing Member of Tekla Capital Management LLC (Since 2002); Director: Hotspot Therapeutics, Inc. (since 2021); IlluminOss Medical, Inc. (2011-2020); Veniti, Inc. (2015-2018); Joslin Diabetes Center (2016-2019); Decipher Biosciences Inc. (2016-2018).</span></p></td><td colspan="1">&#160;</td></tr></table><p style="margin:3pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Times New Roman, Times, serif"><sup>1</sup> The Address for each Trustee is: c/o Tekla Capital Management LLC, 100 Federal Street, 19th Floor, Boston, Massachusetts, 02110, 617-772-8500.</span></p><p style="margin:1pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Times New Roman, Times, serif"><sup>2</sup> Each Trustee currently is serving a three year term.</span></p><p style="margin:1pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Times New Roman, Times, serif"><sup>3</sup> Trustee considered to be an "interested person" within the meaning of the Investment Company Act of 1940, as amended (the "1940 Act"), through position or affiliation with the Adviser.</span></p></div><p style="text-align:center"><br /><span style="font-size:13px;font-family:Times New Roman PS, Times New Roman, Times">5</span></p><hr style="height:2px;text-align:center;width:100%;background-color:gray;page-break-after:always" /><div style="margin:8pt 0pt 8pt 0pt"><p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">The following table sets forth, for each Trustee, the aggregate dollar range of equity securities owned by such Trustee in HQH, THQ and THW and in the aggregate in all funds overseen by a Trustee in the fund complex as of March 31, 2023. The information as to beneficial ownership is based upon statements furnished by each Trustee.</span></p><table border="0" cellpadding="0" cellspacing="0" width="100%"><tr><td colspan="3" style="padding:6pt 0.7pt 0pt 0pt;border-top:none;border-right:none;border-left:none;border-image:initial;border-bottom:1pt solid windowtext;text-align:left;margin-top:0pt;margin-bottom:0pt" valign="bottom"><p style="margin-top:0pt;margin-bottom:0pt"><span style="font-size:8pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><strong style="margin-top:0pt;margin-bottom:0pt">Name of Trustee </strong></span></p><p style="margin-top:0pt;margin-bottom:0pt"><span style="font-size:8pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><strong style="margin-top:0pt;margin-bottom:0pt">or&#160;</strong></span><span style="font-size:8pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><strong style="margin-top:0pt;margin-bottom:0pt">Nominee</strong></span></p></td><td colspan="1">&#160;</td><td colspan="3" style="padding:6pt 0.7pt 0pt 0pt;border-top:none;border-right:none;border-left:none;border-image:initial;border-bottom:1pt solid windowtext;text-align:center;margin-top:0pt;margin-bottom:0pt" valign="bottom"><p style="margin-top:0pt;margin-bottom:0pt"><span style="font-size:8pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><strong style="margin-top:0pt;margin-bottom:0pt">Dollar Range of </strong></span></p><p style="margin-top:0pt;margin-bottom:0pt"><span style="font-size:8pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><strong style="margin-top:0pt;margin-bottom:0pt">Equity Securities </strong></span></p><p style="margin-top:0pt;margin-bottom:0pt"><span style="font-size:8pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><strong style="margin-top:0pt;margin-bottom:0pt">in HQH</strong></span></p></td><td colspan="1">&#160;</td><td colspan="3" style="padding:6pt 0.7pt 0pt 0pt;border-top:none;border-right:none;border-left:none;border-image:initial;border-bottom:1pt solid windowtext;text-align:center;margin-top:0pt;margin-bottom:0pt" valign="bottom"><p style="margin-top:0pt;margin-bottom:0pt"><span style="font-size:8pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><strong style="margin-top:0pt;margin-bottom:0pt">Dollar Range of </strong></span></p><p style="margin-top:0pt;margin-bottom:0pt"><span style="font-size:8pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><strong style="margin-top:0pt;margin-bottom:0pt">Equity Securities </strong></span></p><p style="margin-top:0pt;margin-bottom:0pt"><span style="font-size:8pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><strong style="margin-top:0pt;margin-bottom:0pt">in THQ</strong></span></p></td><td colspan="1">&#160;</td><td colspan="3" style="padding:6pt 0.7pt 0pt 0pt;border-top:none;border-right:none;border-left:none;border-image:initial;border-bottom:1pt solid windowtext;text-align:center;margin-top:0pt;margin-bottom:0pt" valign="bottom"><p style="margin-top:0pt;margin-bottom:0pt"><span style="font-size:8pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><strong style="margin-top:0pt;margin-bottom:0pt">Dollar Range of </strong></span></p><p style="margin-top:0pt;margin-bottom:0pt"><span style="font-size:8pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><strong style="margin-top:0pt;margin-bottom:0pt">Equity Securities </strong></span></p><p style="margin-top:0pt;margin-bottom:0pt"><span style="font-size:8pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><strong style="margin-top:0pt;margin-bottom:0pt">in THW</strong></span></p></td><td colspan="1">&#160;</td><td colspan="3" style="padding:6pt 0.7pt 0pt 0pt;border-top:none;border-right:none;border-left:none;border-image:initial;border-bottom:1pt solid windowtext;text-align:center;margin-top:0pt;margin-bottom:0pt" valign="bottom"><p style="margin-top:0pt;margin-bottom:0pt"><span style="font-size:8pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><strong style="margin-top:0pt;margin-bottom:0pt">Aggregate Dollar </strong></span></p><p style="margin-top:0pt;margin-bottom:0pt"><span style="font-size:8pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><strong style="margin-top:0pt;margin-bottom:0pt">Range of Equity </strong></span></p><p style="margin-top:0pt;margin-bottom:0pt"><span style="font-size:8pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><strong style="margin-top:0pt;margin-bottom:0pt">Securities in All </strong></span></p><p style="margin-top:0pt;margin-bottom:0pt"><span style="font-size:8pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><strong style="margin-top:0pt;margin-bottom:0pt">Funds Overseen </strong></span></p><p style="margin-top:0pt;margin-bottom:0pt"><span style="font-size:8pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><strong style="margin-top:0pt;margin-bottom:0pt">by Trustee in </strong></span></p><p style="margin-top:0pt;margin-bottom:0pt"><span style="font-size:8pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><strong style="margin-top:0pt;margin-bottom:0pt">Fund Complex</strong></span></p></td><td colspan="1">&#160;</td></tr><tr><td colspan="19" style="padding:2pt .7pt 0pt 0pt;text-align:left;width:562;background-color:#cceeff" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:10pt;font-family:Times New Roman, Times, serif"><strong>Independent Trustees</strong></span></p></td><td colspan="1" style="background-color:#cceeff">&#160;</td></tr><tr><td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;width:102" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">Jeffrey A. Bailey</span></p></td><td colspan="1">&#160;</td><td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;width:80" valign="bottom"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">$</span><span style="font-size:10pt;font-family:Times New Roman, Times, serif">10,001-$50,000</span></td><td colspan="1">&#160;</td><td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;width:80" valign="bottom"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">$</span><span style="font-size:10pt;font-family:Times New Roman, Times, serif">10,001-$50,000</span></td><td colspan="1">&#160;</td><td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;width:80" valign="bottom"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">$</span><span style="font-size:10pt;font-family:Times New Roman, Times, serif">10,001-$50,000</span></td><td colspan="1">&#160;</td><td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;width:80" valign="bottom"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">$</span><span style="font-size:10pt;font-family:Times New Roman, Times, serif">10,001-$50,000</span></td><td colspan="1">&#160;</td></tr><tr><td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;width:102;background-color:#cceeff" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">Kathleen L. Goetz</span></p></td><td colspan="1" style="background-color:#cceeff">&#160;</td><td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;width:80;background-color:#cceeff" valign="bottom"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">$</span><span style="font-size:10pt;font-family:Times New Roman, Times, serif">0-$10,000</span></td><td colspan="1" style="background-color:#cceeff">&#160;</td><td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;width:80;background-color:#cceeff" valign="bottom"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">$</span><span style="font-size:10pt;font-family:Times New Roman, Times, serif">10,001-$50,000</span></td><td colspan="1" style="background-color:#cceeff">&#160;</td><td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;width:80;background-color:#cceeff" valign="bottom"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">$</span><span style="font-size:10pt;font-family:Times New Roman, Times, serif">10,001-$50,000</span></td><td colspan="1" style="background-color:#cceeff">&#160;</td><td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;width:80;background-color:#cceeff" valign="bottom"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">$</span><span style="font-size:10pt;font-family:Times New Roman, Times, serif">10,001-$50,000</span></td><td colspan="1" style="background-color:#cceeff">&#160;</td></tr><tr><td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;width:102" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">Rakesh K. Jain</span></p></td><td colspan="1">&#160;</td><td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;width:80" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">None</span></p></td><td colspan="1">&#160;</td><td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;width:80" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">None</span></p></td><td colspan="1">&#160;</td><td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;width:80" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">None</span></p></td><td colspan="1">&#160;</td><td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;width:80" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">None</span></p></td><td colspan="1">&#160;</td></tr><tr><td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;width:102;background-color:#cceeff" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">Thomas M. Kent</span></p></td><td colspan="1" style="background-color:#cceeff">&#160;</td><td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;width:80;background-color:#cceeff" valign="bottom"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">$</span><span style="font-size:10pt;font-family:Times New Roman, Times, serif">10,001-$50,000</span></td><td colspan="1" style="background-color:#cceeff">&#160;</td><td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;width:80;background-color:#cceeff" valign="bottom"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">$</span><span style="font-size:10pt;font-family:Times New Roman, Times, serif">10,001-$50,000</span></td><td colspan="1" style="background-color:#cceeff">&#160;</td><td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;width:80;background-color:#cceeff" valign="bottom"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">$</span><span style="font-size:10pt;font-family:Times New Roman, Times, serif">10,001-$50,000</span></td><td colspan="1" style="background-color:#cceeff">&#160;</td><td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;width:109;background-color:#cceeff" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">Over $100,000</span></p></td><td colspan="1" style="background-color:#cceeff">&#160;</td></tr><tr><td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;width:102" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">W. Mark Watson</span></p></td><td colspan="1">&#160;</td><td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;width:80" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">None</span></p></td><td colspan="1">&#160;</td><td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;width:80" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">None</span></p></td><td colspan="1">&#160;</td><td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;width:80" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">None</span></p></td><td colspan="1">&#160;</td><td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;width:80" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">None</span></p></td><td colspan="1">&#160;</td></tr><tr><td colspan="19" style="padding:6pt .7pt 0pt 0pt;text-align:left;width:562;background-color:#cceeff" valign="bottom"><span style="font-size:10pt;font-family:Times New Roman, Times, serif"><strong>Interested </strong></span><span style="font-size:10pt;font-family:Times New Roman, Times, serif"><strong>Trustee</strong></span></td><td colspan="1" style="background-color:#cceeff">&#160;</td></tr><tr><td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;width:102" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">Daniel R. Omstead</span></p></td><td colspan="1">&#160;</td><td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;width:109" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">Over $100,000</span></p></td><td colspan="1">&#160;</td><td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;width:109" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">Over $100,000</span></p></td><td colspan="1">&#160;</td><td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;width:109" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">Over $100,000</span></p></td><td colspan="1">&#160;</td><td colspan="3" style="padding:2pt .7pt 0pt 0pt;text-align:left;width:109" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">Over $100,000</span></p></td><td colspan="1">&#160;</td></tr></table><p style="margin:6pt 0pt 0pt 0pt"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">Although Trustees are encouraged to attend the annual meetings of shareholders to the extent they are able, none of the Funds has a formal policy with regard to Board members' attendance at annual meetings of shareholders. Last year, seven of the Trustees then in office attended the 2022 joint annual meeting of shareholders.</span></p><p style="margin:6pt 0pt 0pt 0pt"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">Shareholders wishing to send communications to the Board of any Fund may communicate with members of the Board by submitting a written communication directed to the Board in care of Tekla Capital Management LLC, 100 Federal Street, 19th Floor, Boston, MA 02110.</span></p><p style="margin:6pt 0pt 0pt 0pt"><span style="font-size:10pt;font-family:Times New Roman, Times, serif"><strong>Trustees &#8211; Leadership Structure and Oversight Responsibilities</strong></span></p><p style="margin:6pt 0pt 0pt 0pt"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">Overall responsibility for general oversight of each Fund rests with the Board. The Board of each Fund is comprised of six individuals, five of whom are not "interested persons" of the Fund as defined in the 1940 Act ("Independent Trustees"). The Chairman of the Board is an Independent Trustee. The Chairman presides at meetings of the Trustees, participates in the preparation of the agenda for meetings of the Board, and acts as a liaison between the Independent Trustees and the Fund's management between Board meetings. Except for any duties specified herein, the designation as Chairman does not impose any obligations or standards greater than or different from other Trustees.</span></p><p style="margin:6pt 0pt 0pt 0pt"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">The Board of each Fund holds regular quarterly meetings each year to consider and address matters involving the Fund. The Board also may hold special meetings to address matters arising between regular meetings. The Independent Trustees also meet outside the presence of management in executive session at least quarterly and have engaged independent legal counsel to assist them in performing their oversight responsibilities.</span></p><p style="margin:6pt 0pt 0pt 0pt"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">The Board of each Fund has established Audit, Governance and Nominating, Valuation and Qualified Legal Compliance Committees to assist the Board in the oversight of the management and affairs of the Fund. All of the members of these Committees are Independent Trustees, except for Dr. Omstead, who serves on the Valuation Committee. From time to time the Board may establish additional committees or informal working groups to deal with specific matters.</span></p><p style="margin:6pt 0pt 0pt 0pt"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">Each Fund is subject to a number of risks including investment, compliance, operational and valuation risks. Although the Adviser and the officers of each Fund are responsible for managing these risks on a day-to-day basis, the Board of each Fund has adopted, and periodically reviews, policies and </span></p></div><p style="text-align:center"><br /><span style="font-size:13px;font-family:Times New Roman PS, Times New Roman, Times">6</span></p><hr style="height:2px;text-align:center;width:100%;background-color:gray;page-break-after:always" /><div style="margin:8pt 0pt 8pt 0pt"><p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">procedures designed to address these risks. As part of its regular oversight, the Board of each Fund, directly or through a Committee, interacts with the Fund's Chief Compliance Officer, the Fund's independent public accounting firm and the Fund's legal counsel. These interactions include discussing the Fund's risk management and controls with the independent registered public accounting firm engaged by the Fund, reviewing valuation policies and procedures and the valuations of specific restricted securities, and receiving periodic reports from the Fund's Chief Compliance Officer regarding compliance matters relating to the Fund and its major service providers, including results of the implementation and testing of the Fund's and such providers' compliance programs. The Board's oversight function is facilitated by management reporting processes designed to provide information to the Board regarding the identification, assessment, and management of critical risks and the controls and policies and procedures used to mitigate those risks. The Board reviews its role in supervising the Fund's risk management from time to time and may change the manner in which it fulfills its oversight responsibilities at its discretion at any time.</span></p><p style="margin:6pt 0pt 0pt 0pt"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">The Board of each Fund has determined that its leadership structure is appropriate for the Fund because it enables the Board to exercise informed and independent judgment over matters under its purview, allocates responsibility among committees in a manner that fosters effective oversight and allows the Board to devote appropriate resources to specific issues in a flexible manner as they arise. The Board periodically reviews its leadership structure as well as its overall structure, composition, and functioning and may make changes at its discretion at any time.</span></p><p style="margin:6pt 0pt 0pt 0pt"><span style="font-size:10pt;font-family:Times New Roman, Times, serif"><strong>Standing Committees</strong></span></p><p style="margin:6pt 0pt 0pt 0pt"><span style="font-size:10pt;font-family:Times New Roman, Times, serif"><i>Audit Committee.</i></span><span style="font-size:10pt;font-family:Times New Roman, Times, serif"> Each Fund has an Audit Committee comprised solely of Independent Trustees who are "independent" as defined in the New York Stock Exchange ("NYSE") Listing Standards. The Board of each Fund has adopted a written charter for the Audit Committee. The Audit Committee charter is available at www.teklacap.com/funds/hqh/fund/literature. The principal purpose of each Fund's Audit Committee is to assist the Board in fulfilling its responsibility to oversee management's conduct of the Fund's financial reporting process, including reviewing the financial reports and other financial information provided by the Fund, the Fund's systems of internal accounting and financial controls and the annual independent audit process.</span></p><p style="margin:6pt 0pt 0pt 0pt"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">Each Audit Committee's role is one of oversight, and it is recognized that each Fund's management is responsible for preparing each Fund's financial statements and that each Fund's independent registered public accountant is responsible for auditing those financial statements. Although each Audit Committee member must be financially literate and one member must have accounting or financial management expertise (as determined by the Board in its business judgment), Audit Committee members are not professionally engaged in the practice of accounting or auditing and are not experts in the fields of accounting or auditing, including with respect to auditor independence. Audit Committee members rely, without independent verification, on the information provided to them and on the representations made by management and each Fund's independent registered public accountants.</span></p><p style="margin:5.5pt 0pt 0pt 0pt"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">The members of each Fund's Audit Committee are Mr. Kent, Ms. Goetz and Mr. Watson. Mr. Kent is the Chairman of each Fund's Audit Committee. The Audit Committee of each Fund held four meetings during the fiscal year ended September 30, 2022.</span></p><p style="margin:5.5pt 0pt 0pt 0pt"><span style="font-size:10pt;font-family:Times New Roman, Times, serif"><i>Governance and Nominating Committee.</i></span><span style="font-size:10pt;font-family:Times New Roman, Times, serif"> Each Fund has a Governance and Nominating Committee comprised solely of Independent Trustees who are "independent" as defined in the NYSE Listing Standards. The Committee charter is not available on the Fund's website but the written charter is included as Exhibit A to this Proxy Statement dated April 17, 2023.</span></p></div><p style="text-align:center"><br /><span style="font-size:13px;font-family:Times New Roman PS, Times New Roman, Times">7</span></p><hr style="height:2px;text-align:center;width:100%;background-color:gray;page-break-after:always" /><div style="margin:8pt 0pt 8pt 0pt"><p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">The principal missions of the Governance and Nominating Committee of each Fund are to (i) review, evaluate, and enhance the effectiveness of the Board in its role in governing the Fund and overseeing the management of the Fund and (ii) promote the effective participation of qualified individuals on the Board, on committees of the Board, and as executive officers of the Fund. The Committee shall consider the Corporate Governance Guidelines that have been approved by the Board in fulfilling its missions.</span></p><p style="margin:5.5pt 0pt 0pt 0pt"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">The Committee of each Fund reviews, discusses and makes recommendations to the Board relating to those issues that pertain to the effectiveness of the Board in carrying out its responsibilities in governing the Fund and overseeing the Fund's management. The Committee makes nominations for Trustees and officers of the Fund and for membership on all committees of the Board and submits such nominations to the full Board for consideration.</span></p><p style="margin:5.5pt 0pt 0pt 0pt"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">Each Fund's By-Laws require that each prospective trustee candidate have a college degree or equivalent business experience and provide a list of minimum qualifications for trustees, which include expertise, experience or relationships relevant to the business of the Fund. Each Fund's By-Laws also require that a candidate not be serving in any of various positions with another investment company (as defined in the 1940 Act) that focuses its investments in the healthcare and/or life sciences industries, unless such investment company is managed by the Fund's investment adviser or an affiliate, or in various positions with the investment adviser, sponsor or equivalent of such an investment company. Each Committee may also take into account other factors when considering and evaluating potential trustee candidates, including but not limited to: (i) availability and commitment to attend meetings and perform responsibilities of the Board; (ii) relevant industry and related experience; (iii) educational background; (iv) financial expertise; (v) the candidate's ability, judgment and expertise; and (vi) the overall diversity of the Board's composition.</span></p><p style="margin:5.5pt 0pt 0pt 0pt"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">The Committee of each Fund may identify prospective trustees from any reasonable source, including, but not limited to, the consultation of third-party trustee search services. The Committee will consider potential trustee candidates recommended by shareholders, provided that the proposed candidates (i) satisfy any minimum qualifications of the Fund for its trustees; (ii) are not "interested persons" (as that term is defined in Section 2(a)(19) of the 1940 Act) of the Fund or the Adviser; and (iii) are "independent" as defined in the NYSE Listing Standards. In order to be evaluated by the Committee, trustee candidates recommended by shareholders must also meet certain eligibility requirements as set out in the Committees' charter. Other than those eligibility requirements, the Committee shall not evaluate shareholder trustee nominees in a different manner than other nominees. The standard of the Committee is to treat all equally qualified nominees in the same manner.</span></p><p style="margin:5.5pt 0pt 0pt 0pt"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">All recommendations by shareholders must be received by a Fund by the deadline for submission of any shareholder proposals which would be included in the Fund's proxy statement for the next annual meeting of the Fund. Each shareholder or shareholder group must meet the requirements stated in the Committee's charter in order to recommend a candidate. A shareholder or shareholder group may not submit more than one candidate per year. When recommending a trustee candidate, shareholders must include in their notice to the Fund's Secretary: (i) the shareholder's contact information; (ii) the trustee candidate's contact information and the number of Fund shares owned by the proposed candidate; (iii) all information regarding the candidate that would be required to be disclosed in solicitations of proxies for elections of trustees required by Regulation 14A of the Securities Act of 1934, as amended (the "Exchange Act"); and (iv) a notarized letter executed by the trustee candidate, stating his or her intention to be a nominee and be named in the Fund's proxy statement, if nominated by the Board, and </span></p></div><p style="text-align:center"><br /><span style="font-size:13px;font-family:Times New Roman PS, Times New Roman, Times">8</span></p><hr style="height:2px;text-align:center;width:100%;background-color:gray;page-break-after:always" /><div style="margin:8pt 0pt 8pt 0pt"><p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">to serve as a trustee, if so elected. Once a recommendation has been timely received in proper form, the candidate will be asked to complete an eligibility questionnaire to assist the Fund in assessing the candidate's qualifications as a potential Independent Trustee and as someone who is "independent" under the NYSE Listing Standards. The Committee will make such determinations in its sole discretion and such determinations shall be final.</span></p><p style="margin:5.5pt 0pt 0pt 0pt"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">The members of each Fund's Committee are Mr. Bailey, Dr. Jain and Mr. Kent. Dr. Jain is the Chairman of the Committee. The Governance and Nominating Committee of each Fund held five meetings during the fiscal year ended September 30, 2022.</span></p><p style="margin:6pt 0pt 0pt 0pt"><span style="font-size:10pt;font-family:Times New Roman, Times, serif"><i>Valuation Committee.</i></span><span style="font-size:10pt;font-family:Times New Roman, Times, serif"> Each Fund's Board has delegated to the Fund's Valuation Committee general responsibility for determining, subject to Board ratification, in accordance with the Fund's valuation procedures, the value of assets held by the Fund on any day on which the net asset value per share is determined. The Valuation Committee may appoint, and has appointed, a Sub-Committee made up of employees and officers of the Adviser to deal in the first instance with day to day valuation decisions, subject to oversight by the Valuation Committee. The Valuation Committee shall meet as often as necessary to ensure that each action taken by the Sub-Committee is reviewed within a calendar quarter of the occurrence. In connection with its review, the Valuation Committee shall ratify or revise the pricing methodologies authorized by the Sub-Committee since the last meeting of the Valuation Committee. The Valuation Committee is charged with the responsibility of determining the fair value of the Fund's securities or other assets in situations set forth in the Fund's valuation procedures.</span></p><p style="margin:6pt 0pt 0pt 0pt"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">The members of each Fund's Valuation Committee are Mr. Bailey, Ms. Goetz, Dr. Omstead and Mr. Watson. Mr. Bailey is the Chairman of each Fund's Valuation Committee. The Valuation Committee of each Fund held four meetings during the fiscal year ended September 30, 2022.</span></p><p style="margin:6pt 0pt 0pt 0pt"><span style="font-size:10pt;font-family:Times New Roman, Times, serif"><i>Qualified Legal Compliance Committee.</i></span><span style="font-size:10pt;font-family:Times New Roman, Times, serif"> Each Fund has a Qualified Legal Compliance Committee ("QLCC") comprised solely of Independent Trustees. The Board of each Fund has adopted a written charter for the QLCC. The principal purpose of the Fund's QLCC is to review and respond to reports of Evidence of a Material Violation (as defined in the QLCC charter). Reporting Evidence of a Material Violation is required under the Standards of Professional Conduct for Attorneys adopted by the U.S. Securities and Exchange Commission (the "SEC") under the Sarbanes-Oxley Act of 2002 (the "Standards"). Under the Standards, if an attorney appearing and practicing before the SEC in the representation of an issuer, such as the Fund, becomes aware of Evidence of a Material Violation by the issuer or by any officer, trustee, employee or agent of the issuer, the Standards provide for the attorney to report such evidence to the issuer's QLCC forthwith. In discharging its role, the QLCC is granted the power to investigate any Evidence of a Material Violation brought to its attention with full access to all books, records, facilities and personnel of the Fund and the power to retain outside counsel, auditors or other experts for this purpose.</span></p><p style="margin:4pt 0pt 0pt 0pt"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">The members of each Fund's QLCC are Dr. Jain and Mr. Kent. Mr. Kent is the Chairman of each Fund's QLCC. Each Fund's QLCC had no cause to meet during the fiscal year ended September 30, 2022.</span></p><p style="margin:4pt 0pt 0pt 0pt"><span style="font-size:10pt;font-family:Times New Roman, Times, serif"><i>Attendance.</i></span><span style="font-size:10pt;font-family:Times New Roman, Times, serif"> During the fiscal year ended September 30, 2022, HQH, THQ and THW's Boards each held five meetings; each Fund's Audit Committee held four meetings; each Fund's Governance and Nominating Committee held five meetings; and each Fund's Valuation Committee held four meetings.</span></p></div><p style="text-align:center"><br /><span style="font-size:13px;font-family:Times New Roman PS, Times New Roman, Times">9</span></p><hr style="height:2px;text-align:center;width:100%;background-color:gray;page-break-after:always" /><div style="margin:8pt 0pt 8pt 0pt"><p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">Each of the incumbent Trustees attended at least 100% of the aggregate number of meetings of the Boards of each Fund during the period for which he or she served as a Trustee. Each of the incumbent Trustees attended at least 100% of the aggregate number of meetings of the Committees of the Board of each Fund on which such Trustee served during the period that he or she has served.</span></p><p style="margin:4pt 0pt 0pt 0pt"><span style="font-size:10pt;font-family:Times New Roman, Times, serif"><strong>Compensation of Trustees and Officers</strong></span></p><p style="margin:3pt 0pt 0pt 0pt"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">For the fiscal year ended September 30, 2022, each Fund paid an annual fee of $17,500 (the annual fee was $16,250 from January 1, 2021 through December 31, 2021) to its Independent Trustees and the Chairman of the Board receives an additional annual fee of $5,000. Additionally, each Fund paid each Independent Trustee $1,000 for each Board and $750 for each Committee meeting (from January 1, 2021 through December 31, 2021 each Fund paid $250 for each Board and Committee meeting attended by telephone). The Chairman of the Audit Committee, the Valuation Committee and the Governance and Nominating Committee of each Fund each received an additional annual fee of $2,000. Independent Trustees are also reimbursed for travel expenses incurred in connection with attending such meetings. For the fiscal year ended September 30, 2022, the Independent Trustees as a group received $2,098 from HQH, $2,037 from THQ and $1,140 from THW for reimbursed expenses.</span></p><p style="margin:4pt 0pt 0pt 0pt"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">Each Fund has entered into a Services Agreement (the "Agreement") with the Adviser. Pursuant to the terms of the Agreement, each Fund reimburses the Adviser for a portion of the payment of salary and provision of benefits to each Fund's Chief Compliance Officer. Trustees and officers of each Fund who hold positions with the Adviser receive indirect compensation from the investment advisory fee paid to the Adviser by each Fund.</span></p><p style="margin:4pt 0pt 0pt 0pt"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">The following table sets forth information regarding compensation of the Trustees and Executive Officer by each Fund for the fiscal year ended September 30, 2022, but does not include reimbursed expenses as described above.</span></p><p style="margin:4pt 0pt 0pt 0pt;text-align:center"><span style="font-size:10pt;font-family:Times New Roman, Times, serif"><strong>Compensation Table</strong></span></p><table border="0" cellpadding="0" cellspacing="0" width="100%"><tr><td colspan="3" style="padding:4pt 0.7pt 0pt 0pt;border-top:none;border-right:none;border-left:none;border-image:initial;border-bottom:1pt solid windowtext;text-align:left;margin-top:0pt;margin-bottom:0pt" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><strong style="margin-top:0pt;margin-bottom:0pt">Name of Person, Position</strong></span></p></td><td colspan="1">&#160;</td><td colspan="11" style="padding:4pt 0.7pt 0pt 0pt;border-top:none;border-right:none;border-left:none;border-image:initial;border-bottom:1pt solid windowtext;text-align:center;margin-top:0pt;margin-bottom:0pt" valign="bottom"><p style="margin-top:0pt;margin-bottom:0pt"><span style="font-size:8pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><strong style="margin-top:0pt;margin-bottom:0pt">Aggregate</strong></span></p><p style="margin-top:0pt;margin-bottom:0pt"><span style="font-size:8pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><strong style="margin-top:0pt;margin-bottom:0pt">Compensation</strong></span></p><p style="margin-top:0pt;margin-bottom:0pt"><span style="font-size:8pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><strong style="margin-top:0pt;margin-bottom:0pt">from each Fund</strong></span></p></td><td colspan="1">&#160;</td><td colspan="3" style="padding:4pt 0.7pt 0pt 0pt;border-top:none;border-right:none;border-left:none;border-image:initial;border-bottom:1pt solid windowtext;text-align:center;margin-top:0pt;margin-bottom:0pt" valign="bottom"><p style="margin-top:0pt;margin-bottom:0pt"><span style="font-size:8pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><strong style="margin-top:0pt;margin-bottom:0pt">Pension or</strong></span></p><p style="margin-top:0pt;margin-bottom:0pt"><span style="font-size:8pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><strong style="margin-top:0pt;margin-bottom:0pt">Retirement</strong></span></p><p style="margin-top:0pt;margin-bottom:0pt"><span style="font-size:8pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><strong style="margin-top:0pt;margin-bottom:0pt">Benefits Accrued</strong></span></p><p style="margin-top:0pt;margin-bottom:0pt"><span style="font-size:8pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><strong style="margin-top:0pt;margin-bottom:0pt">as&#160;</strong></span><span style="font-size:8pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><strong style="margin-top:0pt;margin-bottom:0pt">part of each</strong></span></p><p style="margin-top:0pt;margin-bottom:0pt"><span style="font-size:8pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><strong style="margin-top:0pt;margin-bottom:0pt">Fund's Expenses</strong></span></p></td><td colspan="1">&#160;</td><td colspan="3" style="padding:4pt 0.7pt 0pt 0pt;border-top:none;border-right:none;border-left:none;border-image:initial;border-bottom:1pt solid windowtext;text-align:center;margin-top:0pt;margin-bottom:0pt" valign="bottom"><p style="margin-top:0pt;margin-bottom:0pt"><span style="font-size:8pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><strong style="margin-top:0pt;margin-bottom:0pt">Estimated</strong></span></p><p style="margin-top:0pt;margin-bottom:0pt"><span style="font-size:8pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><strong style="margin-top:0pt;margin-bottom:0pt">Annual</strong></span></p><p style="margin-top:0pt;margin-bottom:0pt"><span style="font-size:8pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><strong style="margin-top:0pt;margin-bottom:0pt">Benefits upon</strong></span></p><p style="margin-top:0pt;margin-bottom:0pt"><span style="font-size:8pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><strong style="margin-top:0pt;margin-bottom:0pt">Retirement</strong></span></p></td><td colspan="1">&#160;</td><td colspan="3" style="padding:4pt 0.7pt 0pt 0pt;border-top:none;border-right:none;border-left:none;border-image:initial;border-bottom:1pt solid windowtext;text-align:center;margin-top:0pt;margin-bottom:0pt" valign="bottom"><p style="margin-top:0pt;margin-bottom:0pt"><span style="font-size:8pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><strong style="margin-top:0pt;margin-bottom:0pt">Total</strong></span></p><p style="margin-top:0pt;margin-bottom:0pt"><span style="font-size:8pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><strong style="margin-top:0pt;margin-bottom:0pt">Compensation</strong></span></p><p style="margin-top:0pt;margin-bottom:0pt"><span style="font-size:8pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><strong style="margin-top:0pt;margin-bottom:0pt">from All Funds</strong></span></p><p style="margin-top:0pt;margin-bottom:0pt"><span style="font-size:8pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><strong style="margin-top:0pt;margin-bottom:0pt">in&#160;</strong></span><span style="font-size:8pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><strong style="margin-top:0pt;margin-bottom:0pt">Fund Complex</strong></span></p><p style="margin-top:0pt;margin-bottom:0pt"><span style="font-size:8pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><strong style="margin-top:0pt;margin-bottom:0pt">Paid to Trustees</strong></span></p></td><td colspan="1">&#160;</td></tr><tr><td colspan="3" style="padding:4pt .7pt 0pt 0pt;text-align:left;width:134;background-color:#cceeff" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:9pt;font-family:Times New Roman, Times, serif"><strong>Independent Trustees*</strong></span></p></td><td colspan="1" style="background-color:#cceeff">&#160;</td><td colspan="3" style="padding:4pt .7pt 0pt 0pt;text-align:left;width:73;background-color:#cceeff" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:9pt;font-family:Times New Roman, Times, serif"><strong>HQH</strong></span></p></td><td colspan="1" style="background-color:#cceeff">&#160;</td><td colspan="3" style="padding:4pt .7pt 0pt 0pt;text-align:left;width:73;background-color:#cceeff" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:9pt;font-family:Times New Roman, Times, serif"><strong>THQ</strong></span></p></td><td colspan="1" style="background-color:#cceeff">&#160;</td><td colspan="3" style="padding:4pt .7pt 0pt 0pt;text-align:left;width:68;background-color:#cceeff" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:9pt;font-family:Times New Roman, Times, serif"><strong>THW</strong></span></p></td><td colspan="1" style="background-color:#cceeff">&#160;</td><td colspan="3" style="padding:4pt .7pt 0pt 0pt;width:93;background-color:#cceeff" valign="bottom">&#160;</td><td colspan="1" style="background-color:#cceeff">&#160;</td><td colspan="3" style="padding:4pt .7pt 0pt 0pt;width:82;background-color:#cceeff" valign="bottom">&#160;</td><td colspan="1" style="background-color:#cceeff">&#160;</td><td colspan="3" style="padding:4pt .7pt 0pt 0pt;width:107;background-color:#cceeff" valign="bottom">&#160;</td><td colspan="1" style="background-color:#cceeff">&#160;</td></tr><tr><td colspan="3" style="padding:1pt .7pt 0pt 0pt;text-align:left;width:134" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:9pt;font-family:Times New Roman, Times, serif">Jeffrey A. Bailey</span></p></td><td colspan="1">&#160;</td><td colspan="1" style="padding:1pt .7pt 0pt 0pt;text-align:right;width:20" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:9pt;font-family:Times New Roman, Times, serif">$</span></p></td><td colspan="1" style="padding:1pt .7pt 0pt 0pt;text-align:right;width:45" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:9pt;font-family:Times New Roman, Times, serif">30,021</span></p></td><td colspan="1" style="padding:1pt .7pt 0pt 0pt;width:8" valign="bottom">&#160;</td><td colspan="1" style="width:8">&#160;</td><td colspan="1" style="padding:1pt .7pt 0pt 0pt;text-align:right;width:20" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:9pt;font-family:Times New Roman, Times, serif">$</span></p></td><td colspan="1" style="padding:1pt .7pt 0pt 0pt;text-align:right;width:45" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:9pt;font-family:Times New Roman, Times, serif">30,021</span></p></td><td colspan="1" style="padding:1pt .7pt 0pt 0pt;width:8" valign="bottom">&#160;</td><td colspan="1" style="width:8">&#160;</td><td colspan="1" style="padding:1pt .7pt 0pt 0pt;text-align:right;width:20" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:9pt;font-family:Times New Roman, Times, serif">$</span></p></td><td colspan="1" style="padding:1pt .7pt 0pt 0pt;text-align:right;width:40" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:9pt;font-family:Times New Roman, Times, serif">30,021</span></p></td><td colspan="1" style="padding:1pt .7pt 0pt 0pt;width:8" valign="bottom">&#160;</td><td colspan="1" style="width:8">&#160;</td><td colspan="1" style="padding:1pt .7pt 0pt 0pt;width:8" valign="bottom">&#160;</td><td colspan="1" style="padding:1pt .7pt 0pt 0pt;text-align:right;width:77" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:9pt;font-family:Times New Roman, Times, serif">N/A</span></p></td><td colspan="1" style="padding:1pt .7pt 0pt 0pt;width:8" valign="bottom">&#160;</td><td colspan="1" style="width:8">&#160;</td><td colspan="1" style="padding:1pt .7pt 0pt 0pt;width:8" valign="bottom">&#160;</td><td colspan="1" style="padding:1pt .7pt 0pt 0pt;text-align:right;width:66" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:9pt;font-family:Times New Roman, Times, serif">N/A</span></p></td><td colspan="1" style="padding:1pt .7pt 0pt 0pt;width:8" valign="bottom">&#160;</td><td colspan="1" style="width:8">&#160;</td><td colspan="1" style="padding:1pt .7pt 0pt 0pt;text-align:right;width:20" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:9pt;font-family:Times New Roman, Times, serif">$</span></p></td><td colspan="1" style="padding:1pt .7pt 0pt 0pt;text-align:right;width:79" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:9pt;font-family:Times New Roman, Times, serif">120,083</span></p></td><td colspan="1" style="padding:1pt .7pt 0pt 0pt;width:8" valign="bottom">&#160;</td><td colspan="1" style="width:8">&#160;</td></tr><tr><td colspan="3" style="padding:1pt .7pt 0pt 0pt;text-align:left;width:134;background-color:#cceeff" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:9pt;font-family:Times New Roman, Times, serif">Kathleen L. Goetz*</span></p></td><td colspan="1" style="background-color:#cceeff">&#160;</td><td colspan="1" style="padding:1pt .7pt 0pt 0pt;text-align:right;width:20;background-color:#cceeff" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:9pt;font-family:Times New Roman, Times, serif">$</span></p></td><td colspan="1" style="padding:1pt .7pt 0pt 0pt;text-align:right;width:45;background-color:#cceeff" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:9pt;font-family:Times New Roman, Times, serif">23,979</span></p></td><td colspan="1" style="padding:1pt .7pt 0pt 0pt;width:8;background-color:#cceeff" valign="bottom">&#160;</td><td colspan="1" style="width:8;background-color:#cceeff">&#160;</td><td colspan="1" style="padding:1pt .7pt 0pt 0pt;text-align:right;width:20;background-color:#cceeff" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:9pt;font-family:Times New Roman, Times, serif">$</span></p></td><td colspan="1" style="padding:1pt .7pt 0pt 0pt;text-align:right;width:45;background-color:#cceeff" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:9pt;font-family:Times New Roman, Times, serif">23,979</span></p></td><td colspan="1" style="padding:1pt .7pt 0pt 0pt;width:8;background-color:#cceeff" valign="bottom">&#160;</td><td colspan="1" style="width:8;background-color:#cceeff">&#160;</td><td colspan="1" style="padding:1pt .7pt 0pt 0pt;text-align:right;width:20;background-color:#cceeff" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:9pt;font-family:Times New Roman, Times, serif">$</span></p></td><td colspan="1" style="padding:1pt .7pt 0pt 0pt;text-align:right;width:40;background-color:#cceeff" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:9pt;font-family:Times New Roman, Times, serif">23,979</span></p></td><td colspan="1" style="padding:1pt .7pt 0pt 0pt;width:8;background-color:#cceeff" valign="bottom">&#160;</td><td colspan="1" style="width:8;background-color:#cceeff">&#160;</td><td colspan="1" style="padding:1pt .7pt 0pt 0pt;width:8;background-color:#cceeff" valign="bottom">&#160;</td><td colspan="1" style="padding:1pt .7pt 0pt 0pt;text-align:right;width:77;background-color:#cceeff" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:9pt;font-family:Times New Roman, Times, serif">N/A</span></p></td><td colspan="1" style="padding:1pt .7pt 0pt 0pt;width:8;background-color:#cceeff" valign="bottom">&#160;</td><td colspan="1" style="width:8;background-color:#cceeff">&#160;</td><td colspan="1" style="padding:1pt .7pt 0pt 0pt;width:8;background-color:#cceeff" valign="bottom">&#160;</td><td colspan="1" style="padding:1pt .7pt 0pt 0pt;text-align:right;width:66;background-color:#cceeff" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:9pt;font-family:Times New Roman, Times, serif">N/A</span></p></td><td colspan="1" style="padding:1pt .7pt 0pt 0pt;width:8;background-color:#cceeff" valign="bottom">&#160;</td><td colspan="1" style="width:8;background-color:#cceeff">&#160;</td><td colspan="1" style="padding:1pt .7pt 0pt 0pt;text-align:right;width:20;background-color:#cceeff" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:9pt;font-family:Times New Roman, Times, serif">$</span></p></td><td colspan="1" style="padding:1pt .7pt 0pt 0pt;text-align:right;width:79;background-color:#cceeff" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:9pt;font-family:Times New Roman, Times, serif">95,917</span></p></td><td colspan="1" style="padding:1pt .7pt 0pt 0pt;width:8;background-color:#cceeff" valign="bottom">&#160;</td><td colspan="1" style="width:8;background-color:#cceeff">&#160;</td></tr><tr><td colspan="3" style="padding:1pt .7pt 0pt 0pt;text-align:left;width:134" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:9pt;font-family:Times New Roman, Times, serif">Rakesh K. Jain, Ph.D.</span></p></td><td colspan="1">&#160;</td><td colspan="1" style="padding:1pt .7pt 0pt 0pt;text-align:right;width:20" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:9pt;font-family:Times New Roman, Times, serif">$</span></p></td><td colspan="1" style="padding:1pt .7pt 0pt 0pt;text-align:right;width:45" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:9pt;font-family:Times New Roman, Times, serif">28,104</span></p></td><td colspan="1" style="padding:1pt .7pt 0pt 0pt;width:8" valign="bottom">&#160;</td><td colspan="1" style="width:8">&#160;</td><td colspan="1" style="padding:1pt .7pt 0pt 0pt;text-align:right;width:20" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:9pt;font-family:Times New Roman, Times, serif">$</span></p></td><td colspan="1" style="padding:1pt .7pt 0pt 0pt;text-align:right;width:45" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:9pt;font-family:Times New Roman, Times, serif">28,104</span></p></td><td colspan="1" style="padding:1pt .7pt 0pt 0pt;width:8" valign="bottom">&#160;</td><td colspan="1" style="width:8">&#160;</td><td colspan="1" style="padding:1pt .7pt 0pt 0pt;text-align:right;width:20" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:9pt;font-family:Times New Roman, Times, serif">$</span></p></td><td colspan="1" style="padding:1pt .7pt 0pt 0pt;text-align:right;width:40" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:9pt;font-family:Times New Roman, Times, serif">28,104</span></p></td><td colspan="1" style="padding:1pt .7pt 0pt 0pt;width:8" valign="bottom">&#160;</td><td colspan="1" style="width:8">&#160;</td><td colspan="1" style="padding:1pt .7pt 0pt 0pt;width:8" valign="bottom">&#160;</td><td colspan="1" style="padding:1pt .7pt 0pt 0pt;text-align:right;width:77" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:9pt;font-family:Times New Roman, Times, serif">N/A</span></p></td><td colspan="1" style="padding:1pt .7pt 0pt 0pt;width:8" valign="bottom">&#160;</td><td colspan="1" style="width:8">&#160;</td><td colspan="1" style="padding:1pt .7pt 0pt 0pt;width:8" valign="bottom">&#160;</td><td colspan="1" style="padding:1pt .7pt 0pt 0pt;text-align:right;width:66" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:9pt;font-family:Times New Roman, Times, serif">N/A</span></p></td><td colspan="1" style="padding:1pt .7pt 0pt 0pt;width:8" valign="bottom">&#160;</td><td colspan="1" style="width:8">&#160;</td><td colspan="1" style="padding:1pt .7pt 0pt 0pt;text-align:right;width:20" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:9pt;font-family:Times New Roman, Times, serif">$</span></p></td><td colspan="1" style="padding:1pt .7pt 0pt 0pt;text-align:right;width:79" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:9pt;font-family:Times New Roman, Times, serif">112,417</span></p></td><td colspan="1" style="padding:1pt .7pt 0pt 0pt;width:8" valign="bottom">&#160;</td><td colspan="1" style="width:8">&#160;</td></tr><tr><td colspan="3" style="padding:1pt .7pt 0pt 0pt;text-align:left;width:134;background-color:#cceeff" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:9pt;font-family:Times New Roman, Times, serif">Thomas M. Kent, CPA</span></p></td><td colspan="1" style="background-color:#cceeff">&#160;</td><td colspan="1" style="padding:1pt .7pt 0pt 0pt;text-align:right;width:20;background-color:#cceeff" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:9pt;font-family:Times New Roman, Times, serif">$</span></p></td><td colspan="1" style="padding:1pt .7pt 0pt 0pt;text-align:right;width:45;background-color:#cceeff" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:9pt;font-family:Times New Roman, Times, serif">29,938</span></p></td><td colspan="1" style="padding:1pt .7pt 0pt 0pt;width:8;background-color:#cceeff" valign="bottom">&#160;</td><td colspan="1" style="width:8;background-color:#cceeff">&#160;</td><td colspan="1" style="padding:1pt .7pt 0pt 0pt;text-align:right;width:20;background-color:#cceeff" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:9pt;font-family:Times New Roman, Times, serif">$</span></p></td><td colspan="1" style="padding:1pt .7pt 0pt 0pt;text-align:right;width:45;background-color:#cceeff" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:9pt;font-family:Times New Roman, Times, serif">29,938</span></p></td><td colspan="1" style="padding:1pt .7pt 0pt 0pt;width:8;background-color:#cceeff" valign="bottom">&#160;</td><td colspan="1" style="width:8;background-color:#cceeff">&#160;</td><td colspan="1" style="padding:1pt .7pt 0pt 0pt;text-align:right;width:20;background-color:#cceeff" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:9pt;font-family:Times New Roman, Times, serif">$</span></p></td><td colspan="1" style="padding:1pt .7pt 0pt 0pt;text-align:right;width:40;background-color:#cceeff" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:9pt;font-family:Times New Roman, Times, serif">29,938</span></p></td><td colspan="1" style="padding:1pt .7pt 0pt 0pt;width:8;background-color:#cceeff" valign="bottom">&#160;</td><td colspan="1" style="width:8;background-color:#cceeff">&#160;</td><td colspan="1" style="padding:1pt .7pt 0pt 0pt;width:8;background-color:#cceeff" valign="bottom">&#160;</td><td colspan="1" style="padding:1pt .7pt 0pt 0pt;text-align:right;width:77;background-color:#cceeff" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:9pt;font-family:Times New Roman, Times, serif">N/A</span></p></td><td colspan="1" style="padding:1pt .7pt 0pt 0pt;width:8;background-color:#cceeff" valign="bottom">&#160;</td><td colspan="1" style="width:8;background-color:#cceeff">&#160;</td><td colspan="1" style="padding:1pt .7pt 0pt 0pt;width:8;background-color:#cceeff" valign="bottom">&#160;</td><td colspan="1" style="padding:1pt .7pt 0pt 0pt;text-align:right;width:66;background-color:#cceeff" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:9pt;font-family:Times New Roman, Times, serif">N/A</span></p></td><td colspan="1" style="padding:1pt .7pt 0pt 0pt;width:8;background-color:#cceeff" valign="bottom">&#160;</td><td colspan="1" style="width:8;background-color:#cceeff">&#160;</td><td colspan="1" style="padding:1pt .7pt 0pt 0pt;text-align:right;width:20;background-color:#cceeff" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:9pt;font-family:Times New Roman, Times, serif">$</span></p></td><td colspan="1" style="padding:1pt .7pt 0pt 0pt;text-align:right;width:79;background-color:#cceeff" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:9pt;font-family:Times New Roman, Times, serif">119,750</span></p></td><td colspan="1" style="padding:1pt .7pt 0pt 0pt;width:8;background-color:#cceeff" valign="bottom">&#160;</td><td colspan="1" style="width:8;background-color:#cceeff">&#160;</td></tr><tr><td colspan="3" style="padding:1pt .7pt 0pt 0pt;text-align:left;width:134" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:9pt;font-family:Times New Roman, Times, serif">Oleg M. Pohotsky, MBA, JD**</span></p></td><td colspan="1">&#160;</td><td colspan="1" style="padding:1pt .7pt 0pt 0pt;text-align:right;width:20" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:9pt;font-family:Times New Roman, Times, serif">$</span></p></td><td colspan="1" style="padding:1pt .7pt 0pt 0pt;text-align:right;width:45" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:9pt;font-family:Times New Roman, Times, serif">25,625</span></p></td><td colspan="1" style="padding:1pt .7pt 0pt 0pt;width:8" valign="bottom">&#160;</td><td colspan="1" style="width:8">&#160;</td><td colspan="1" style="padding:1pt .7pt 0pt 0pt;text-align:right;width:20" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:9pt;font-family:Times New Roman, Times, serif">$</span></p></td><td colspan="1" style="padding:1pt .7pt 0pt 0pt;text-align:right;width:45" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:9pt;font-family:Times New Roman, Times, serif">25,625</span></p></td><td colspan="1" style="padding:1pt .7pt 0pt 0pt;width:8" valign="bottom">&#160;</td><td colspan="1" style="width:8">&#160;</td><td colspan="1" style="padding:1pt .7pt 0pt 0pt;text-align:right;width:20" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:9pt;font-family:Times New Roman, Times, serif">$</span></p></td><td colspan="1" style="padding:1pt .7pt 0pt 0pt;text-align:right;width:40" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:9pt;font-family:Times New Roman, Times, serif">25,625</span></p></td><td colspan="1" style="padding:1pt .7pt 0pt 0pt;width:8" valign="bottom">&#160;</td><td colspan="1" style="width:8">&#160;</td><td colspan="1" style="padding:1pt .7pt 0pt 0pt;width:8" valign="bottom">&#160;</td><td colspan="1" style="padding:1pt .7pt 0pt 0pt;text-align:right;width:77" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:9pt;font-family:Times New Roman, Times, serif">N/A</span></p></td><td colspan="1" style="padding:1pt .7pt 0pt 0pt;width:8" valign="bottom">&#160;</td><td colspan="1" style="width:8">&#160;</td><td colspan="1" style="padding:1pt .7pt 0pt 0pt;width:8" valign="bottom">&#160;</td><td colspan="1" style="padding:1pt .7pt 0pt 0pt;text-align:right;width:66" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:9pt;font-family:Times New Roman, Times, serif">N/A</span></p></td><td colspan="1" style="padding:1pt .7pt 0pt 0pt;width:8" valign="bottom">&#160;</td><td colspan="1" style="width:8">&#160;</td><td colspan="1" style="padding:1pt .7pt 0pt 0pt;text-align:right;width:20" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:9pt;font-family:Times New Roman, Times, serif">$</span></p></td><td colspan="1" style="padding:1pt .7pt 0pt 0pt;text-align:right;width:79" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:9pt;font-family:Times New Roman, Times, serif">102,500</span></p></td><td colspan="1" style="padding:1pt .7pt 0pt 0pt;width:8" valign="bottom">&#160;</td><td colspan="1" style="width:8">&#160;</td></tr><tr><td colspan="3" style="padding:1pt .7pt 0pt 0pt;text-align:left;width:134;background-color:#cceeff" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:9pt;font-family:Times New Roman, Times, serif">William S. Reardon*</span></p></td><td colspan="1" style="background-color:#cceeff">&#160;</td><td colspan="1" style="padding:1pt .7pt 0pt 0pt;text-align:right;width:20;background-color:#cceeff" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:9pt;font-family:Times New Roman, Times, serif">$</span></p></td><td colspan="1" style="padding:1pt .7pt 0pt 0pt;text-align:right;width:45;background-color:#cceeff" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:9pt;font-family:Times New Roman, Times, serif">22,396</span></p></td><td colspan="1" style="padding:1pt .7pt 0pt 0pt;width:8;background-color:#cceeff" valign="bottom">&#160;</td><td colspan="1" style="width:8;background-color:#cceeff">&#160;</td><td colspan="1" style="padding:1pt .7pt 0pt 0pt;text-align:right;width:20;background-color:#cceeff" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:9pt;font-family:Times New Roman, Times, serif">$</span></p></td><td colspan="1" style="padding:1pt .7pt 0pt 0pt;text-align:right;width:45;background-color:#cceeff" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:9pt;font-family:Times New Roman, Times, serif">22,396</span></p></td><td colspan="1" style="padding:1pt .7pt 0pt 0pt;width:8;background-color:#cceeff" valign="bottom">&#160;</td><td colspan="1" style="width:8;background-color:#cceeff">&#160;</td><td colspan="1" style="padding:1pt .7pt 0pt 0pt;text-align:right;width:20;background-color:#cceeff" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:9pt;font-family:Times New Roman, Times, serif">$</span></p></td><td colspan="1" style="padding:1pt .7pt 0pt 0pt;text-align:right;width:40;background-color:#cceeff" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:9pt;font-family:Times New Roman, Times, serif">22,396</span></p></td><td colspan="1" style="padding:1pt .7pt 0pt 0pt;width:8;background-color:#cceeff" valign="bottom">&#160;</td><td colspan="1" style="width:8;background-color:#cceeff">&#160;</td><td colspan="1" style="padding:1pt .7pt 0pt 0pt;width:8;background-color:#cceeff" valign="bottom">&#160;</td><td colspan="1" style="padding:1pt .7pt 0pt 0pt;text-align:right;width:77;background-color:#cceeff" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:9pt;font-family:Times New Roman, Times, serif">N/A</span></p></td><td colspan="1" style="padding:1pt .7pt 0pt 0pt;width:8;background-color:#cceeff" valign="bottom">&#160;</td><td colspan="1" style="width:8;background-color:#cceeff">&#160;</td><td colspan="1" style="padding:1pt .7pt 0pt 0pt;width:8;background-color:#cceeff" valign="bottom">&#160;</td><td colspan="1" style="padding:1pt .7pt 0pt 0pt;text-align:right;width:66;background-color:#cceeff" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:9pt;font-family:Times New Roman, Times, serif">N/A</span></p></td><td colspan="1" style="padding:1pt .7pt 0pt 0pt;width:8;background-color:#cceeff" valign="bottom">&#160;</td><td colspan="1" style="width:8;background-color:#cceeff">&#160;</td><td colspan="1" style="padding:1pt .7pt 0pt 0pt;text-align:right;width:20;background-color:#cceeff" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:9pt;font-family:Times New Roman, Times, serif">$</span></p></td><td colspan="1" style="padding:1pt .7pt 0pt 0pt;text-align:right;width:79;background-color:#cceeff" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:9pt;font-family:Times New Roman, Times, serif">89,583</span></p></td><td colspan="1" style="padding:1pt .7pt 0pt 0pt;width:8;background-color:#cceeff" valign="bottom">&#160;</td><td colspan="1" style="width:8;background-color:#cceeff">&#160;</td></tr><tr><td colspan="3" style="padding:1pt .7pt 0pt 0pt;text-align:left;width:134" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:9pt;font-family:Times New Roman, Times, serif">W. Mark Watson*</span></p></td><td colspan="1">&#160;</td><td colspan="1" style="padding:1pt .7pt 0pt 0pt;text-align:right;width:20" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:9pt;font-family:Times New Roman, Times, serif">$</span></p></td><td colspan="1" style="padding:1pt .7pt 0pt 0pt;text-align:right;width:45" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:9pt;font-family:Times New Roman, Times, serif">11,083</span></p></td><td colspan="1" style="padding:1pt .7pt 0pt 0pt;width:8" valign="bottom">&#160;</td><td colspan="1" style="width:8">&#160;</td><td colspan="1" style="padding:1pt .7pt 0pt 0pt;text-align:right;width:20" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:9pt;font-family:Times New Roman, Times, serif">$</span></p></td><td colspan="1" style="padding:1pt .7pt 0pt 0pt;text-align:right;width:45" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:9pt;font-family:Times New Roman, Times, serif">11,083</span></p></td><td colspan="1" style="padding:1pt .7pt 0pt 0pt;width:8" valign="bottom">&#160;</td><td colspan="1" style="width:8">&#160;</td><td colspan="1" style="padding:1pt .7pt 0pt 0pt;text-align:right;width:20" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:9pt;font-family:Times New Roman, Times, serif">$</span></p></td><td colspan="1" style="padding:1pt .7pt 0pt 0pt;text-align:right;width:40" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:9pt;font-family:Times New Roman, Times, serif">11,083</span></p></td><td colspan="1" style="padding:1pt .7pt 0pt 0pt;width:8" valign="bottom">&#160;</td><td colspan="1" style="width:8">&#160;</td><td colspan="1" style="padding:1pt .7pt 0pt 0pt;width:8" valign="bottom">&#160;</td><td colspan="1" style="padding:1pt .7pt 0pt 0pt;text-align:right;width:77" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:9pt;font-family:Times New Roman, Times, serif">N/A</span></p></td><td colspan="1" style="padding:1pt .7pt 0pt 0pt;width:8" valign="bottom">&#160;</td><td colspan="1" style="width:8">&#160;</td><td colspan="1" style="padding:1pt .7pt 0pt 0pt;width:8" valign="bottom">&#160;</td><td colspan="1" style="padding:1pt .7pt 0pt 0pt;text-align:right;width:66" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:9pt;font-family:Times New Roman, Times, serif">N/A</span></p></td><td colspan="1" style="padding:1pt .7pt 0pt 0pt;width:8" valign="bottom">&#160;</td><td colspan="1" style="width:8">&#160;</td><td colspan="1" style="padding:1pt .7pt 0pt 0pt;text-align:right;width:20" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:9pt;font-family:Times New Roman, Times, serif">$</span></p></td><td colspan="1" style="padding:1pt .7pt 0pt 0pt;text-align:right;width:79" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:9pt;font-family:Times New Roman, Times, serif">44,333</span></p></td><td colspan="1" style="padding:1pt .7pt 0pt 0pt;width:8" valign="bottom">&#160;</td><td colspan="1" style="width:8">&#160;</td></tr><tr><td colspan="27" style="padding:4pt .7pt 0pt 0pt;width:670;background-color:#cceeff" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:9pt;font-family:Times New Roman, Times, serif"><strong>Interested Trustee</strong></span></p></td><td colspan="1" style="background-color:#cceeff">&#160;</td></tr><tr><td colspan="3" style="padding:1pt .7pt 0pt 0pt;text-align:left;width:134" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:9pt;font-family:Times New Roman, Times, serif">Daniel R. Omstead, Ph.D.</span></p></td><td colspan="1">&#160;</td><td colspan="1" style="padding:1pt .7pt 0pt 0pt;text-align:right;width:20" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:9pt;font-family:Times New Roman, Times, serif">$</span></p></td><td colspan="1" style="padding:1pt .7pt 0pt 0pt;text-align:right;width:45" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:9pt;font-family:Times New Roman, Times, serif">0</span></p></td><td colspan="1" style="padding:1pt .7pt 0pt 0pt;width:8" valign="bottom">&#160;</td><td colspan="1" style="width:8">&#160;</td><td colspan="1" style="padding:1pt .7pt 0pt 0pt;text-align:right;width:20" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:9pt;font-family:Times New Roman, Times, serif">$</span></p></td><td colspan="1" style="padding:1pt .7pt 0pt 0pt;text-align:right;width:45" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:9pt;font-family:Times New Roman, Times, serif">0</span></p></td><td colspan="1" style="padding:1pt .7pt 0pt 0pt;width:8" valign="bottom">&#160;</td><td colspan="1" style="width:8">&#160;</td><td colspan="1" style="padding:1pt .7pt 0pt 0pt;text-align:right;width:20" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:9pt;font-family:Times New Roman, Times, serif">$</span></p></td><td colspan="1" style="padding:1pt .7pt 0pt 0pt;text-align:right;width:40" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:9pt;font-family:Times New Roman, Times, serif">0</span></p></td><td colspan="1" style="padding:1pt .7pt 0pt 0pt;width:8" valign="bottom">&#160;</td><td colspan="1" style="width:8">&#160;</td><td colspan="1" style="padding:1pt .7pt 0pt 0pt;width:8" valign="bottom">&#160;</td><td colspan="1" style="padding:1pt .7pt 0pt 0pt;text-align:right;width:77" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:9pt;font-family:Times New Roman, Times, serif">N/A</span></p></td><td colspan="1" style="padding:1pt .7pt 0pt 0pt;width:8" valign="bottom">&#160;</td><td colspan="1" style="width:8">&#160;</td><td colspan="1" style="padding:1pt .7pt 0pt 0pt;width:8" valign="bottom">&#160;</td><td colspan="1" style="padding:1pt .7pt 0pt 0pt;text-align:right;width:66" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:9pt;font-family:Times New Roman, Times, serif">N/A</span></p></td><td colspan="1" style="padding:1pt .7pt 0pt 0pt;width:8" valign="bottom">&#160;</td><td colspan="1" style="width:8">&#160;</td><td colspan="1" style="padding:1pt .7pt 0pt 0pt;text-align:right;width:20" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:9pt;font-family:Times New Roman, Times, serif">$</span></p></td><td colspan="1" style="padding:1pt .7pt 0pt 0pt;text-align:right;width:79" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:9pt;font-family:Times New Roman, Times, serif">0</span></p></td><td colspan="1" style="padding:1pt .7pt 0pt 0pt;width:8" valign="bottom">&#160;</td><td colspan="1" style="width:8">&#160;</td></tr><tr><td colspan="27" style="padding:4pt .7pt 0pt 0pt;width:670;background-color:#cceeff" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:9pt;font-family:Times New Roman, Times, serif"><strong>Executive Officer</strong></span></p></td><td colspan="1" style="background-color:#cceeff">&#160;</td></tr><tr><td colspan="3" style="padding:1pt .7pt 0pt 0pt;text-align:left;width:134" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:9pt;font-family:Times New Roman, Times, serif">Laura Woodward</span></p></td><td colspan="1">&#160;</td><td colspan="1" style="padding:1pt .7pt 0pt 0pt;text-align:right;width:20" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:9pt;font-family:Times New Roman, Times, serif">$</span></p></td><td colspan="1" style="padding:1pt .7pt 0pt 0pt;text-align:right;width:45" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:9pt;font-family:Times New Roman, Times, serif">139,755</span></p></td><td colspan="1" style="padding:1pt .7pt 0pt 0pt;width:8" valign="bottom">&#160;</td><td colspan="1" style="width:8">&#160;</td><td colspan="1" style="padding:1pt .7pt 0pt 0pt;text-align:right;width:20" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:9pt;font-family:Times New Roman, Times, serif">$</span></p></td><td colspan="1" style="padding:1pt .7pt 0pt 0pt;text-align:right;width:45" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:9pt;font-family:Times New Roman, Times, serif">111,837</span></p></td><td colspan="1" style="padding:1pt .7pt 0pt 0pt;width:8" valign="bottom">&#160;</td><td colspan="1" style="width:8">&#160;</td><td colspan="1" style="padding:1pt .7pt 0pt 0pt;text-align:right;width:20" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:9pt;font-family:Times New Roman, Times, serif">$</span></p></td><td colspan="1" style="padding:1pt .7pt 0pt 0pt;text-align:right;width:40" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:9pt;font-family:Times New Roman, Times, serif">54,976</span></p></td><td colspan="1" style="padding:1pt .7pt 0pt 0pt;width:8" valign="bottom">&#160;</td><td colspan="1" style="width:8">&#160;</td><td colspan="1" style="padding:1pt .7pt 0pt 0pt;width:8" valign="bottom">&#160;</td><td colspan="1" style="padding:1pt .7pt 0pt 0pt;text-align:right;width:77" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:9pt;font-family:Times New Roman, Times, serif">N/A</span></p></td><td colspan="1" style="padding:1pt .7pt 0pt 0pt;width:8" valign="bottom">&#160;</td><td colspan="1" style="width:8">&#160;</td><td colspan="1" style="padding:1pt .7pt 0pt 0pt;width:8" valign="bottom">&#160;</td><td colspan="1" style="padding:1pt .7pt 0pt 0pt;text-align:right;width:66" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:9pt;font-family:Times New Roman, Times, serif">N/A</span></p></td><td colspan="1" style="padding:1pt .7pt 0pt 0pt;width:8" valign="bottom">&#160;</td><td colspan="1" style="width:8">&#160;</td><td colspan="1" style="padding:1pt .7pt 0pt 0pt;width:20" valign="bottom">&#160;</td><td colspan="1" style="padding:1pt .7pt 0pt 0pt;text-align:right;width:79" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:9pt;font-family:Times New Roman, Times, serif">N/A</span></p></td><td colspan="1" style="padding:1pt .7pt 0pt 0pt;width:8" valign="bottom">&#160;</td><td colspan="1" style="width:8">&#160;</td></tr></table><p style="margin:6pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Times New Roman, Times, serif">* Kathleen L. Goetz was appointed as a Trustee effective December 9, 2021. W. Mark Watson was appointed as a Trustee effective June 9, 2022. Mr. Reardon is not standing for election at the Annual Meeting and has retired as a Trustee effective June 9, 2022.</span></p><p style="margin:2pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Times New Roman, Times, serif">** Mr. Pohotsky served as an Independent Trustee until he passed away on July 13, 2022.</span></p></div><p style="text-align:center"><br /><span style="font-size:13px;font-family:Times New Roman PS, Times New Roman, Times">10</span></p><hr style="height:2px;text-align:center;width:100%;background-color:gray;page-break-after:always" /></div><div style="margin:8pt 0pt 8pt 0pt"><p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:10pt;font-family:Times New Roman, Times, serif"><strong>Executive Officers</strong></span></p><p style="margin:6pt 0pt 0pt 0pt"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">Set forth below is information for at least the last five years with respect to the executive officers of each Fund who do not also serve as Trustees. Each officer has been elected by the Board of each Fund and serves at the pleasure of the Board.</span></p><p style="margin:6pt 0pt 0pt 0pt"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">Laura Woodward, CPA (54), 100 Federal Street, 19th Floor, Boston MA 02110: Chief Compliance Officer of HQH, HQL and Tekla Capital Management LLC (since 2009), of THQ (since 2014) and of THW (since 2015); Secretary and Treasurer, HQH and HQL (since 2009), of THQ (since 2014) and of THW (since 2015); Senior Manager, PricewaterhouseCoopers LLP (prior to 2009).</span></p><p style="margin:6pt 0pt 0pt 0pt"><span style="font-size:10pt;font-family:Times New Roman, Times, serif"><strong>Required Vote</strong></span></p><p style="margin:6pt 0pt 0pt 0pt"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">Each Fund's Declaration of Trust states that the Trustees shall be elected by a plurality of each Fund's shares voting at the Annual Meeting. </span><span style="font-size:10pt;font-family:Times New Roman, Times, serif"><strong>The Trustees recommend a vote FOR all nominees.</strong></span><span style="font-size:10pt;font-family:Times New Roman, Times, serif"> Plurality voting means the nominee for each seat receiving the greatest number of votes will be elected.</span></p><p style="margin:12pt 0pt 0pt 0pt;text-align:center"><span style="font-size:10pt;font-family:Times New Roman, Times, serif"><strong>INFORMATION PERTAINING TO THE ADVISER</strong></span></p><p style="margin:6pt 0pt 0pt 0pt"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">The Adviser is a limited liability company organized under the laws of Delaware. Under each Fund's Investment Advisory Agreement, the Adviser is responsible for the management of the Fund's assets, subject to the supervision of the Board. The Adviser manages the investments of each Fund in accordance with its investment objective and policies. The Adviser is also obligated to supervise and perform certain administrative and management services and is obligated to provide the office space, facilities, equipment and personnel necessary to perform its duties. Except for a portion of the salary of each Funds' Chief Compliance Officer, the salaries of all officers of each Fund and all personnel of each Fund or of the Adviser performing services relating to research, statistical or investment activities, and of all Trustees who are "interested persons" of the Fund or of the Adviser (as defined in the 1940 Act), are paid by the Adviser. The Adviser is located at 100 Federal Street, 19th Floor, Boston, MA 02110.</span></p><p style="margin:6pt 0pt 0pt 0pt"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">Daniel R. Omstead, Ph.D. serves as President and Chief Executive Officer of the Adviser. The address for Dr. Omstead is c/o Tekla Capital Management LLC at 100 Federal Street, 19th Floor, Boston, MA 02110.</span></p><p style="margin:12pt 0pt 0pt 0pt;text-align:center"><span style="font-size:10pt;font-family:Times New Roman, Times, serif"><strong>REPORT OF THE AUDIT COMMITTEE OF EACH FUND</strong></span></p><p style="margin:6pt 0pt 0pt 0pt"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">Each Fund's Audit Committee reviewed and discussed the Fund's audited financial statements with management for the Fund's fiscal year ended September 30, 2022, and discussed with the Fund's independent registered public accountants, Deloitte &#38; Touche LLP, the matters required to be discussed by the applicable requirements of the Public Company Accounting Oversight Board ("PCAOB") and the SEC. Each Fund's Audit Committee received written disclosures and the letter from Deloitte &#38; Touche LLP required by applicable requirements of the PCAOB Ethics and Independence Rule 3526 regarding Deloitte &#38; Touche's communications with the Audit Committee concerning independence and discussed with Deloitte &#38; Touche LLP its independence. Based on its review and discussions with management and Deloitte &#38; Touche LLP, the Fund's Audit Committee recommended to the Board that the Fund's audited financial statements for the Fund's fiscal year ended September 30, 2022, be included in the Fund's Annual Report filed with the SEC.</span></p></div><p style="text-align:center"><br /><span style="font-family:Times New Roman PS, Times New Roman, Times;font-size:13px">11</span></p><hr style="height:2px;text-align:center;width:100%;background-color:gray;page-break-after:always" /><div style="margin:8pt 0pt 8pt 0pt"><p style="margin:0pt 0pt 0pt 0pt;text-align:center"><span style="font-size:10pt;font-family:Times New Roman, Times, serif"><strong>SUBMITTED BY THE AUDIT COMMITTEE OF EACH FUND</strong></span></p><p style="margin:6pt 0pt 0pt 0pt;text-align:center"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">Thomas M. Kent, CPA<br />Kathleen L. Goetz<br />W. Mark Watson</span></p><p style="margin:12pt 0pt 0pt 0pt;text-align:center"><span style="font-size:10pt;font-family:Times New Roman, Times, serif"><strong>Proposal 2<br />RATIFICATION OR REJECTION OF SELECTION OF INDEPENDENT<br />REGISTERED PUBLIC ACCOUNTANTS</strong></span></p><p style="margin:6pt 0pt 0pt 0pt"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">Each Fund's Audit Committee has approved the appointment of Deloitte &#38; Touche LLP as the independent registered public accountants for the fiscal year ending September 30, 2023, and the Board of each Fund, including the Independent Trustees, subsequently unanimously approved the appointment.</span></p><p style="margin:6pt 0pt 0pt 0pt"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">Services to be performed by Deloitte &#38; Touche LLP for each Fund will consist of the examination of the annual financial statements of the Fund, consultation on financial, accounting and reporting matters, review and consultation regarding various filings with the SEC and attendance at some meetings of the Board. Deloitte &#38; Touche LLP also will perform non-audit services consisting of review of income tax returns of each Fund.</span></p><p style="margin:6pt 0pt 0pt 0pt"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">A representative of Deloitte &#38; Touche LLP is expected to participate in the Joint Annual Meeting and to be available for questioning and have an opportunity to make a statement.</span></p><p style="margin:6pt 0pt 0pt 0pt"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">The following tables set forth the aggregate fees billed for professional services rendered by Deloitte &#38; Touche LLP to each Fund during each Fund's two most recent fiscal years:</span></p><table border="0" cellpadding="0" cellspacing="0" width="100%"><tr><td colspan="3" style="padding:6pt .7pt 0pt 0pt;border:none;border-bottom:solid windowtext 1pt;text-align:left;width:41" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Times New Roman, Times, serif"><strong>Fund</strong></span></p></td><td colspan="1">&#160;</td><td colspan="3" style="padding:6pt .7pt 0pt 0pt;border:none;border-bottom:solid windowtext 1pt;text-align:center;width:70" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Times New Roman, Times, serif"><strong>Fiscal year</strong></span></p></td><td colspan="1">&#160;</td><td colspan="3" style="padding:6pt .7pt 0pt 0pt;border:none;border-bottom:solid windowtext 1pt;text-align:center;width:84" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Times New Roman, Times, serif"><strong>Audit Fees</strong></span></p></td><td colspan="1">&#160;</td><td colspan="3" style="padding:6pt .7pt 0pt 0pt;border:none;border-bottom:solid windowtext 1pt;text-align:center;width:114" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Times New Roman, Times, serif"><strong>Audit-Related Fees</strong></span></p></td><td colspan="1">&#160;</td><td colspan="3" style="padding:6pt .7pt 0pt 0pt;border:none;border-bottom:solid windowtext 1pt;text-align:center;width:75" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Times New Roman, Times, serif"><strong>Tax Fees</strong></span></p></td><td colspan="1">&#160;</td><td colspan="3" style="padding:6pt .7pt 0pt 0pt;border:none;border-bottom:solid windowtext 1pt;text-align:center;width:97" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Times New Roman, Times, serif"><strong>All Other Fees</strong></span></p></td><td colspan="1">&#160;</td></tr><tr><td colspan="3" style="padding:4pt .7pt 0pt 0pt;text-align:left;width:41;background-color:#cceeff" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">HQH</span></p></td><td colspan="1" style="background-color:#cceeff">&#160;</td><td colspan="1" style="padding:4pt .7pt 0pt 0pt;width:8;background-color:#cceeff" valign="bottom">&#160;</td><td colspan="1" style="padding:4pt .7pt 0pt 0pt;text-align:right;width:54;background-color:#cceeff" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">2022</span></p></td><td colspan="1" style="padding:4pt .7pt 0pt 0pt;width:8;background-color:#cceeff" valign="bottom">&#160;</td><td colspan="1" style="width:8;background-color:#cceeff">&#160;</td><td colspan="1" style="padding:4pt .7pt 0pt 0pt;text-align:right;width:21;background-color:#cceeff" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">$</span></p></td><td colspan="1" style="padding:4pt .7pt 0pt 0pt;text-align:right;width:55;background-color:#cceeff" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">114,230</span></p></td><td colspan="1" style="padding:4pt .7pt 0pt 0pt;width:8;background-color:#cceeff" valign="bottom">&#160;</td><td colspan="1" style="width:8;background-color:#cceeff">&#160;</td><td colspan="1" style="padding:4pt .7pt 0pt 0pt;text-align:right;width:21;background-color:#cceeff" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">$</span></p></td><td colspan="1" style="padding:4pt .7pt 0pt 0pt;text-align:right;width:85;background-color:#cceeff" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">0</span></p></td><td colspan="1" style="padding:4pt .7pt 0pt 0pt;width:8;background-color:#cceeff" valign="bottom">&#160;</td><td colspan="1" style="width:8;background-color:#cceeff">&#160;</td><td colspan="1" style="padding:4pt .7pt 0pt 0pt;text-align:right;width:21;background-color:#cceeff" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">$</span></p></td><td colspan="1" style="padding:4pt .7pt 0pt 0pt;text-align:right;width:46;background-color:#cceeff" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">6,670</span></p></td><td colspan="1" style="padding:4pt .7pt 0pt 0pt;width:8;background-color:#cceeff" valign="bottom">&#160;</td><td colspan="1" style="width:8;background-color:#cceeff">&#160;</td><td colspan="1" style="padding:4pt .7pt 0pt 0pt;text-align:right;width:21;background-color:#cceeff" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">$</span></p></td><td colspan="1" style="padding:4pt .7pt 0pt 0pt;text-align:right;width:68;background-color:#cceeff" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">0</span></p></td><td colspan="1" style="padding:4pt .7pt 0pt 0pt;width:8;background-color:#cceeff" valign="bottom">&#160;</td><td colspan="1" style="width:8;background-color:#cceeff">&#160;</td></tr><tr><td colspan="3" style="padding:0pt .7pt 0pt 0pt;width:41" valign="bottom">&#160;</td><td colspan="1">&#160;</td><td colspan="1" style="padding:0pt .7pt 0pt 0pt;width:8" valign="bottom">&#160;</td><td colspan="1" style="padding:0pt .7pt 0pt 0pt;text-align:right;width:54" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">2021</span></p></td><td colspan="1" style="padding:0pt .7pt 0pt 0pt;width:8" valign="bottom">&#160;</td><td colspan="1" style="width:8">&#160;</td><td colspan="1" style="padding:0pt .7pt 0pt 0pt;text-align:right;width:21" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">$</span></p></td><td colspan="1" style="padding:0pt .7pt 0pt 0pt;text-align:right;width:55" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">109,150</span></p></td><td colspan="1" style="padding:0pt .7pt 0pt 0pt;width:8" valign="bottom">&#160;</td><td colspan="1" style="width:8">&#160;</td><td colspan="1" style="padding:0pt .7pt 0pt 0pt;text-align:right;width:21" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">$</span></p></td><td colspan="1" style="padding:0pt .7pt 0pt 0pt;text-align:right;width:85" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">0</span></p></td><td colspan="1" style="padding:0pt .7pt 0pt 0pt;width:8" valign="bottom">&#160;</td><td colspan="1" style="width:8">&#160;</td><td colspan="1" style="padding:0pt .7pt 0pt 0pt;text-align:right;width:21" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">$</span></p></td><td colspan="1" style="padding:0pt .7pt 0pt 0pt;text-align:right;width:46" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">6,180</span></p></td><td colspan="1" style="padding:0pt .7pt 0pt 0pt;width:8" valign="bottom">&#160;</td><td colspan="1" style="width:8">&#160;</td><td colspan="1" style="padding:0pt .7pt 0pt 0pt;text-align:right;width:21" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">$</span></p></td><td colspan="1" style="padding:0pt .7pt 0pt 0pt;text-align:right;width:68" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">0</span></p></td><td colspan="1" style="padding:0pt .7pt 0pt 0pt;width:8" valign="bottom">&#160;</td><td colspan="1" style="width:8">&#160;</td></tr><tr><td colspan="3" style="padding:4pt .7pt 0pt 0pt;text-align:left;width:41;background-color:#cceeff" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">THQ</span></p></td><td colspan="1" style="background-color:#cceeff">&#160;</td><td colspan="1" style="padding:4pt .7pt 0pt 0pt;width:8;background-color:#cceeff" valign="bottom">&#160;</td><td colspan="1" style="padding:4pt .7pt 0pt 0pt;text-align:right;width:54;background-color:#cceeff" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">2022</span></p></td><td colspan="1" style="padding:4pt .7pt 0pt 0pt;width:8;background-color:#cceeff" valign="bottom">&#160;</td><td colspan="1" style="width:8;background-color:#cceeff">&#160;</td><td colspan="1" style="padding:4pt .7pt 0pt 0pt;text-align:right;width:21;background-color:#cceeff" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">$</span></p></td><td colspan="1" style="padding:4pt .7pt 0pt 0pt;text-align:right;width:55;background-color:#cceeff" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">72,930</span></p></td><td colspan="1" style="padding:4pt .7pt 0pt 0pt;width:8;background-color:#cceeff" valign="bottom">&#160;</td><td colspan="1" style="width:8;background-color:#cceeff">&#160;</td><td colspan="1" style="padding:4pt .7pt 0pt 0pt;text-align:right;width:21;background-color:#cceeff" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">$</span></p></td><td colspan="1" style="padding:4pt .7pt 0pt 0pt;text-align:right;width:85;background-color:#cceeff" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">0</span></p></td><td colspan="1" style="padding:4pt .7pt 0pt 0pt;width:8;background-color:#cceeff" valign="bottom">&#160;</td><td colspan="1" style="width:8;background-color:#cceeff">&#160;</td><td colspan="1" style="padding:4pt .7pt 0pt 0pt;text-align:right;width:21;background-color:#cceeff" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">$</span></p></td><td colspan="1" style="padding:4pt .7pt 0pt 0pt;text-align:right;width:46;background-color:#cceeff" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">6,670</span></p></td><td colspan="1" style="padding:4pt .7pt 0pt 0pt;width:8;background-color:#cceeff" valign="bottom">&#160;</td><td colspan="1" style="width:8;background-color:#cceeff">&#160;</td><td colspan="1" style="padding:4pt .7pt 0pt 0pt;text-align:right;width:21;background-color:#cceeff" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">$</span></p></td><td colspan="1" style="padding:4pt .7pt 0pt 0pt;text-align:right;width:68;background-color:#cceeff" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">0</span></p></td><td colspan="1" style="padding:4pt .7pt 0pt 0pt;width:8;background-color:#cceeff" valign="bottom">&#160;</td><td colspan="1" style="width:8;background-color:#cceeff">&#160;</td></tr><tr><td colspan="3" style="padding:0pt .7pt 0pt 0pt;width:41" valign="bottom">&#160;</td><td colspan="1">&#160;</td><td colspan="1" style="padding:0pt .7pt 0pt 0pt;width:8" valign="bottom">&#160;</td><td colspan="1" style="padding:0pt .7pt 0pt 0pt;text-align:right;width:54" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">2021</span></p></td><td colspan="1" style="padding:0pt .7pt 0pt 0pt;width:8" valign="bottom">&#160;</td><td colspan="1" style="width:8">&#160;</td><td colspan="1" style="padding:0pt .7pt 0pt 0pt;text-align:right;width:21" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">$</span></p></td><td colspan="1" style="padding:0pt .7pt 0pt 0pt;text-align:right;width:55" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">70,030</span></p></td><td colspan="1" style="padding:0pt .7pt 0pt 0pt;width:8" valign="bottom">&#160;</td><td colspan="1" style="width:8">&#160;</td><td colspan="1" style="padding:0pt .7pt 0pt 0pt;text-align:right;width:21" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">$</span></p></td><td colspan="1" style="padding:0pt .7pt 0pt 0pt;text-align:right;width:85" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">0</span></p></td><td colspan="1" style="padding:0pt .7pt 0pt 0pt;width:8" valign="bottom">&#160;</td><td colspan="1" style="width:8">&#160;</td><td colspan="1" style="padding:0pt .7pt 0pt 0pt;text-align:right;width:21" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">$</span></p></td><td colspan="1" style="padding:0pt .7pt 0pt 0pt;text-align:right;width:46" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">6,180</span></p></td><td colspan="1" style="padding:0pt .7pt 0pt 0pt;width:8" valign="bottom">&#160;</td><td colspan="1" style="width:8">&#160;</td><td colspan="1" style="padding:0pt .7pt 0pt 0pt;text-align:right;width:21" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">$</span></p></td><td colspan="1" style="padding:0pt .7pt 0pt 0pt;text-align:right;width:68" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">0</span></p></td><td colspan="1" style="padding:0pt .7pt 0pt 0pt;width:8" valign="bottom">&#160;</td><td colspan="1" style="width:8">&#160;</td></tr><tr><td colspan="3" style="padding:4pt .7pt 0pt 0pt;text-align:left;width:41;background-color:#cceeff" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">THW</span></p></td><td colspan="1" style="background-color:#cceeff">&#160;</td><td colspan="1" style="padding:4pt .7pt 0pt 0pt;width:8;background-color:#cceeff" valign="bottom">&#160;</td><td colspan="1" style="padding:4pt .7pt 0pt 0pt;text-align:right;width:54;background-color:#cceeff" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">2022</span></p></td><td colspan="1" style="padding:4pt .7pt 0pt 0pt;width:8;background-color:#cceeff" valign="bottom">&#160;</td><td colspan="1" style="width:8;background-color:#cceeff">&#160;</td><td colspan="1" style="padding:4pt .7pt 0pt 0pt;text-align:right;width:21;background-color:#cceeff" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">$</span></p></td><td colspan="1" style="padding:4pt .7pt 0pt 0pt;text-align:right;width:55;background-color:#cceeff" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">72,930</span></p></td><td colspan="1" style="padding:4pt .7pt 0pt 0pt;width:8;background-color:#cceeff" valign="bottom">&#160;</td><td colspan="1" style="width:8;background-color:#cceeff">&#160;</td><td colspan="1" style="padding:4pt .7pt 0pt 0pt;text-align:right;width:21;background-color:#cceeff" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">$</span></p></td><td colspan="1" style="padding:4pt .7pt 0pt 0pt;text-align:right;width:85;background-color:#cceeff" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">0</span></p></td><td colspan="1" style="padding:4pt .7pt 0pt 0pt;width:8;background-color:#cceeff" valign="bottom">&#160;</td><td colspan="1" style="width:8;background-color:#cceeff">&#160;</td><td colspan="1" style="padding:4pt .7pt 0pt 0pt;text-align:right;width:21;background-color:#cceeff" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">$</span></p></td><td colspan="1" style="padding:4pt .7pt 0pt 0pt;text-align:right;width:46;background-color:#cceeff" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">14,170</span></p></td><td colspan="1" style="padding:4pt .7pt 0pt 0pt;width:8;background-color:#cceeff" valign="bottom">&#160;</td><td colspan="1" style="width:8;background-color:#cceeff">&#160;</td><td colspan="1" style="padding:4pt .7pt 0pt 0pt;text-align:right;width:21;background-color:#cceeff" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">$</span></p></td><td colspan="1" style="padding:4pt .7pt 0pt 0pt;text-align:right;width:68;background-color:#cceeff" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">0</span></p></td><td colspan="1" style="padding:4pt .7pt 0pt 0pt;width:8;background-color:#cceeff" valign="bottom">&#160;</td><td colspan="1" style="width:8;background-color:#cceeff">&#160;</td></tr><tr><td colspan="3" style="padding:0pt .7pt 0pt 0pt;width:41" valign="bottom">&#160;</td><td colspan="1">&#160;</td><td colspan="1" style="padding:0pt .7pt 0pt 0pt;width:8" valign="bottom">&#160;</td><td colspan="1" style="padding:0pt .7pt 0pt 0pt;text-align:right;width:54" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">2021</span></p></td><td colspan="1" style="padding:0pt .7pt 0pt 0pt;width:8" valign="bottom">&#160;</td><td colspan="1" style="width:8">&#160;</td><td colspan="1" style="padding:0pt .7pt 0pt 0pt;text-align:right;width:21" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">$</span></p></td><td colspan="1" style="padding:0pt .7pt 0pt 0pt;text-align:right;width:55" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">70,030</span></p></td><td colspan="1" style="padding:0pt .7pt 0pt 0pt;width:8" valign="bottom">&#160;</td><td colspan="1" style="width:8">&#160;</td><td colspan="1" style="padding:0pt .7pt 0pt 0pt;text-align:right;width:21" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">$</span></p></td><td colspan="1" style="padding:0pt .7pt 0pt 0pt;text-align:right;width:85" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">0</span></p></td><td colspan="1" style="padding:0pt .7pt 0pt 0pt;width:8" valign="bottom">&#160;</td><td colspan="1" style="width:8">&#160;</td><td colspan="1" style="padding:0pt .7pt 0pt 0pt;text-align:right;width:21" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">$</span></p></td><td colspan="1" style="padding:0pt .7pt 0pt 0pt;text-align:right;width:46" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">11,955</span></p></td><td colspan="1" style="padding:0pt .7pt 0pt 0pt;width:8" valign="bottom">&#160;</td><td colspan="1" style="width:8">&#160;</td><td colspan="1" style="padding:0pt .7pt 0pt 0pt;text-align:right;width:21" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">$</span></p></td><td colspan="1" style="padding:0pt .7pt 0pt 0pt;text-align:right;width:68" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">0</span></p></td><td colspan="1" style="padding:0pt .7pt 0pt 0pt;width:8" valign="bottom">&#160;</td><td colspan="1" style="width:8">&#160;</td></tr></table><p style="margin:6pt 0pt 0pt 0pt"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">All of the services described in the table above were approved by each Audit Committee pursuant to its pre-approval policies and procedures (the "Pre-Approval Policies and Procedures") which are summarized below to the extent that such services were required to be pre-approved by each Audit Committee.</span></p><p style="margin:6pt 0pt 0pt 0pt"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">The aggregate non-audit fees billed by Deloitte &#38; Touche LLP for services rendered to each Fund and to the Adviser, or an affiliate thereof that provides ongoing services to each Fund, amounted to $6,670, $6,670 and $14,170 for the fiscal year ended September 30, 2022 for HQH, THQ and THW, respectively, and to $6,180, $6,180 and $11,955 for the fiscal year ended September 30, 2021 for HQH, THQ and THW, respectively.</span></p><p style="margin:6pt 0pt 0pt 0pt"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">Each Fund's Audit Committee has adopted Pre-Approval Policies and Procedures pursuant to which the Committee pre-approves all audit and non-audit services provided by the Fund's independent auditor (the "Auditor") and any non-audit services provided by the Auditor to the Fund's investment adviser and service affiliates ("Service Affiliates") during the period of the Auditor's engagement to </span></p></div><p style="text-align:center"><br /><span style="font-family:Times New Roman PS, Times New Roman, Times;font-size:13px">12</span></p><hr style="height:2px;text-align:center;width:100%;background-color:gray;page-break-after:always" /><div style="margin:8pt 0pt 8pt 0pt"><p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">provide audit services to the Fund, if those services directly impact the Fund's operations and financial reporting. Audit services include those typically associated with the annual audit such as evaluation of internal controls. Non-Audit services include certain services that are audit-related, such as consultations regarding financial accounting and reporting standards and tax services. Certain services may not be provided by the Auditor to the Fund's or the Fund's Service Affiliates without jeopardizing the Auditor's independence. These services are deemed prohibited services and include certain management functions; human resources services; broker-dealer, investment adviser or investment banking services; legal services; and expert services unrelated to the audit. Other services are conditionally prohibited and may be provided, if the Audit Committee reasonably concludes that the results of the services will not be subject to audit procedures during an audit of the Fund's financial statements. These types of services include bookkeeping; financial information systems design and implementation; appraisal or valuation services; actuarial services; and internal audit outsourcing services.</span></p><p style="margin:6pt 0pt 0pt 0pt"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">The Pre-Approval Policies and Procedures of each Fund's Audit Committee require Audit Committee approval of the engagement of the Auditor for each fiscal year and approval of the engagement by at least a majority of the Fund's Independent Trustees. In determining whether to engage the Auditor for its audit services, each Fund's Audit Committee will consider the Auditor's proposed fees for the engagement, in light of the scope and nature of the audit services that the Fund will receive. The Pre-Approval Policies and Procedures also permit each Fund's Audit Committee to pre-approve the provisions of types or categories of permissible non-audit services for the Fund and its Service Affiliates on an annual basis at the time of the Auditor's engagement and on a project-by-project basis. At the time of the annual engagement of each Fund's Auditor, each Audit Committee is to receive a list of the categories of expected non-audit services with a description and an estimated budget of fees. In their pre-approval, each Audit Committee should determine that the provision of the service is consistent with, and will not impair, the ongoing independence of the Auditor and set any limits on fees or other conditions they find appropriate. Non-audit services may also be approved on a project-by-project basis by each Audit Committee consistent with the same standards for determination and information.</span></p><p style="margin:6pt 0pt 0pt 0pt"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">Each Audit Committee may also appoint a member of each Committee to pre-approve non-audit services that have not been pre-approved or material changes in the nature or cost of any non-audit services previously pre-approved. The member may not pre-approve any project the estimated budget (or budgeted range) of fees of which exceed or may exceed $15,000. Any actions by the member are to be ratified by the Audit Committee by the time of its next scheduled meeting. Each Fund's Pre-Approval Policies and Procedures are reviewed annually by the Fund's Audit Committee, and the Fund maintains a record of the decisions made by the Committee pursuant to these procedures.</span></p><p style="margin:6pt 0pt 0pt 0pt"><span style="font-size:10pt;font-family:Times New Roman, Times, serif"><strong>Required Vote</strong></span></p><p style="margin:6pt 0pt 0pt 0pt"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">The selection of Deloitte &#38; Touche LLP as each Fund's independent public accountants for the fiscal year ending September 30, 2023 is submitted to shareholders for ratification and requires approval by a majority of each Fund's shares voting at the Joint Annual Meeting. </span><span style="font-size:10pt;font-family:Times New Roman, Times, serif"><strong>The Trustees recommend a vote FOR the selection of Deloitte &#38; Touche LLP as the independent registered public accountants of each Fund.</strong></span></p></div><p style="text-align:center"><br /><span style="font-family:Times New Roman PS, Times New Roman, Times;font-size:13px">13</span></p><hr style="height:2px;text-align:center;width:100%;background-color:gray;page-break-after:always" /><div style="margin:8pt 0pt 8pt 0pt"><p style="margin:0pt 0pt 0pt 0pt;text-align:center"><span style="font-size:10pt;font-family:Times New Roman, Times, serif"><strong>INFORMATION PERTAINING TO THE CUSTODIAN AND ADMINISTRATOR AND<br />TRANSFER AGENT, DIVIDEND DISBURSING AGENT AND REGISTRAR</strong></span></p><p style="margin:6pt 0pt 0pt 0pt"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">Each Fund's securities and cash are held under a custodian contract by State Street Bank and Trust Company ("State Street"), whose principal business address is One Lincoln Street, Boston, MA 02111. State Street is also the Administrator of each Fund and also performs certain accounting related functions for each Fund, including calculation of net asset value and net income.</span></p><p style="margin:6pt 0pt 0pt 0pt"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">Computershare Inc. serves as Dividend Disbursing Agent. Computershare Trust Company, N.A., a fully owned subsidiary of Computershare Inc., serves as (1) the Plan Agent for each Fund's Dividend Reinvestment Plan and (2) the Transfer Agent and Registrar for Shares of each Fund. Computershare Trust Company, N.A. and Computershare Inc. have their principal business at 150 Royall Street, Canton, MA 02021.</span></p><p style="margin:12pt 0pt 0pt 0pt;text-align:center"><span style="font-size:10pt;font-family:Times New Roman, Times, serif"><strong>SECTION 16(a) BENEFICIAL OWNERSHIP REPORTING COMPLIANCE</strong></span></p><p style="margin:6pt 0pt 0pt 0pt"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">Section 16(a) of the Exchange Act and Section 30(j) of the 1940 Act, as applied to each Fund, require the Fund's officers and trustees, investment manager, affiliates of the investment manager, and persons who beneficially own more than ten percent of a registered class of the Fund's outstanding securities ("Reporting Persons") to file reports of ownership of the Fund's securities and changes in such ownership with the SEC and the NYSE. Such persons are required by SEC regulations to furnish the Fund with copies of all such filings.</span></p><p style="margin:6pt 0pt 0pt 0pt"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">Based solely upon its review of the copies of such forms received by it, and written representations from certain Reporting Persons that no year-end reports were required for those persons, each Fund believes that during the fiscal year ended September 30, 2022, its Reporting Persons complied with all applicable filing requirements.</span></p><p style="margin:12pt 0pt 0pt 0pt;text-align:center"><span style="font-size:10pt;font-family:Times New Roman, Times, serif"><strong>OTHER BUSINESS</strong></span></p><p style="margin:6pt 0pt 0pt 0pt"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">As of the date of this Joint Proxy Statement, the Board of each Fund is not aware that any matters are to be presented for action at the Joint Annual Meeting other than those described above. Should other business properly be brought before the Joint Annual Meeting, it is intended that the accompanying Proxy will be voted thereon in accordance with the judgment of the persons named as proxies.</span></p><p style="margin:12pt 0pt 0pt 0pt;text-align:center"><span style="font-size:10pt;font-family:Times New Roman, Times, serif"><strong>PROXIES AND VOTING AT THE JOINT ANNUAL MEETING</strong></span></p><p style="margin:6pt 0pt 0pt 0pt"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">Shareholders who execute proxies may revoke them at any time before they are voted by written notice to the Secretary of the Fund at 100 Federal Street, 19th Floor, Boston, MA 02110, or by casting a vote at the Joint Annual Meeting. Instructions on how to attend the meeting and vote in person can be obtained by calling (617) 772-8500. All valid proxies received prior to the Joint Annual Meeting, or any adjournment(s) or postponements(s) thereof, will be voted at the Joint Annual Meeting and any adjournments or postponements thereof.</span></p><p style="margin:6pt 0pt 0pt 0pt"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">The representation in person or by proxy of a majority of the outstanding shares of each Fund is necessary to constitute a quorum for transacting business at the Joint Annual Meeting. For purposes of determining the presence of a quorum, abstentions and broker "non-votes" will be treated as shares that are present. Broker non-votes are proxies received by each Fund from brokers or nominees when the broker or nominee has neither received instructions from the beneficial owner or other persons entitled to vote nor has discretionary power to vote on a particular matter. Proposals 1 and 2 to be </span></p></div><p style="text-align:center"><br /><span style="font-family:Times New Roman PS, Times New Roman, Times;font-size:13px">14</span></p><hr style="height:2px;text-align:center;width:100%;background-color:gray;page-break-after:always" /><div style="margin:8pt 0pt 8pt 0pt"><p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">voted upon by the shareholders involve matters that the NYSE considers to be routine and within the discretion of brokers to vote if no customer instructions are received.</span></p><p style="margin:6pt 0pt 0pt 0pt"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">Proposal 1 requires the approval of a plurality of shares voting at the Joint Annual Meeting (i.e., the nominee for each seat receiving the greatest number of votes will be elected). </span></p><p style="margin:6pt 0pt 0pt 0pt"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">Proposal 2 requires the approval of a majority of all votes validly cast at the Joint Annual Meeting.</span></p><p style="margin:6pt 0pt 0pt 0pt"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">Abstentions and broker non-votes will be considered shares present or represented by a proxy but will not be considered shares voted. As a result, they will have no effect on Proposals 1 or 2.</span></p><p style="margin:6pt 0pt 0pt 0pt"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">Matters on which a choice has been provided will be voted as indicated on the proxy card and, if no instruction is given, the persons named as proxies will vote the shares represented thereby FOR all nominees for election as Trustee and FOR Proposal 2 and will use their best judgment in connection with the transaction of such other business as may properly come before the Joint Annual Meeting or any adjournment(s) or postponement(s) thereof.</span></p><p style="margin:6pt 0pt 0pt 0pt"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">In the event that sufficient votes in accordance with the Trustees' recommendations on any Proposal are not received by June 8, 2023 or the necessary quorum has not been obtained, or if other matters arise requiring shareholder attention, the persons named as proxies on the enclosed proxy card may propose one or more adjournments of the Joint Annual Meeting to permit further solicitation. Any such adjournment will require approval by a majority of the votes validly cast on the matter at the session of the Joint Annual Meeting to be adjourned. When voting on a proposed adjournment, the persons named as proxies will vote FOR the proposed adjournment all shares that they are entitled to vote with respect to each item, unless directed to vote AGAINST an item, in which case such shares will be voted AGAINST the proposed adjournment with respect to that item. A shareholder vote may be taken on one or more items prior to such adjournment, if sufficient votes have been received and it is otherwise appropriate. Abstentions and broker non-votes will be disregarded for purposes of voting on adjournment.</span></p><p style="margin:6pt 0pt 0pt 0pt"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">As of April 12, 2023, there were:</span></p><table border="0" cellpadding="0" cellspacing="0" width="100%"><tr><td colspan="3" style="padding:6pt .7pt 0pt 0pt;width:176" valign="bottom">&#160;</td><td colspan="1">&#160;</td><td colspan="3" style="padding:6pt .7pt 0pt 0pt;border:none;border-bottom:solid windowtext 1pt;text-align:center;width:77" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Times New Roman, Times, serif"><strong>HQH</strong></span></p></td><td colspan="1">&#160;</td><td colspan="3" style="padding:6pt .7pt 0pt 0pt;border:none;border-bottom:solid windowtext 1pt;text-align:center;width:77" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Times New Roman, Times, serif"><strong>THQ</strong></span></p></td><td colspan="1">&#160;</td><td colspan="3" style="padding:6pt .7pt 0pt 0pt;border:none;border-bottom:solid windowtext 1pt;text-align:center;width:77" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Times New Roman, Times, serif"><strong>THW</strong></span></p></td><td colspan="1">&#160;</td></tr><tr><td colspan="3" style="padding:4pt .7pt 0pt 0pt;text-align:left;width:176;background-color:#cceeff" valign="bottom"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">Shares of beneficial interest issued </span><br /><span style="font-size:10pt;font-family:Times New Roman, Times, serif">and outstanding</span></td><td colspan="1" style="background-color:#cceeff">&#160;</td><td colspan="1" style="padding:4pt .7pt 0pt 0pt;width:8;background-color:#cceeff" valign="bottom">&#160;</td><td colspan="1" style="padding:4pt .7pt 0pt 0pt;text-align:right;width:61;background-color:#cceeff" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">48,351,111</span></p></td><td colspan="1" style="padding:4pt .7pt 0pt 0pt;width:8;background-color:#cceeff" valign="bottom">&#160;</td><td colspan="1" style="width:8;background-color:#cceeff">&#160;</td><td colspan="1" style="padding:4pt .7pt 0pt 0pt;width:8;background-color:#cceeff" valign="bottom">&#160;</td><td colspan="1" style="padding:4pt .7pt 0pt 0pt;text-align:right;width:61;background-color:#cceeff" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">41,356,057</span></p></td><td colspan="1" style="padding:4pt .7pt 0pt 0pt;width:8;background-color:#cceeff" valign="bottom">&#160;</td><td colspan="1" style="width:8;background-color:#cceeff">&#160;</td><td colspan="1" style="padding:4pt .7pt 0pt 0pt;width:8;background-color:#cceeff" valign="bottom">&#160;</td><td colspan="1" style="padding:4pt .7pt 0pt 0pt;text-align:right;width:61;background-color:#cceeff" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt;white-space:nowrap"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">37,918,893</span></p></td><td colspan="1" style="padding:4pt .7pt 0pt 0pt;width:8;background-color:#cceeff" valign="bottom">&#160;</td><td colspan="1" style="width:8;background-color:#cceeff">&#160;</td></tr></table><p style="margin:6pt 0pt 0pt 0pt"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">Shareholders of each Fund will be entitled to one vote for each share held. Only shareholders of record at the close of business on April 12, 2023, the record date, will be entitled to vote at the Joint Annual Meeting. As of March 31, 2023, the Trustees and officers of each Fund individually and as a group beneficially owned less than 1% of the outstanding voting securities of the Fund. To the best of each Fund's knowledge, based upon filings made with the SEC, as of April 12, 2023, the below persons or groups beneficially owned more than 5% of the voting securities of the Fund:</span></p><table border="0" cellpadding="0" cellspacing="0" width="100%"><tr><td colspan="3" style="padding:6pt .7pt 0pt 0pt;border:none;border-bottom:solid windowtext 1pt;text-align:left;width:88" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Times New Roman, Times, serif"><strong>(1) Title of class</strong></span></p></td><td colspan="1">&#160;</td><td colspan="3" style="padding:6pt .7pt 0pt 0pt;border:none;border-bottom:solid windowtext 1pt;text-align:center;width:175" valign="bottom"><span style="font-size:8pt;font-family:Times New Roman, Times, serif"><strong>(2) Name and address of</strong></span><br /><span style="font-size:8pt;font-family:Times New Roman, Times, serif"><strong>beneficial owner</strong></span></td><td colspan="1">&#160;</td><td colspan="3" style="padding:6pt .7pt 0pt 0pt;border:none;border-bottom:solid windowtext 1pt;text-align:center;width:124" valign="bottom"><span style="font-size:8pt;font-family:Times New Roman, Times, serif"><strong>(3) Amount and nature of</strong></span><br /><span style="font-size:8pt;font-family:Times New Roman, Times, serif"><strong>beneficial ownership</strong></span></td><td colspan="1">&#160;</td><td colspan="3" style="padding:6pt .7pt 0pt 0pt;border:none;border-bottom:solid windowtext 1pt;text-align:center;width:115" valign="bottom"><p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Times New Roman, Times, serif"><strong>(4) Percent of class</strong></span></p></td><td colspan="1">&#160;</td></tr><tr><td colspan="3" style="padding:2pt .7pt 6pt 0pt;text-align:left;width:88;background-color:#cceeff" valign="top"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">HQH Common </span><br /><span style="font-size:10pt;font-family:Times New Roman, Times, serif">Stock</span></td><td colspan="1" style="background-color:#cceeff">&#160;</td><td colspan="3" style="padding:2pt .7pt 6pt 0pt;text-align:left;width:175;background-color:#cceeff" valign="top"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">Morgan Stanley Smith Barney LLC</span><br /><span style="font-size:10pt;font-family:Times New Roman, Times, serif">1585 </span><span style="font-size:10pt;font-family:Times New Roman, Times, serif">Broadway</span><br /><span style="font-size:10pt;font-family:Times New Roman, Times, serif">New York, NY 10036</span></td><td colspan="1" style="background-color:#cceeff">&#160;</td><td colspan="3" style="padding:2pt .7pt 6pt 0pt;text-align:left;width:108;background-color:#cceeff" valign="top"><p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">3,118,800 shares</span></p></td><td colspan="1" style="background-color:#cceeff">&#160;</td><td colspan="3" style="padding:2pt .7pt 6pt 0pt;text-align:left;width:83;background-color:#cceeff" valign="top"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">6.6</span><span style="font-size:10pt;font-family:Times New Roman, Times, serif">%</span></td><td colspan="1" style="background-color:#cceeff">&#160;</td></tr></table></div><div style="margin:8pt 0pt;text-align:center"><br /><span style="font-family:Times New Roman PS, Times New Roman, Times;font-size:13px">15</span></div><hr style="height:2px;text-align:center;width:100%;background-color:gray;page-break-after:always" /><p style="text-align:center"><span style="font-size:10pt"><span><span style="font-family:Times New Roman,Times,serif"><strong>PROPOSALS FOR 2024 ANNUAL MEETING</strong></span></span></span></p><p style="margin:6pt 0pt 0pt 0pt"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">Shareholder proposals for each Fund's 2024 Annual Meeting must be received by U.S. mail, a private courier service, or hand delivery and be addressed to the Fund's Secretary at the Fund's executive offices at 100 Federal Street, 19th Floor, Boston, Massachusetts 02110 no later than December 18, 2023 for inclusion in the Fund's 2024 proxy statement and form of proxy, unless the meeting date is more than 30 days before or after June 8, 2024, in which case the proposal must be submitted a reasonable time before the time the Fund begins to print and send its proxy materials for the 2024 Annual Meeting. Submission of such proposals does not insure that they will be included in the Fund's 2024 proxy statement or submitted for a vote at the Fund's 2024 Annual Meeting.</span></p><p style="margin:6pt 0pt 0pt 0pt"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">In addition, shareholder proposals for each Fund's 2024 Annual Meeting (other than proposals submitted for inclusion in the Fund's 2024 proxy statement) must be submitted to the Fund's Secretary between February 9, 2024 and March 10, 2024, unless the meeting date is more than 30 days before or after June 8, 2024, in which case the proposal must be submitted by the later of the close of business on (1) the date 90 days prior to the 2024 Annual Meeting date or (2) the tenth business day following the date on which the 2024 Annual Meeting date is first publicly announced or disclosed. </span></p><p style="margin:12pt 0pt 0pt 0pt;text-align:center"><span style="font-size:10pt;font-family:Times New Roman, Times, serif"><strong>GENERAL</strong></span></p><p style="margin:6pt 0pt 0pt 0pt"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">Each Fund will pay the cost of preparing, printing and mailing the enclosed proxy card(s) and Joint Proxy Statement and all other costs incurred in connection with the solicitation of proxies, including any additional solicitation made by letter, internet, telephone or telegraph. The solicitation of proxies will be largely by mail. In addition, certain officers of the Fund and certain employees of the Adviser, who will receive no compensation for their services other than their regular salaries, may solicit the return of proxies personally or by telephone or facsimile. Banks, brokerage houses, nominees and other fiduciaries will be requested to forward the proxy soliciting materials to the beneficial owners of the shares of each Fund. Each Fund may reimburse brokerage houses, nominees and other fiduciaries for postage and reasonable expenses incurred by them in forwarding of proxy material to beneficial owners.</span></p><p style="margin:6pt 0pt 0pt 0pt"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">A number of banks, brokers and financial institutions have instituted "householding". Under this practice, only one Joint Proxy Statement may be delivered to multiple shareholders who share the same address and satisfy other conditions. Each Fund will deliver promptly a separate copy of this Joint Proxy Statement to a shareholder at a shared address upon request. To request a separate copy of this Joint Proxy Statement, write or call the Fund at the address and phone number set forth above.</span></p><p style="margin:12pt 0pt 0pt 0pt;text-align:center"><span style="font-size:10pt;font-family:Times New Roman, Times, serif"><strong>IMPORTANT NOTICE REGARDING THE AVAILABILITY OF PROXY<br />MATERIALS FOR THE SHAREHOLDER MEETING TO BE HELD ON JUNE 8, 2023</strong></span></p><p style="margin:6pt 0pt 0pt 0pt"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">The Joint Proxy Statement for the Joint Annual Meeting of Shareholders of Tekla Healthcare Investors, Tekla Healthcare Opportunities Fund and Tekla World Healthcare Fund and form of proxy are available at www.proxy-direct.com/TKL-33282.</span></p><p style="margin:12pt 0pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">TEKLA HEALTHCARE INVESTORS<br />TEKLA HEALTHCARE OPPORTUNITIES FUND<br />TEKLA WORLD HEALTHCARE FUND</span></p><p style="margin:6pt 0pt 0pt 0pt;text-align:left"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">April 17, 2023</span></p><p style="text-align:center"><br /><span style="font-size:13px;font-family:Times New Roman PS, Times New Roman, Times">16</span></p><hr style="height:2px;text-align:center;width:100%;background-color:gray;page-break-after:always" /><div style="margin:8pt 0pt 8pt 0pt"><p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:10pt;font-family:Times New Roman, Times, serif"><strong>EXHIBIT A</strong></span></p><p style="margin:6pt 0pt 0pt 0pt"><span style="font-size:10pt;font-family:Times New Roman, Times, serif"><strong><span style="text-decoration:underline">Governance and Nominating Committee Charter</span></strong></span></p><p style="margin:6pt 0pt 0pt 0pt"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">For convenience, this Charter refers to the Funds and their respective Boards of Trustees (each the "Board"), and their respective Governance and Nominating Committees (each the "Committee" or the "Governance and Nominating Committee") in the singular. However, this Charter applies to each Fund, its Board and its Committee independently.</span></p><p style="margin:6pt 0pt 0pt 0pt"><span style="font-size:10pt;font-family:Times New Roman, Times, serif"><strong><i>Committee Membership</i></strong></span></p><p style="margin:6pt 0pt 0pt 0pt"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">The Committee shall consist entirely of trustees of the Fund who (1) are not "interested persons," as that term is defined in the Investment Company Act of 1940, as amended (the "1940 Act"), of the Fund or the Fund's investment adviser and (2) are "independent" as defined in the New York Stock Exchange ("NYSE") Listing Standards ("Independent Trustees"). The President of the Fund, although not a member of the Committee, will cooperate with the Committee by assisting the Committee to discharge its responsibilities, including by recommending candidates and recruiting them for the Board or to serve as executive officers of the Fund.</span></p><p style="margin:6pt 0pt 0pt 0pt"><span style="font-size:10pt;font-family:Times New Roman, Times, serif"><strong><i>Missions</i></strong></span></p><p style="margin:6pt 0pt 0pt 0pt"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">The principal missions of the Committee are (i) to review, evaluate, and enhance the effectiveness of the Board in its role in governing the Fund and overseeing the management of the Fund and (ii) to promote the effective participation of qualified individuals on the Board, on committees of the Board, and as executive officers of the Fund. The Committee shall consider the Corporate Governance Guidelines attached to this Charter as Appendix A in fulfilling its missions.</span></p><p style="margin:6pt 0pt 0pt 0pt"><span style="font-size:10pt;font-family:Times New Roman, Times, serif"><strong><i>Governance Function</i></strong></span></p><p style="margin:6pt 0pt 0pt 0pt"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">The Committee shall review, discuss, and make recommendations to the Board relating to those issues that pertain to the effectiveness of the Board in carrying out its responsibilities in governing the Fund and overseeing the management of the Fund. These may include, but are not limited to, issues relating to:</span></p><p style="margin:6pt 0pt 0pt 0pt"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">1.&#160;&#160;the selection of the Fund's investment adviser (the "Adviser") and approval of the Fund's investment advisory contract;</span></p><p style="margin:6pt 0pt 0pt 0pt"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">2.&#160;&#160;the selection and approval of the Fund's outside counsel ("Fund Counsel");</span></p><p style="margin:6pt 0pt 0pt 0pt"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">3.&#160;&#160;the composition of the Board, including:</span></p><p style="margin:6pt 0pt 0pt 0pt"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">(a)&#160;&#160;the size of the Board and the qualifications and representative areas of expertise of the members of the Board; and</span></p><p style="margin:6pt 0pt 0pt 0pt"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">(b)&#160;&#160;retirement and succession policies relating to members of the Board;</span></p><p style="margin:6pt 0pt 0pt 0pt"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">4.&#160;&#160;the members of the Board, including:</span></p><p style="margin:6pt 0pt 0pt 0pt"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">(a)&#160;&#160;guidelines relating to ownership of shares of the Fund by members of the Board;</span></p><p style="margin:6pt 0pt 0pt 0pt"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">(b)&#160;&#160;whether members of the Board may not serve in a similar capacity on the board of a registered investment company (i) which is not sponsored or advised by the Adviser or its affiliates and (ii) which the Committee in its discretion has determined to be competitive with the Fund taking into account such registered investment company's investment mandate;</span></p></div><p style="text-align:center"><br /><span style="font-size:13px;font-family:Times New Roman PS, Times New Roman, Times">17</span></p><hr style="height:2px;text-align:center;width:100%;background-color:gray;page-break-after:always" /><div style="margin:8pt 0pt 8pt 0pt"><p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">(c)&#160;&#160;continuing education of members of the Board; and</span></p><p style="margin:6pt 0pt 0pt 0pt"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">(d)&#160;&#160;identification of best practices for members of the Board;</span></p><p style="margin:6pt 0pt 0pt 0pt"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">5.&#160;&#160;the meetings of the Board, including:</span></p><p style="margin:6pt 0pt 0pt 0pt"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">(a)&#160;&#160;coordination with the Chairman of the Board in developing the agenda for the meetings of the Board, with the assistance of the Adviser and Fund Counsel;</span></p><p style="margin:6pt 0pt 0pt 0pt"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">(b)&#160;&#160;frequency of meetings of the Board; and</span></p><p style="margin:6pt 0pt 0pt 0pt"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">(c)&#160;&#160;Board meeting attendance policies;</span></p><p style="margin:6pt 0pt 0pt 0pt"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">6.&#160;&#160;the role of the Independent Trustees, including:</span></p><p style="margin:6pt 0pt 0pt 0pt"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">(a)&#160;&#160;limitations on the ability of Independent Trustees to act and function independently of the Board and the Adviser; and</span></p><p style="margin:6pt 0pt 0pt 0pt"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">(b)&#160;&#160;the quality of information received by the Independent Trustees;</span></p><p style="margin:6pt 0pt 0pt 0pt"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">7.&#160;&#160;compensation for Independent Trustees;</span></p><p style="margin:6pt 0pt 0pt 0pt"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">8.&#160;&#160;the role of the committees of the Board, including:</span></p><p style="margin:6pt 0pt 0pt 0pt"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">(a)&#160;&#160;number and type of committees; and</span></p><p style="margin:6pt 0pt 0pt 0pt"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">(b)&#160;&#160;periodic approval of the charter and scope of the responsibilities of each committee;</span></p><p style="margin:6pt 0pt 0pt 0pt"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">9.&#160;&#160;the relationship between the Board and management, including:</span></p><p style="margin:6pt 0pt 0pt 0pt"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">(a)&#160;&#160;oversight of and communication with management;</span></p><p style="margin:6pt 0pt 0pt 0pt"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">(b)&#160;&#160;coordination with management to ensure that management has developed an appropriate plan to deal with succession and potential crisis management situations; and</span></p><p style="margin:6pt 0pt 0pt 0pt"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">10.&#160;&#160;Board self-evaluation.</span></p><p style="margin:6pt 0pt 0pt 0pt"><span style="font-size:10pt;font-family:Times New Roman, Times, serif"><strong><i>Nominating Function &#8211; Board</i></strong></span></p><p style="margin:6pt 0pt 0pt 0pt"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">1.&#160;&#160;The Committee shall make nominations for trustees and officers of the Fund and submit such nominations to the full Board. The Committee shall evaluate candidates' qualifications for such positions and, in the case of candidates for election to the Board, whether they would qualify as Independent Trustees. The Committee shall also consider the effect of any relationships beyond those delineated in the 1940 Act that might impair independence (e.g. business, financial or family relationships with the Adviser). In determining candidates' qualifications for Board membership, the Committee shall consider factors which may be delineated in this Charter or the Fund's By-Laws and may consider such other factors as it may determine to be relevant to fulfilling the role of being a member of the Board.</span></p><p style="margin:6pt 0pt 0pt 0pt"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">2.&#160;&#160;The Committee may consider potential trustee candidates recommended by shareholders, provided that the proposed candidates: (i) satisfy any minimum qualifications of the Fund for its trustees; and (ii) qualify as Independent Trustees. In order for the Committee to evaluate any nominee recommended by a shareholder or shareholder group, potential trustee candidates and nominating shareholders or shareholder groups must satisfy the requirements provided in Appendix B to this Charter. The Committee shall not otherwise evaluate shareholder trustee nominees in a different manner than other nominees, and the standard of the Committee is to treat all equally qualified </span></p></div><p style="text-align:center"><br /><span style="font-size:13px;font-family:Times New Roman PS, Times New Roman, Times">18</span></p><hr style="height:2px;text-align:center;width:100%;background-color:gray;page-break-after:always" /><div style="margin:8pt 0pt 8pt 0pt"><p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">nominees in the same manner. Once a nomination has been timely received in proper form, the nominee will be asked to complete an eligibility questionnaire to assist the Committee in assessing the nominee's qualifications as a potential Independent Trustee. The Committee will make such determinations in its sole discretion and such determinations shall be final.</span></p><p style="margin:6pt 0pt 0pt 0pt"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">3.&#160;&#160;The Committee may identify prospective trustees from any reasonable source, including, but not limited to, the consultation of third-party trustee search services.</span></p><p style="margin:6pt 0pt 0pt 0pt"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">4.&#160;&#160;The Committee requires that each prospective trustee have a college degree or equivalent business experience. In addition to the requirements delineated in the Fund's By-Laws, the Committee may take into account a wide variety of factors in considering prospective trustees, including (but not limited to): (i) availability and commitment of a candidate to attend meetings and perform his or her responsibilities on the Board; (ii) relevant industry and related experience; (iii) educational background; (iv) financial expertise; (v) the candidate's ability, judgment and expertise; and (vi) overall diversity of the Board's composition.</span></p><p style="margin:6pt 0pt 0pt 0pt"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">6.&#160;&#160;The Committee shall evaluate the participation and contribution of each trustee coming to the end of his or her term before deciding whether to recommend reelection. The Committee may seek the views of other trustees to assist them in this evaluation.</span></p><p style="margin:6pt 0pt 0pt 0pt"><span style="font-size:10pt;font-family:Times New Roman, Times, serif"><strong><i>Nominating Function &#8211; Committees</i></strong></span></p><p style="margin:6pt 0pt 0pt 0pt"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">The Committee shall make nominations for membership on all committees of the Board and submit such nominations to the full Board and shall review committee assignments as necessary.</span></p><p style="margin:6pt 0pt 0pt 0pt"><span style="font-size:10pt;font-family:Times New Roman, Times, serif"><strong><i>Other Powers and Responsibilities</i></strong></span></p><p style="margin:6pt 0pt 0pt 0pt"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">1.&#160;&#160;The Committee shall meet at least annually so it can carry out its review of the investment advisory agreement, recommend the selection of an Adviser, and consider Board and Committee nominations. The Committee shall meet at such other time or times as the Committee or the Board may determine appropriate or necessary and is empowered to hold special meetings as circumstances require.</span></p><p style="margin:6pt 0pt 0pt 0pt"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">2.&#160;&#160;The Committee shall have the resources and authority appropriate to discharge its responsibilities, including authority to utilize Fund Counsel and to retain experts or other persons with specific competence at the expense of the Fund.</span></p><p style="margin:6pt 0pt 0pt 0pt"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">3.&#160;&#160;The Committee shall review this Charter periodically and recommend any changes to the Board.</span></p></div><p style="text-align:center"><br /><span style="font-size:13px;font-family:Times New Roman PS, Times New Roman, Times">19</span></p><hr style="height:2px;text-align:center;width:100%;background-color:gray;page-break-after:always" /><div style="margin:8pt 0pt 8pt 0pt"><p style="margin:0pt 0pt 0pt 0pt;text-align:center"><span style="font-size:10pt;font-family:Times New Roman, Times, serif"><strong>APPENDIX A</strong></span></p><p style="margin:6pt 0pt 0pt 0pt;text-align:center"><span style="font-size:10pt;font-family:Times New Roman, Times, serif"><strong>Corporate Governance Guidelines</strong></span></p><p style="margin:6pt 0pt 0pt 0pt"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">1.&#160;&#160;General</span></p><p style="margin:6pt 0pt 0pt 0pt"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">The intent is that the Board shall, wherever possible, comply in its structure and operations with the guidelines issued by the NYSE and the Securities and Exchange Commission ("SEC").</span></p><p style="margin:6pt 0pt 0pt 0pt"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">2.&#160;&#160;Board Composition</span></p><p style="margin:6pt 0pt 0pt 0pt"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">(a)&#160;&#160;The Fund's Declaration of Trust, as amended, provides that the Trustees shall be at least three and not more than fifteen in number, as fixed by the Trustees, and the number of Trustees is currently fixed at seven.</span></p><p style="margin:6pt 0pt 0pt 0pt"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">(b)&#160;&#160;Independent Trustees shall represent at least 75% of Board membership.</span></p><p style="margin:6pt 0pt 0pt 0pt"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">(c)&#160;&#160;The President of the Adviser, and such other officers of the Adviser as the Board may designate, shall be included among those nominated for Board membership, but they shall not be considered as Independent Trustees.</span></p><p style="margin:6pt 0pt 0pt 0pt"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">(d)&#160;&#160;The Board shall seek to be broadly representative of the various skills and experience deemed necessary to ensure sound oversight of the Fund.</span></p><p style="margin:6pt 0pt 0pt 0pt"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">3.&#160;&#160;Selection of Chairman of the Board</span></p><p style="margin:6pt 0pt 0pt 0pt"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">The Board shall annually elect its own Chairman from among those Independent Trustees elected by the shareholders. This election shall take place at the first Board meeting following the annual meeting of shareholders or upon the initiative of a two-thirds majority of the trustees.</span></p><p style="margin:6pt 0pt 0pt 0pt"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">4.&#160;&#160;General Expectations</span></p><p style="margin:6pt 0pt 0pt 0pt"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">(a)&#160;&#160;In serving as a trustee, each trustee must exercise duties of care and loyalty to the Fund.</span></p><p style="margin:6pt 0pt 0pt 0pt"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">(b)&#160;&#160;Each Independent Trustee is expected to be knowledgeable about Fund business and financial operations through Board and Board committee meetings and personal inquiry and observation, and to contribute to the Board's oversight of the Fund's investment performance.</span></p><p style="margin:6pt 0pt 0pt 0pt"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">(c)&#160;&#160;Each trustee is expected to devote sufficient time and attention to carrying out his or her duties and responsibilities as a trustee of the Fund and to ensure that other commitments or responsibilities do not materially interfere with his or her duties and responsibilities to the Fund.</span></p><p style="margin:6pt 0pt 0pt 0pt"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">(d)&#160;&#160;The criteria to be used to evaluate candidates to serve as trustees, which will be reviewed from time to time by the Board or the Governance and Nominating Committee, will stress personal and professional integrity, sound judgment, relevant experience, a proven record of professional accomplishment, and a commitment to devote sufficient time and attention to Fund matters, among other relevant factors. In the case of a candidate to serve as an Independent Trustee, independence will be required in terms of both the letter and spirit of applicable law.</span></p><p style="margin:6pt 0pt 0pt 0pt"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">5.&#160;&#160;Retirement of Trustees</span></p><p style="margin:6pt 0pt 0pt 0pt"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">Trustees shall serve for a three-year term upon nomination by the Committee and election by the shareholders. No person may be nominated for election to the Board, if that person is 75 years of age or older at the time of consideration, unless such nomination is approved by at least 66</span><span style="font-size:5pt;font-family:Times New Roman, Times, serif"><sup>2</sup></span><span style="font-size:10pt;font-family:Times New Roman, Times, serif">/</span><span style="font-size:5pt;font-family:Times New Roman, Times, serif"><sub>3</sub></span><span style="font-size:10pt;font-family:Times New Roman, Times, serif">% of the Independent Trustees.</span></p></div><p style="text-align:center"><br /><span style="font-size:13px;font-family:Times New Roman PS, Times New Roman, Times">20</span></p><hr style="height:2px;text-align:center;width:100%;background-color:gray;page-break-after:always" /><div style="margin:8pt 0pt 8pt 0pt"><p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">6.&#160;&#160;Independent Trustee Sessions</span></p><p style="margin:6pt 0pt 0pt 0pt"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">Independent Trustees are expected to meet in separate session at least once each quarter, typically in conjunction with the regularly scheduled Board meeting for that quarter. In such sessions, Independent Trustees are expected to engage in candid discussions about Fund management performance and other sensitive matters deemed appropriate.</span></p><p style="margin:6pt 0pt 0pt 0pt"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">7.&#160;&#160;Independent Trustee Authority to Hire Staff</span></p><p style="margin:6pt 0pt 0pt 0pt"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">Independent Trustees may hire their own staff to the extent deemed necessary to help Independent Trustees deal with matters on which they deem outside assistance to be necessary.</span></p><p style="margin:6pt 0pt 0pt 0pt"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">8.&#160;&#160;Committees of the Board</span></p><p style="margin:6pt 0pt 0pt 0pt"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">(a)&#160;&#160;The Board shall have four Committees:</span></p><p style="margin:6pt 0pt 0pt 0pt"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">(i)&#160;&#160;an Audit Committee;</span></p><p style="margin:6pt 0pt 0pt 0pt"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">(ii)&#160;&#160;a Valuation Committee;</span></p><p style="margin:6pt 0pt 0pt 0pt"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">(iii)&#160;&#160;a Governance and Nominating Committee; and</span></p><p style="margin:6pt 0pt 0pt 0pt"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">(iv)&#160;&#160;a Qualified Legal Compliance Committee.</span></p><p style="margin:6pt 0pt 0pt 0pt"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">(b)&#160;&#160;A Compensation Committee, generally required by SEC and NYSE guidelines, is not deemed necessary as personnel of the Adviser serve as the Fund's officers, and the compensation of such personnel is determined and payable by the Adviser (with the exception of the Fund's Chief Compliance Officer). Oversight of the Adviser's budget, including compensation, shall be a factor in the Board's approval of the Adviser's investment advisory contract.</span></p><p style="margin:6pt 0pt 0pt 0pt"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">(c)&#160;&#160;Each of the Board's committees shall have a charter (or policies and procedures), which shall have been approved by the Board. The Governance and Nominating Committee shall review periodically each such charter and recommend any changes to the Board. The Audit Committee shall review its charter annually to comply with NYSE Listing Standards and recommend any changes to the Board.</span></p><p style="margin:6pt 0pt 0pt 0pt"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">(d)&#160;&#160;Committee Chairman and members shall be nominated by the Governance and Nominating Committee and approved by the Board.</span></p><p style="margin:6pt 0pt 0pt 0pt"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">(e)&#160;&#160;The Audit Committee, Governance and Nominating Committee and Qualified Legal Compliance Committee shall each consist solely of Independent Trustees.</span></p><p style="margin:6pt 0pt 0pt 0pt"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">9.&#160;&#160;Board Meetings</span></p><p style="margin:6pt 0pt 0pt 0pt"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">(a)&#160;&#160;The Board is expected to meet no less than four times per year, including one meeting which coincides with the annual meeting of shareholders.</span></p><p style="margin:6pt 0pt 0pt 0pt"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">(b)&#160;&#160;Trustees are expected to attend all Board meetings in person. Where conflicts prevent attendance in person, trustees may attend by telephone or video conference. It is expected that, during their term, trustees shall attend no fewer than 50% of Board meetings in person and no less than 75% of meetings where a majority of Independent Trustees must be present in person.</span></p><p style="margin:6pt 0pt 0pt 0pt"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">(c)&#160;&#160;Agendas for Board meetings shall be proposed by the Adviser and Fund Counsel and approved by the Chairman of the Board at least two weeks in advance of each Board meeting and one month in advance of the annual meeting of shareholders.</span></p></div><p style="text-align:center"><br /><span style="font-size:13px;font-family:Times New Roman PS, Times New Roman, Times">21</span></p><hr style="height:2px;text-align:center;width:100%;background-color:gray;page-break-after:always" /><div style="margin:8pt 0pt 8pt 0pt"><p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">(d)&#160;&#160;Minutes for each Board meeting shall be prepared and circulated within a reasonable period of time following each Board meeting and shall highlight items on which follow-up action is required.</span></p><p style="margin:6pt 0pt 0pt 0pt"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">(e)&#160;&#160;In their role as trustees, all trustees owe a duty of loyalty to the shareholders and to the Fund. This duty of loyalty mandates that the best interests of the shareholders and the Fund take precedence over any interests possessed by a trustee. In the event of any conflict of interests, a trustee shall promptly disclose such conflict to the Chairman of the Board and Fund Counsel and recuse him or herself from any discussions or votes involving the conflict.</span></p><p style="margin:6pt 0pt 0pt 0pt"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">(f)&#160;&#160;The proceedings of the Board and its committees are confidential. Each trustee shall maintain the confidentiality of information received as part of his or her duty as a trustee.</span></p><p style="margin:6pt 0pt 0pt 0pt"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">10.&#160;&#160;Board Access to Senior Management and Key Service Providers</span></p><p style="margin:6pt 0pt 0pt 0pt"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">Trustees must have reasonable access to Fund management and senior management of the Adviser. Trustees must have reasonable access to Fund Counsel, auditors, and other key service providers. Independent Trustees must have reasonable access to independent legal counsel. The Chairman of the Board is responsible for fostering constructive interaction between Fund management and the Board. The chairman of each committee is responsible for fostering constructive interaction between Fund management and the committee.</span></p><p style="margin:6pt 0pt 0pt 0pt"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">11.&#160;&#160;Trustee Education</span></p><p style="margin:6pt 0pt 0pt 0pt"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">(a)&#160;&#160;New trustees will review background materials and participate in an orientation program that includes discussions with incumbent trustees and senior management. Topics covered will include investment operations, compliance practices and operations, financial operations, and organizational structure.</span></p><p style="margin:6pt 0pt 0pt 0pt"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">(b)&#160;&#160;Continuing trustee education will be a standing agenda item for each regularly scheduled meeting to cover timely topics based on industry developments and Fund operations.</span></p><p style="margin:6pt 0pt 0pt 0pt"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">12.&#160;&#160;Review of Strategic Planning</span></p><p style="margin:6pt 0pt 0pt 0pt"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">The Board will periodically review the continued organizational strength of the Fund, Fund management, and the Adviser to ensure the Fund's continued short-term and long-term viability. At least biannually, the Board will review the Fund's annual and longer term strategic business plans and management development and succession plan.</span></p><p style="margin:6pt 0pt 0pt 0pt"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">13.&#160;&#160;Board Compensation</span></p><p style="margin:6pt 0pt 0pt 0pt"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">The Independent Trustees will establish and periodically review their compensation.</span></p><p style="margin:6pt 0pt 0pt 0pt"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">14.&#160;&#160;Insurance Coverage and Indemnification</span></p><p style="margin:6pt 0pt 0pt 0pt"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">The Fund will maintain directors' and officers'/errors and omissions insurance coverage and/or indemnification that is adequate to ensure the independence and effectiveness of the Independent Trustees. The Independent Trustees will periodically review the effectiveness of such insurance coverage and/or indemnification.</span></p><p style="margin:6pt 0pt 0pt 0pt"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">15.&#160;&#160;Board Evaluation</span></p><p style="margin:6pt 0pt 0pt 0pt"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">The Governance and Nominating Committee shall prepare a Board self-evaluation instrument that each trustee shall complete annually.</span></p></div><p style="text-align:center"><br /><span style="font-size:13px;font-family:Times New Roman PS, Times New Roman, Times">22</span></p><hr style="height:2px;text-align:center;width:100%;background-color:gray;page-break-after:always" /><div style="margin:8pt 0pt 8pt 0pt"><p style="margin:0pt 0pt 0pt 0pt;text-align:center"><span style="font-size:10pt;font-family:Times New Roman, Times, serif"><strong>Appendix B</strong></span></p><p style="margin:6pt 0pt 0pt 0pt;text-align:center"><span style="font-size:10pt;font-family:Times New Roman, Times, serif"><strong>Procedures and Eligibility Requirements for<br />Shareholder Submission of Nominee Candidates</strong></span><span style="font-size:10pt;font-family:Times New Roman, Times, serif"><sup>1</sup></span></p><p style="margin:6pt 0pt 0pt 0pt"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">A.&#160;&#160;Nominee Requirements</span></p><p style="margin:6pt 0pt 0pt 0pt"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">Trustee nominees recommended by shareholders must fulfill the following requirements:</span></p><p style="margin:6pt 0pt 0pt 0pt"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">1.&#160;&#160;The nominee may not be the nominating shareholder, a member of the nominating shareholder group, or a member of the immediate family of the nominating shareholder or any member of the nominating shareholder group.</span></p><p style="margin:6pt 0pt 0pt 0pt"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">2.&#160;&#160;Neither the nominee nor any member of the nominee's immediate family may be currently employed or employed within the last year by any nominating shareholder entity or entity in a nominating shareholder group.</span></p><p style="margin:6pt 0pt 0pt 0pt"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">3.&#160;&#160;Neither the nominee nor any immediate family member of the nominee is permitted to have accepted directly or indirectly, during the year of the election for which the nominee's name was submitted, during the immediately preceding calendar year, or during the year when the nominee's name was submitted, any consulting, advisory, or other compensatory fee from the nominating shareholder or any member of a nominating shareholder group.</span></p><p style="margin:6pt 0pt 0pt 0pt"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">4.&#160;&#160;The nominee may not be an executive officer, director (or person performing similar functions) of the nominating shareholder or any member of the nominating shareholder group, or of an affiliate of the nominating shareholder or any such member of the nominating shareholder group.</span></p><p style="margin:6pt 0pt 0pt 0pt"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">5.&#160;&#160;The nominee may not control (as "control" is defined in the 1940 Act) the nominating shareholder or any member of the nominating shareholder group (or in the case of a holder or member that is a fund, an interested person of such holder or member as defined by Section 2(a)(19) of the 1940 Act).</span></p><p style="margin:6pt 0pt 0pt 0pt"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">B.&#160;&#160;Nominating Shareholder or Shareholder Group Requirements</span></p><p style="margin:6pt 0pt 0pt 0pt"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">The nominating shareholder or shareholder group must meet the following requirements:</span></p><p style="margin:6pt 0pt 0pt 0pt"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">1.&#160;&#160;Any shareholder or shareholder group submitting a proposed nominee must beneficially own, either individually or in the aggregate, more than 5% of the Fund's securities that are eligible to vote at the time of submission of the nominee and at the time of the meeting where the nominee may be elected. Each of the securities used for purposes of calculating the required ownership must have been held continuously for at least two years as of the date of the nomination. In addition, such securities must continue to be held through the date of the meeting. The nominating shareholder or shareholder group must also bear the economic risk of the investment, and the securities used for purposes of calculating the required ownership cannot be held "short."</span></p><p style="margin:6pt 0pt 0pt 0pt"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">2.&#160;&#160;The nominating shareholder or shareholder group must also submit a certification which provides the number of shares which the person or group has (i) sole power to vote or direct the vote; (ii) shared power to vote or direct the vote; (iii) sole power to dispose or direct the disposition of such shares; and (iv) shared power to dispose or direct the disposition of such shares. In addition, the certification shall provide that the shares have been held continuously for at least 2 years.</span></p></div><div style="margin:8pt 0pt 8pt 0pt"><p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:8pt;font-family:Times New Roman, Times, serif"><sup>1</sup>&#160;&#160;Appendix B applies only to trustee nominee recommendations made by shareholders to the Governance and Nominating Committee. Refer to the Fund's By-laws regarding submission of shareholder proposals for the election of trustees. Unless otherwise specified herein, please refer to the Securities Exchange Act of 1934 and regulations thereunder for interpretations of terms used in this Appendix B.</span></p></div><p style="text-align:center"><br /><span style="font-size:13px;font-family:Times New Roman PS, Times New Roman, Times">23</span></p><hr style="height:2px;text-align:center;width:100%;background-color:gray;page-break-after:always" /><div style="margin:8pt 0pt 8pt 0pt"><p style="margin:0pt 0pt 0pt 0pt"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">C.&#160;&#160;Deadlines and Limitations</span></p><p style="margin:6pt 0pt 0pt 0pt"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">1.&#160;&#160;A nominating shareholder or shareholder group may not submit more than one nominee per year.</span></p><p style="margin:6pt 0pt 0pt 0pt"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">2.&#160;&#160;All nominee submissions must be received by the Fund by the deadline for submission of any shareholder proposals which would be included in the Fund's proxy statement for the next annual meeting of the Fund.</span></p><p style="margin:6pt 0pt 0pt 0pt"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">D.&#160;&#160;Making a Submission</span></p><p style="margin:6pt 0pt 0pt 0pt"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">Shareholders recommending potential trustee candidates must substantiate compliance with these requirements at the time of submitting their proposed trustee candidate to the attention of the Fund's Secretary. Notice to the Fund's Secretary should include: (i) the shareholder's contact information; (ii) the trustee candidate's contact information and the number of Fund shares owned by the proposed candidate; (iii) all information regarding the candidate that would be required to be disclosed in solicitations of proxies for elections of trustees required by Regulation 14A of the 1934 Act; and (iv) a notarized letter executed by the trustee candidate, stating his or her intention to stand for election and be named in the Fund's proxy statement, if nominated by the Board, and to serve as a trustee, if so elected.</span></p></div><p style="text-align:center"><br /><span style="font-size:13px;font-family:Times New Roman PS, Times New Roman, Times">24</span></p><hr style="height:2px;text-align:center;width:100%;background-color:gray;page-break-after:always" /></div><div style="font: 10pt Times New Roman, Times, Serif"><div>

</div><p style="margin: 0">&#xa0;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Arial, Helvetica, Sans-Serif; width: 100%">
  <tr style="font-family: Arial, Helvetica, Sans-Serif; vertical-align: bottom">
    <td style="text-align: left; font-family: Arial, Helvetica, Sans-Serif; vertical-align: bottom"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"><b>TEKLA
    HEALTHCARE INVESTORS</b></span></td>
    <td style="font: bold 14pt Arial, Helvetica, Sans-Serif; text-align: left; vertical-align: top">EVERY VOTE IS IMPORTANT</td></tr>
  <tr style="font-family: Arial, Helvetica, Sans-Serif; vertical-align: bottom">
    <td style="text-align: left; font-family: Arial, Helvetica, Sans-Serif; vertical-align: bottom"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"><b>PO
    Box 43131</b></span></td>
    <td style="font: bold 14pt Arial, Helvetica, Sans-Serif; text-align: left; vertical-align: top"><span style="font-size: 10pt">&#xa0;</span></td></tr>
  <tr style="font-family: Arial, Helvetica, Sans-Serif; vertical-align: bottom">
    <td style="text-align: left; font-family: Arial, Helvetica, Sans-Serif; width: 60%; vertical-align: top"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"><b>Providence,
    RI 02940-3131</b></span></td>
    <td style="font: bold 14pt Arial, Helvetica, Sans-Serif; text-align: left; width: 40%; vertical-align: top"><span style="font-family: Arial, Helvetica, Sans-Serif">EASY
    VOTING OPTIONS:</span></td></tr>
  </table><div>


</div><p style="font: bold 14pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 5in"><span style="font-family: Arial, Helvetica, Sans-Serif"><b>&#xa0;</b></span></p><div>

</div><p style="font: bold 14pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 5in"></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Arial, Helvetica, Sans-Serif; width: 100%">
  <tr style="font-family: Arial, Helvetica, Sans-Serif">
    <td style="font-family: Arial, Helvetica, Sans-Serif; width: 60%"><span style="font-family: Arial, Helvetica, Sans-Serif">&#xa0;</span></td>
    <td style="font-family: Arial, Helvetica, Sans-Serif; text-align: left; width: 15%"><span style="font-family: Arial, Helvetica, Sans-Serif"><img alt="" src="tm233915d1_def14aimg06.jpg" style="height: 86px; width: 89px" />&#xa0;</span></td>
    <td style="font: 9pt Arial, Helvetica, Sans-Serif; text-align: center; width: 25%; vertical-align: middle"><p style="font: 9pt Arial, Helvetica, Sans-Serif; margin: 0pt 0"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"><b>VOTE
                                            ON THE INTERNET<br />
                                            Log on to:<br />
                                            <span style="color: Blue"><span style="text-decoration: underline">www.proxy-direct.com</span></span></b></span></p>

<p style="font: 9pt Arial, Helvetica, Sans-Serif; margin: 0pt 0"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"><b>or
scan the QR code<br />
Follow the on-screen instructions<br />
<i>available 24 hours</i></b></span></p></td></tr>
  </table><div>
</div><p style="font: bold 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 5in"><span style="font-family: Arial, Helvetica, Sans-Serif"><b>&#xa0;</b></span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Arial, Helvetica, Sans-Serif; width: 100%">
  <tr style="font-family: Arial, Helvetica, Sans-Serif">
    <td style="font-family: Arial, Helvetica, Sans-Serif; width: 60%"><span style="font-family: Arial, Helvetica, Sans-Serif">&#xa0;</span></td>
    <td style="font-family: Arial, Helvetica, Sans-Serif; text-align: left; width: 15%"><span style="font-family: Arial, Helvetica, Sans-Serif"><img alt="" src="tm233915d1_def14aimg03.jpg" style="height: 100px; width: 75px" />&#xa0;</span></td>
    <td style="font: 9pt Arial, Helvetica, Sans-Serif; text-align: center; width: 25%; vertical-align: middle"><p style="font: 9pt Arial, Helvetica, Sans-Serif; margin: 0pt 0"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"><b>VOTE
                                            BY PHONE<br />
                                            Call 1-800-337-3503<br />
                                            Follow the recorded instructions<br />
                                            <i>available 24 hours</i></b></span></p></td></tr>
  </table><div>
</div><p style="margin: 0pt 0; font-family: Arial, Helvetica, Sans-Serif"><span style="font-family: Arial, Helvetica, Sans-Serif">&#xa0;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Arial, Helvetica, Sans-Serif; width: 100%">
  <tr style="font-family: Arial, Helvetica, Sans-Serif">
    <td style="font-family: Arial, Helvetica, Sans-Serif; width: 60%"><span style="font-family: Arial, Helvetica, Sans-Serif">&#xa0;</span></td>
    <td style="font-family: Arial, Helvetica, Sans-Serif; text-align: left; width: 15%"><span style="font-family: Arial, Helvetica, Sans-Serif"><img alt="" src="tm233915d1_def14aimg04.jpg" /></span></td>
    <td style="font: 9pt Arial, Helvetica, Sans-Serif; text-align: center; width: 25%; vertical-align: middle"><p style="font: 9pt Arial, Helvetica, Sans-Serif; margin: 0pt 0"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"><b>VOTE
                                            BY MAIL<br />
                                            Vote, sign and date this Proxy <br />
                                            Card and return in the <br />
                                            postage-paid envelope</b></span></p></td></tr>
  </table><div>
</div><p style="margin: 0pt 0; font-family: Arial, Helvetica, Sans-Serif"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 12pt">&#xa0;</span></p><div>

</div><p style="margin: 0pt 0; font-family: Arial, Helvetica, Sans-Serif"></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Arial, Helvetica, Sans-Serif; width: 100%">
  <tr style="font-family: Arial, Helvetica, Sans-Serif">
    <td style="font-family: Arial, Helvetica, Sans-Serif; width: 60%"><span style="font-family: Arial, Helvetica, Sans-Serif">&#xa0;</span></td>
    <td style="font-family: Arial, Helvetica, Sans-Serif; text-align: left; width: 15%"><span style="font-family: Arial, Helvetica, Sans-Serif"><img alt="" src="tm233915d1_def14aimg05.jpg" /></span></td>
    <td style="font: 9pt Arial, Helvetica, Sans-Serif; vertical-align: middle; text-align: center; width: 25%"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"><b>VOTE
    IN PERSON <br />
    Attend Shareholder Meeting<br />
    100 Federal Street, 19<sup>th</sup> Floor<br />
    Boston, MA 02110<br />
    on June 8, 2023 <br />
    at 12:00 P.M. Eastern Time</b></span></td></tr>
  </table><div>
</div><p style="margin: 0pt 0; font-family: Times New Roman, Serif"><span style="font-family: Arial, Helvetica, Sans-Serif">&#xa0;</span></p><div>

</div><p style="margin: 0pt 0; font-family: Arial, Helvetica, Sans-Serif"><span style="font-family: Arial, Helvetica, Sans-Serif">&#xa0;</span></p><div>

</div><p style="margin: 0pt 0; font-family: Arial, Helvetica, Sans-Serif"><span style="font-family: Arial, Helvetica, Sans-Serif">&#xa0;</span></p><div>

</div><p style="font: bold 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center"><span style="font-family: Arial, Helvetica, Sans-Serif"><b>Please
detach at perforation before mailing.</b></span></p><div>

</div><p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center"><span style="font-family: Arial, Helvetica, Sans-Serif"><b>&#xa0;</b></span></p><div>

</div><p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center"><span style="font-family: Arial, Helvetica, Sans-Serif"><b>&#xa0;</b></span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font-family: Arial, Helvetica, Sans-Serif; border-collapse: collapse; width: 100%">
  <tr style="font-family: Arial, Helvetica, Sans-Serif; vertical-align: bottom">
    <td style="font: normal bold 10pt Arial, Helvetica, Sans-Serif; width: 10%; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">PROXY</span></td>
    <td style="font: normal bold 10pt Arial, Helvetica, Sans-Serif; width: 80%; text-align: center"><span style="font-family: Arial, Helvetica, Sans-Serif">TEKLA HEALTHCARE INVESTORS</span></td>
    <td style="font: normal bold 10pt Arial, Helvetica, Sans-Serif; width: 10%; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">&#xa0;</span></td></tr>
  </table><div>


</div><p style="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Arial, Helvetica, Sans-Serif"><b>JOINT ANNUAL MEETING OF SHAREHOLDERS</b></span></p><div>

</div><p style="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Arial, Helvetica, Sans-Serif"><b>TO
BE HELD JUNE 8, 2023</b></span></p><div>

</div><p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center"><span style="font-family: Arial, Helvetica, Sans-Serif"><b>&#xa0;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><b>This
Proxy is Being Solicited on Behalf of the Board of Trustees. </b>The undersigned hereby appoints Jeffrey A. Bailey, Thomas M. Kent, CPA
and Daniel R. Omstead, Ph.D. and each of them, proxies of the undersigned, with full powers of substitution, to vote at the Joint Annual
Meeting of Shareholders of TEKLA HEALTHCARE INVESTORS (the &#x201c;Fund&#x201d;) to be held on June 8, 2023 at 12:00 p.m. at 100 Federal
Street, 19<sup>th</sup> Floor, Boston, Massachusetts 02110, and at any adjournment(s) or postponement(s) thereof, all the shares of the
Fund outstanding in the name of the undersigned as follows on the reverse of this card. We encourage you to check our website: <span style="color: Blue"><span style="text-decoration:underline">www.teklacap.com</span></span>&#xa0;prior
to the Joint Annual Meeting if you plan to attend.</span></p><div>

</div><p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif">&#xa0;</span></p><div>

</div><p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif"><b>THIS
PROXY WILL BE VOTED AS SPECIFIED. IF NO SPECIFICATION IS MADE, THIS PROXY WILL BE VOTED FOR ALL PROPOSALS.</b></span></p><div>

</div><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%">
  <tr style="font-size: 8pt; vertical-align: bottom">
    <td style="font-size: 8pt">&#xa0;</td>
    <td colspan="3" style="font: bold 8pt Arial, Helvetica, Sans-Serif"><span style="font-size: 8pt">VOTE VIA THE INTERNET: www.proxy-direct.com&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;</span></td></tr>
  <tr style="font-size: 8pt; vertical-align: bottom">
    <td style="font-size: 8pt; padding-bottom: 5pt">&#xa0;</td>
    <td colspan="3" style="font: bold 8pt Arial, Helvetica, Sans-Serif; padding-bottom: 5pt"><span style="font-size: 8pt">VOTE VIA THE TELEPHONE: 1-800-337-3503</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-top: 3pt; padding-bottom: 3pt; width: 60%">&#xa0;</td>
    <td style="border: Black 1pt solid; font: bold 10pt Arial, Helvetica, Sans-Serif; background-color: rgb(216,216,216); padding-top: 3pt; padding-bottom: 3pt; width: 20%">&#xa0;</td>
    <td style="border-top: White 1pt solid; font: bold 10pt Arial, Helvetica, Sans-Serif; padding-top: 3pt; padding-bottom: 3pt; width: 5%">&#xa0;</td>
    <td style="border: Black 1pt solid; font: bold 10pt Arial, Helvetica, Sans-Serif; padding-top: 3pt; padding-bottom: 3pt; width: 15%">&#xa0;</td></tr>
  </table><div>



</div><p style="font: bold 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 4.5in; text-align: right"></p><div>

</div><p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 4.5in"><span style="font-family: Arial, Helvetica, Sans-Serif">&#xa0;</span></p><div>

</div><p style="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Arial, Helvetica, Sans-Serif">&#xa0;</span></p><div>

</div><p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center"><span style="font-family: Arial, Helvetica, Sans-Serif">&#xa0;</span></p><div>

</div><p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center"><span style="font-family: Arial, Helvetica, Sans-Serif">&#xa0;</span></p><div>

</div><p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center"><span style="font-family: Arial, Helvetica, Sans-Serif">&#xa0;</span></p><div>

</div><p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center"><span style="font-family: Arial, Helvetica, Sans-Serif">&#xa0;</span></p><div>

</div><p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center"><span style="font-family: Arial, Helvetica, Sans-Serif">&#xa0;</span></p><div>

</div><p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center"><span style="font-family: Arial, Helvetica, Sans-Serif">&#xa0;</span></p><div>

</div><p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center"><span style="font-family: Arial, Helvetica, Sans-Serif">&#xa0;</span></p><div>

</div><p style="font: 8pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center"><span style="font: normal 8pt Arial, Helvetica, Sans-Serif">HQH_33282_040523</span></p><div>

</div><p style="font: bold 8pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 8pt"><b>PLEASE
MARK, SIGN, DATE ON THE REVERSE SIDE AND RETURN THIS PROXY PROMPTLY USING THE ENCLOSED ENVELOPE.</b></span></p><div>

</div><p style="font: bold 8pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center"><span style="font-size: 2pt">&#xa0;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font-size: 8pt; border-collapse: collapse; width: 100%">
  <tr style="font-size: 8pt; vertical-align: bottom">
    <td style="font: 8pt Arial, Helvetica, Sans-Serif; padding-top: 1pt; text-align: left; width: 9%; vertical-align: middle; padding-bottom: 1pt"><span style="font-size: 8pt"><b>xxxxxxxxxxxxxx</b></span></td>
    <td style="font: 8pt Arial, Helvetica, Sans-Serif; padding-top: 1pt; text-align: center; width: 2%; vertical-align: middle; padding-bottom: 1pt"><span style="font-size: 8pt">&#xa0;</span></td>
    <td style="border: Black 1pt solid; font: 8pt Arial, Helvetica, Sans-Serif; padding-top: 1pt; vertical-align: middle; text-align: center; width: 6%; padding-bottom: 1pt"><span style="font-size: 8pt">code</span></td>
    <td style="font: 8pt Arial, Helvetica, Sans-Serif; padding-top: 1pt; text-align: center; width: 83%; vertical-align: middle; padding-bottom: 1pt"><span style="font-size: 8pt">&#xa0;</span></td></tr>
  </table><div>


</div><p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&#xa0;</span></p><div>

</div><p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 1 --><div>
    </div><div style="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="margin: 0pt">&#xa0;</p></div><div>
    </div><div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#xa0;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&#xa0;</span></p><div>

</div><p style="font: bold 14pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center"><span style="font-family: Arial, Helvetica, Sans-Serif"><b>EVERY
SHAREHOLDER&#x2019;S VOTE IS IMPORTANT</b></span></p><div>

</div><p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center"><span style="font-family: Arial, Helvetica, Sans-Serif; font-weight: normal">&#xa0;</span></p><div>

</div><p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center"><span style="font-family: Arial, Helvetica, Sans-Serif; font-weight: normal">&#xa0;</span></p><div>

</div><p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center"><span style="font-family: Arial, Helvetica, Sans-Serif; font-weight: normal">&#xa0;</span></p><div>

</div><p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center"><span style="font-family: Arial, Helvetica, Sans-Serif; font-weight: normal">&#xa0;</span></p><div>

</div><p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center"><span style="font-family: Arial, Helvetica, Sans-Serif; font-weight: normal">&#xa0;</span></p><div>

</div><p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center"><span style="font-family: Arial, Helvetica, Sans-Serif; font-weight: normal">&#xa0;</span></p><div>

</div><p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center"><span style="font-family: Arial, Helvetica, Sans-Serif; font-weight: normal">&#xa0;</span></p><div>

</div><p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center"><span style="font-family: Arial, Helvetica, Sans-Serif; font-weight: normal">&#xa0;</span></p><div>

</div><p style="font: 12pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 12pt"><b>Important
Notice Regarding the Availability of Proxy Materials for the </b></span></p><div>

</div><p style="font: 12pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 12pt"><b>Joint
Annual Shareholder Meeting to Be Held on June 8, 2023.</b></span></p><div>

</div><p style="font: bold 12pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 12pt"><b>The
Joint Proxy Statement and Proxy Card for this meeting are available at: </b></span></p><div>

</div><p style="font: bold 12pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 12pt; color: Blue"><b><span style="text-decoration: underline">https://www.proxy-direct.com/tkl-33282</span></b></span></p><div>

</div><p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center"><span style="font-family: Arial, Helvetica, Sans-Serif; font-weight: normal">&#xa0;</span></p><div>

</div><p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center"><span style="font-family: Arial, Helvetica, Sans-Serif; font-weight: normal">&#xa0;</span></p><div>

</div><p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center"><span style="font-family: Arial, Helvetica, Sans-Serif; font-weight: normal">&#xa0;</span></p><div>

</div><p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center"><span style="font-family: Arial, Helvetica, Sans-Serif; font-weight: normal">&#xa0;</span></p><div>

</div><p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center"><span style="font-family: Arial, Helvetica, Sans-Serif; font-weight: normal">&#xa0;</span></p><div>

</div><p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center"><span style="font-family: Arial, Helvetica, Sans-Serif; font-weight: normal">&#xa0;</span></p><div>

</div><p style="font: bold 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 12pt"><b>IF
YOU VOTE ON THE INTERNET OR BY TELEPHONE,</b></span></p><div>

</div><p style="font: bold 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 12pt"><b>YOU
NEED NOT RETURN THIS PROXY CARD</b></span></p><div>

</div><p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center"><span style="font-family: Arial, Helvetica, Sans-Serif; font-weight: normal">&#xa0;</span></p><div>

</div><p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center"><span style="font-family: Arial, Helvetica, Sans-Serif; font-weight: normal">&#xa0;</span></p><div>

</div><p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center"><span style="font-family: Arial, Helvetica, Sans-Serif; font-weight: normal">&#xa0;</span></p><div>

</div><p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center"><span style="font-family: Arial, Helvetica, Sans-Serif; font-weight: normal">&#xa0;</span></p><div>

</div><p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center"><span style="font-family: Arial, Helvetica, Sans-Serif; font-weight: normal">&#xa0;</span></p><div>

</div><p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center"><span style="font-family: Arial, Helvetica, Sans-Serif; font-weight: normal">&#xa0;</span></p><div>

</div><p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center"><span style="font-family: Arial, Helvetica, Sans-Serif; font-weight: normal">&#xa0;</span></p><div>

</div><p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center"><span style="font-family: Arial, Helvetica, Sans-Serif; font-weight: normal">&#xa0;</span></p><div>

</div><p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center"><span style="font-family: Arial, Helvetica, Sans-Serif; font-weight: normal">&#xa0;</span></p><div>

</div><p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center"></p><div>

</div><p style="font: bold 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center"><span style="font-family: Arial, Helvetica, Sans-Serif"><b>Please
detach at perforation before mailing.</b></span></p><div>

</div><p style="margin: 0pt 0; font-family: Arial, Helvetica, Sans-Serif"><span style="font-family: Arial, Helvetica, Sans-Serif">&#xa0;</span></p><div>

</div><p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: center"><b>&#xa0;</b></p><div>

</div><p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><b>TO
VOTE MARK BLOCKS BELOW IN BLUE OR BLACK INK AS SHOWN IN THIS EXAMPLE: </b></span><b><span style=" font-size: 8pt">&#x2612;</span></b></p><div>

</div><p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><b>&#xa0;</b></span></p><div>

</div><p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"></p><p style="font: 9pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: bold 10pt Arial, Helvetica, Sans-Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="background-color: Black; width: 3%; text-align: center"><span style="color: white">A</span></td>
                                                                                                                                           <td style="text-align: justify; width: 10%">&#xa0;&#xa0;&#xa0;Proposals</td>
                                                                                                                <td style="text-align: justify; width: 87%">The Board of Trustees recommends a vote FOR all the nominees listed and FOR Proposal 2.</td>
</tr></table><div>

</div><p style="font: bold 9pt Arial, Helvetica, Sans-Serif; margin: 0"><span style="font-size: 5pt">&#xa0;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 9pt Arial, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse">
  <tr style="font-size: 9pt; vertical-align: top">
    <td rowspan="2" style="font-size: 9pt; text-align: center"><span style="font-size: 9pt"><b>1.</b></span></td>
    <td colspan="6" rowspan="2" style="font-size: 9pt; text-align: left"><span style="font-size: 9pt">&#xa0;&#xa0;&#xa0;<span style="color: #231F20"><b>The
    election of two Class A Trustees:</b></span></span></td>
    <td style="font-size: 9pt; text-align: center"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 7pt">FOR</span></td>
    <td style="white-space: nowrap; font-size: 9pt; text-align: center"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 7pt">WITHHOLD
    </span></td>
    <td style="font-size: 9pt; text-align: center"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 7pt">FOR ALL</span></td></tr>
  <tr style="font-size: 9pt; vertical-align: top">
    <td style="font-size: 9pt; text-align: center"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 7pt">ALL </span></td>
    <td style="font-size: 9pt; text-align: center"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 7pt">ALL </span></td>
    <td style="font-size: 9pt; text-align: center"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 7pt">EXCEPT</span></td></tr>
  <tr style="font-size: 9pt">
    <td style="font-size: 9pt; vertical-align: top; width: 3%; text-align: center"><span style="font-size: 9pt">&#xa0;</span></td>
    <td style="font-size: 9pt; width: 4%"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">&#xa0;&#xa0;&#xa0;01.</span></td>
    <td style="font-size: 9pt; width: 22%"><span style="font-size: 9pt">Jeffrey A. Bailey</span></td>
    <td style="font-size: 9pt; width: 3%"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">02.</span></td>
    <td style="font-size: 9pt; width: 22%"><span style="font-size: 9pt">Rakesh K. Jain, Ph.D.</span></td>
    <td style="font-size: 9pt; width: 3%"></td>
    <td style="font-size: 9pt; width: 22%"></td>
    <td style="font-size: 9pt; vertical-align: top; width: 7%; text-align: center"><span style="font-size: 9pt">&#x2610;</span></td>
    <td style="font-size: 9pt; vertical-align: top; width: 7%; text-align: center"><span style="font-size: 9pt">&#x2610;</span></td>
    <td style="font-size: 9pt; vertical-align: top; width: 7%; text-align: center"><span style="font-size: 9pt">&#x2610;</span></td></tr>
  </table><div>

</div><p style="font: bold 9pt Arial, Helvetica, Sans-Serif; margin: 0"><span style="font-size: 5pt">&#xa0;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 9pt Arial, Helvetica, Sans-Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="font-size: 9pt; vertical-align: top; text-align: justify">
<td style="font-size: 9pt; width: 3%; text-align: left"></td><td style="font-size: 9pt; text-align: justify; width: 97%"><span style="font-size: 9pt">&#xa0;&#xa0;&#xa0;<b><span style="text-decoration: underline">INSTRUCTIONS:</span>&#xa0;</b>To withhold authority to vote for any individual nominee(s), mark the box</span></td></tr></table><div>

</div><table cellpadding="0" cellspacing="0" style="font: 9pt Arial, Helvetica, Sans-Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="font-size: 9pt; vertical-align: top; text-align: justify">
<td style="font-size: 9pt; width: 3%"></td><td style="font-size: 9pt; text-align: justify; width: 97%"><span style="font-size: 9pt">&#xa0;&#xa0;&#xa0;&#x201c;FOR ALL
                           EXCEPT&#x201d; and write the nominee&#x2019;s number on the line provided below.</span></td>
</tr></table><div>

</div><table cellpadding="0" cellspacing="0" style="font: 9pt Arial, Helvetica, Sans-Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="font-size: 9pt; vertical-align: top; text-align: justify">
<td style="font-size: 9pt; width: 3%"></td><td style="font-size: 9pt; padding-right: 30; padding-left: 10; text-align: justify; width: 60%"><p style="border-bottom: Black 1pt solid; font-size: 9pt; margin-top: 0; margin-bottom: 0"><span style="font-size: 9pt">&#xa0;</span></p>
                                                                    <p style="font-size: 9pt; margin-top: 0; margin-bottom: 0"></p></td><td style="font-size: 9pt; text-align: justify; width: 37%"><span style="font-size: 9pt">&#xa0;</span></td>
</tr></table><div>

</div><p style="font: 9pt Arial, Helvetica, Sans-Serif; margin: 0; text-indent: 0.25in"><span style="font-size: 5pt">&#xa0;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 9pt Arial, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse">
  <tr style="font-size: 9pt; vertical-align: top">
    <td rowspan="2" style="font-size: 9pt; padding-top: 8; width: 3%; text-align: center"><span style="font-size: 9pt"><b>2.</b></span></td>
    <td rowspan="2" style="font-size: 9pt; padding-top: 8; padding-right: 30; padding-left: 10; text-align: justify; width: 76%"><span style="font-size: 9pt">The
    ratification or rejection of the selection of Deloitte &amp; Touche LLP as the independent registered public accountants of the Fund
    for the fiscal year ending September 30, 2023.</span></td>
    <td style="font-size: 9pt; vertical-align: bottom; width: 7%; text-align: center"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 7pt">FOR</span></td>
    <td style="font-size: 9pt; vertical-align: bottom; width: 7%; text-align: center"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 7pt">AGAINST
    </span></td>
    <td style="font-size: 9pt; vertical-align: bottom; width: 7%; text-align: center"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 7pt">ABSTAIN</span></td></tr>
  <tr style="font-size: 9pt; vertical-align: top">
    <td style="font-size: 9pt; text-align: center"><span style="font-size: 9pt">&#x2610;</span></td>
    <td style="font-size: 9pt; text-align: center"><span style="font-size: 9pt">&#x2610;</span></td>
    <td style="font-size: 9pt; text-align: center"><span style="font-size: 9pt">&#x2610;</span></td></tr>
  </table><div>
</div><p style="font: bold 9pt Arial, Helvetica, Sans-Serif; margin: 0"></p><div>

</div><p style="font: bold 9pt Arial, Helvetica, Sans-Serif; margin: 0"><span style="font-size: 5pt">&#xa0;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 9pt Arial, Helvetica, Sans-Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font-size: 9pt; vertical-align: top">
<td style="font-size: 9pt; text-align: center; width: 3%"><span style="font-size: 9pt"><b>3.</b></span></td><td style="font-size: 9pt; padding-right: 30; padding-left: 10; text-align: justify; width: 76%"><span style="font-size: 9pt">The
                                            transaction of such other business as may properly come before the Annual Meeting and any
                                            adjournment(s) or postponement(s) thereof.</span></td>
                                                                  <td style="font-size: 9pt; vertical-align: middle; text-align: center; width: 7%"></td>
                                                                  <td style="font-size: 9pt; vertical-align: middle; text-align: center; width: 7%"></td>
                                                                  <td style="font-size: 9pt; vertical-align: middle; text-align: center; width: 7%"></td></tr></table><div>

</div><p style="font: 9pt Arial, Helvetica, Sans-Serif; margin: 0 99.35pt 0 0.25in; text-align: justify; text-indent: -0.25in"><span style="font-size: 5pt">&#xa0;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 12pt Arial, Helvetica, Sans-Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="vertical-align: middle; background-color: Black; width: 3%; text-align: center"><span style="font-size: 9pt; color: white"><b>B</b></span></td><td style="text-align: justify; width: 97%">&#xa0;&#xa0;<span style="font-size: 10pt"><b>Authorized Signatures &#x2500;
This section must be completed for your vote to be counted. &#x2500; Sign and Date Below</b></span></td>
</tr></table><div>

</div><p style="font: 5pt Arial, Helvetica, Sans-Serif; margin-top: 0; margin-bottom: 0">&#xa0;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 12pt Arial, Helvetica, Sans-Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="text-align: justify; width: 3%"><span style="font-size: 8pt"><b>Note</b>: </span></td>
<td style="padding-left: 5pt; text-align: justify; width: 97%"><span style="font-size: 8pt">Please sign exactly as your name(s) appear(s) on this Proxy Card, and date it. When shares are held jointly,
each holder should sign. When signing as attorney, executor, guardian, administrator, trustee, officer of corporation or other entity
or in another representative capacity, please give the full title under the signature</span><span style="font-size: 7pt">.</span></td>
</tr></table><div>

</div><p style="font: 5pt Arial, Helvetica, Sans-Serif; margin: 0"><b>&#xa0;</b></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 11pt Arial, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="white-space: nowrap; width: 32%"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 8pt"><b>Date (mm/dd/yyyy)  &#x2014;Please print date below</b></span></td>
    <td style="white-space: nowrap; width: 2%">&#xa0;</td>
    <td style="white-space: nowrap; width: 32%"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 8pt"><b>Signature 1 &#x2014; Please keep
    signature within the box</b></span></td>
    <td style="white-space: nowrap; width: 2%">&#xa0;</td>
    <td style="white-space: nowrap; width: 32%"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 8pt"><b>Signature
    2 &#x2014;  Please keep signature within the box</b></span></td></tr>
  <tr style="vertical-align: top">
    <td style="border: Black 1.5pt solid; padding: 3; text-align: center"><span style="font-size: 22"><b>/&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;/</b></span></td>
    <td style="padding: 3"><span style="font-size: 22">&#xa0;</span></td>
    <td style="border: Black 1.5pt solid; padding: 3"><span style="font-size: 22">&#xa0;</span></td>
    <td style="padding: 3"><span style="font-size: 22">&#xa0;</span></td>
    <td style="border: Black 1.5pt solid; padding: 3"><span style="font-size: 22">&#xa0;</span></td></tr>
  </table><div>
</div><p style="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0">&#xa0;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 9pt Arial, Helvetica, Sans-Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="border: Black 1pt solid; padding-top: 3; text-align: center; padding-bottom: 3">Scanner bar code</td>
</tr></table><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; border-collapse: collapse; font-family: Arial, Helvetica, Sans-Serif">
  <tr style="vertical-align: top">
    <td style="text-align: center; width: 34%; font-size: 11pt"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 14pt">xxxxxxxxxxxxxx </span></td>
    <td style="text-align: center; width: 33%; font-size: 11pt"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 14pt">HQH 33282 </span></td>
    <td style="text-align: center; width: 33%; font-size: 11pt"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 14pt">xxxxxxxx</span></td></tr>
  </table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#xa0;</p><div>

</div><p style="margin-top: 0; margin-bottom: 0"></p><div>

</div><!-- Field: Page; Sequence: 2 --><div>
    </div><div style="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="margin: 0pt">&#xa0;</p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#xa0;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#xa0;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Arial, Helvetica, Sans-Serif; width: 100%">
  <tr style="font-family: Arial, Helvetica, Sans-Serif; vertical-align: bottom">
    <td style="text-align: left; font-family: Arial, Helvetica, Sans-Serif; vertical-align: bottom"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"><b>TEKLA HEALTHCARE OPPORTUNITIES FUND</b></span></td>
    <td style="font: bold 14pt Arial, Helvetica, Sans-Serif; text-align: left; vertical-align: top">EVERY VOTE IS IMPORTANT</td></tr>
  <tr style="font-family: Arial, Helvetica, Sans-Serif; vertical-align: bottom">
    <td style="text-align: left; font-family: Arial, Helvetica, Sans-Serif; vertical-align: bottom"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"><b>PO
    Box 43131</b></span></td>
    <td style="font: bold 14pt Arial, Helvetica, Sans-Serif; text-align: left; vertical-align: top"><span style="font-size: 10pt">&#xa0;</span></td></tr>
  <tr style="font-family: Arial, Helvetica, Sans-Serif; vertical-align: bottom">
    <td style="text-align: left; font-family: Arial, Helvetica, Sans-Serif; width: 60%; vertical-align: top"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"><b>Providence,
    RI 02940-3131</b></span></td>
    <td style="font: bold 14pt Arial, Helvetica, Sans-Serif; text-align: left; width: 40%; vertical-align: top"><span style="font-family: Arial, Helvetica, Sans-Serif">EASY
    VOTING OPTIONS:</span></td></tr>
  </table><div>


</div><p style="font: bold 14pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 5in"><span style="font-family: Arial, Helvetica, Sans-Serif"><b>&#xa0;</b></span></p><div>

</div><p style="font: bold 14pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 5in"></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Arial, Helvetica, Sans-Serif; width: 100%">
  <tr style="font-family: Arial, Helvetica, Sans-Serif">
    <td style="font-family: Arial, Helvetica, Sans-Serif; width: 60%"><span style="font-family: Arial, Helvetica, Sans-Serif">&#xa0;</span></td>
    <td style="font-family: Arial, Helvetica, Sans-Serif; text-align: left; width: 15%"><span style="font-family: Arial, Helvetica, Sans-Serif"><img alt="" src="tm233915d1_def14aimg06.jpg" style="height: 86px; width: 89px" />&#xa0;</span></td>
    <td style="font: 9pt Arial, Helvetica, Sans-Serif; text-align: center; width: 25%; vertical-align: middle"><p style="font: 9pt Arial, Helvetica, Sans-Serif; margin: 0pt 0"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"><b>VOTE
                                            ON THE INTERNET<br />
                                            Log on to:<br />
                                            <span style="color: Blue"><span style="text-decoration: underline">www.proxy-direct.com</span></span></b></span></p>

<p style="font: 9pt Arial, Helvetica, Sans-Serif; margin: 0pt 0"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"><b>or
scan the QR code<br />
Follow the on-screen instructions<br />
<i>available 24 hours</i></b></span></p></td></tr>
  </table><div>
</div><p style="font: bold 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 5in"><span style="font-family: Arial, Helvetica, Sans-Serif"><b>&#xa0;</b></span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Arial, Helvetica, Sans-Serif; width: 100%">
  <tr style="font-family: Arial, Helvetica, Sans-Serif">
    <td style="font-family: Arial, Helvetica, Sans-Serif; width: 60%"><span style="font-family: Arial, Helvetica, Sans-Serif">&#xa0;</span></td>
    <td style="font-family: Arial, Helvetica, Sans-Serif; text-align: left; width: 15%"><span style="font-family: Arial, Helvetica, Sans-Serif"><img alt="" src="tm233915d1_def14aimg03.jpg" style="height: 100px; width: 75px" />&#xa0;</span></td>
    <td style="font: 9pt Arial, Helvetica, Sans-Serif; text-align: center; width: 25%; vertical-align: middle"><p style="font: 9pt Arial, Helvetica, Sans-Serif; margin: 0pt 0"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"><b>VOTE
                                            BY PHONE<br />
                                            Call 1-800-337-3503<br />
                                            Follow the recorded instructions<br />
                                            <i>available 24 hours</i></b></span></p></td></tr>
  </table><div>
</div><p style="margin: 0pt 0; font-family: Arial, Helvetica, Sans-Serif"><span style="font-family: Arial, Helvetica, Sans-Serif">&#xa0;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Arial, Helvetica, Sans-Serif; width: 100%">
  <tr style="font-family: Arial, Helvetica, Sans-Serif">
    <td style="font-family: Arial, Helvetica, Sans-Serif; width: 60%"><span style="font-family: Arial, Helvetica, Sans-Serif">&#xa0;</span></td>
    <td style="font-family: Arial, Helvetica, Sans-Serif; text-align: left; width: 15%"><span style="font-family: Arial, Helvetica, Sans-Serif"><img alt="" src="tm233915d1_def14aimg04.jpg" /></span></td>
    <td style="font: 9pt Arial, Helvetica, Sans-Serif; text-align: center; width: 25%; vertical-align: middle"><p style="font: 9pt Arial, Helvetica, Sans-Serif; margin: 0pt 0"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"><b>VOTE
                                            BY MAIL<br />
                                            Vote, sign and date this Proxy <br />
                                            Card and return in the <br />
                                            postage-paid envelope</b></span></p></td></tr>
  </table><div>
</div><p style="margin: 0pt 0; font-family: Arial, Helvetica, Sans-Serif"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 12pt">&#xa0;</span></p><div>

</div><p style="margin: 0pt 0; font-family: Arial, Helvetica, Sans-Serif"></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Arial, Helvetica, Sans-Serif; width: 100%">
  <tr style="font-family: Arial, Helvetica, Sans-Serif">
    <td style="font-family: Arial, Helvetica, Sans-Serif; width: 60%"><span style="font-family: Arial, Helvetica, Sans-Serif">&#xa0;</span></td>
    <td style="font-family: Arial, Helvetica, Sans-Serif; text-align: left; width: 15%"><span style="font-family: Arial, Helvetica, Sans-Serif"><img alt="" src="tm233915d1_def14aimg05.jpg" /></span></td>
    <td style="font: 9pt Arial, Helvetica, Sans-Serif; vertical-align: middle; text-align: center; width: 25%"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"><b>VOTE
    IN PERSON <br />
    Attend Shareholder Meeting<br />
    100 Federal Street, 19<sup>th</sup> Floor<br />
    Boston, MA 02110<br />
    on June 8, 2023 <br />
    at 12:00 P.M. Eastern Time</b></span></td></tr>
  </table><div>
</div><p style="margin: 0pt 0; font-family: Times New Roman, Serif"><span style="font-family: Arial, Helvetica, Sans-Serif">&#xa0;</span></p><div>

</div><p style="margin: 0pt 0; font-family: Times New Roman, Serif"><span style="font-family: Arial, Helvetica, Sans-Serif">&#xa0;</span></p><div>

</div><p style="margin: 0pt 0; font-family: Arial, Helvetica, Sans-Serif"><span style="font-family: Arial, Helvetica, Sans-Serif">&#xa0;</span></p><div>

</div><p style="font: bold 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center"><span style="font-family: Arial, Helvetica, Sans-Serif"><b>Please
detach at perforation before mailing.</b></span></p><div>

</div><p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center"><span style="font-family: Arial, Helvetica, Sans-Serif"><b>&#xa0;</b></span></p><div>

</div><p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center"><span style="font-family: Arial, Helvetica, Sans-Serif"><b>&#xa0;</b></span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font-family: Arial, Helvetica, Sans-Serif; border-collapse: collapse; width: 100%">
  <tr style="font-family: Arial, Helvetica, Sans-Serif; vertical-align: bottom">
    <td style="font: normal bold 10pt Arial, Helvetica, Sans-Serif; width: 10%; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">PROXY</span></td>
    <td style="font: normal bold 10pt Arial, Helvetica, Sans-Serif; width: 80%; text-align: center"><span style="font-family: Arial, Helvetica, Sans-Serif">TEKLA HEALTHCARE OPPORTUNITIES FUND</span></td>
    <td style="font: normal bold 10pt Arial, Helvetica, Sans-Serif; width: 10%; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">&#xa0;</span></td></tr>
  </table><div>


</div><p style="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Arial, Helvetica, Sans-Serif"><b>JOINT
ANNUAL MEETING OF SHAREHOLDERS </b></span></p><div>

</div><p style="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Arial, Helvetica, Sans-Serif"><b>TO
BE HELD JUNE 8, 2023</b></span></p><div>

</div><p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center"><span style="font-family: Arial, Helvetica, Sans-Serif"><b>&#xa0;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif"><b>This
Proxy is Being Solicited on Behalf of the Board of Trustees. </b>The undersigned hereby appoints Jeffrey A. Bailey, Thomas M. Kent, CPA
and Daniel R. Omstead, Ph.D. and each of them, proxies of the undersigned, with full powers of substitution, to vote at the Joint Annual
Meeting of Shareholders of TEKLA HEALTHCARE OPPORTUNITIES FUND (the &#x201c;Fund&#x201d;) to be held on June 8, 2023 at 12:00 p.m. at 100
Federal Street, 19<sup>th</sup> Floor, Boston, Massachusetts 02110, and at any adjournment(s) or postponement(s) thereof, all the shares
of the Fund outstanding in the name of the undersigned as follows on the reverse of this card. We encourage you to check our website:
<span style="color: Blue"><span style="text-decoration:underline">www.teklacap.com</span></span>&#xa0;prior to the Joint Annual Meeting if you plan to attend.</span></p><div>

</div><p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif">&#xa0;</span></p><div>

</div><p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif"><b>THIS
PROXY WILL BE VOTED AS SPECIFIED. IF NO SPECIFICATION IS MADE, THIS PROXY WILL BE VOTED FOR ALL PROPOSALS.</b></span></p><div>

</div><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%">
  <tr style="font-size: 8pt; vertical-align: bottom">
    <td style="font-size: 8pt">&#xa0;</td>
    <td colspan="3" style="font: bold 8pt Arial, Helvetica, Sans-Serif"><span style="font-size: 8pt">VOTE VIA THE INTERNET: www.proxy-direct.com&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;</span></td></tr>
  <tr style="font-size: 8pt; vertical-align: bottom">
    <td style="font-size: 8pt; padding-bottom: 5pt">&#xa0;</td>
    <td colspan="3" style="font: bold 8pt Arial, Helvetica, Sans-Serif; padding-bottom: 5pt"><span style="font-size: 8pt">VOTE VIA THE TELEPHONE: 1-800-337-3503</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-top: 3pt; padding-bottom: 3pt; width: 60%">&#xa0;</td>
    <td style="border: Black 1pt solid; font: bold 10pt Arial, Helvetica, Sans-Serif; background-color: rgb(216,216,216); padding-top: 3pt; padding-bottom: 3pt; width: 20%">&#xa0;</td>
    <td style="border-top: White 1pt solid; font: bold 10pt Arial, Helvetica, Sans-Serif; padding-top: 3pt; padding-bottom: 3pt; width: 5%">&#xa0;</td>
    <td style="border: Black 1pt solid; font: bold 10pt Arial, Helvetica, Sans-Serif; padding-top: 3pt; padding-bottom: 3pt; width: 15%">&#xa0;</td></tr>
  </table><div>



</div><p style="font: bold 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 4.5in; text-align: right"></p><div>

</div><p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 4.5in"><span style="font-family: Arial, Helvetica, Sans-Serif">&#xa0;</span></p><div>

</div><p style="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Arial, Helvetica, Sans-Serif">&#xa0;</span></p><div>

</div><p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center"><span style="font-family: Arial, Helvetica, Sans-Serif">&#xa0;</span></p><div>

</div><p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center"><span style="font-family: Arial, Helvetica, Sans-Serif">&#xa0;</span></p><div>

</div><p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center"><span style="font-family: Arial, Helvetica, Sans-Serif">&#xa0;</span></p><div>

</div><p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center"><span style="font-family: Arial, Helvetica, Sans-Serif">&#xa0;</span></p><div>

</div><p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center"><span style="font-family: Arial, Helvetica, Sans-Serif">&#xa0;</span></p><div>

</div><p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center"><span style="font-family: Arial, Helvetica, Sans-Serif">&#xa0;</span></p><div>

</div><p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center"><span style="font-family: Arial, Helvetica, Sans-Serif">&#xa0;</span></p><div>

</div><p style="font: 8pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center"><span style="font: normal 8pt Arial, Helvetica, Sans-Serif">THQ_33282_040523</span></p><div>

</div><p style="font: bold 8pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 8pt"><b>PLEASE
MARK, SIGN, DATE ON THE REVERSE SIDE AND RETURN THIS PROXY PROMPTLY USING THE ENCLOSED ENVELOPE.</b></span></p><div>

</div><p style="font: bold 8pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center"><span style="font-size: 2pt">&#xa0;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font-size: 8pt; border-collapse: collapse; width: 100%">
  <tr style="font-size: 8pt; vertical-align: bottom">
    <td style="font: 8pt Arial, Helvetica, Sans-Serif; padding-top: 1pt; text-align: left; width: 9%; vertical-align: middle; padding-bottom: 1pt"><span style="font-size: 8pt"><b>xxxxxxxxxxxxxx</b></span></td>
    <td style="font: 8pt Arial, Helvetica, Sans-Serif; padding-top: 1pt; text-align: center; width: 2%; vertical-align: middle; padding-bottom: 1pt"><span style="font-size: 8pt">&#xa0;</span></td>
    <td style="border: Black 1pt solid; font: 8pt Arial, Helvetica, Sans-Serif; padding-top: 1pt; vertical-align: middle; text-align: center; width: 6%; padding-bottom: 1pt"><span style="font-size: 8pt">code</span></td>
    <td style="font: 8pt Arial, Helvetica, Sans-Serif; padding-top: 1pt; text-align: center; width: 83%; vertical-align: middle; padding-bottom: 1pt"><span style="font-size: 8pt">&#xa0;</span></td></tr>
  </table><div>


</div><p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&#xa0;</span></p><div>

</div><p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 3 --><div>
    </div><div style="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="margin: 0pt">&#xa0;</p></div><div>
    </div><div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#xa0;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&#xa0;</span></p><div>

</div><p style="font: bold 14pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center"><span style="font-family: Arial, Helvetica, Sans-Serif"><b>EVERY
SHAREHOLDER&#x2019;S VOTE IS IMPORTANT</b></span></p><div>

</div><p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center"><span style="font-family: Arial, Helvetica, Sans-Serif; font-weight: normal">&#xa0;</span></p><div>

</div><p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center"><span style="font-family: Arial, Helvetica, Sans-Serif; font-weight: normal">&#xa0;</span></p><div>

</div><p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center"><span style="font-family: Arial, Helvetica, Sans-Serif; font-weight: normal">&#xa0;</span></p><div>

</div><p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center"><span style="font-family: Arial, Helvetica, Sans-Serif; font-weight: normal">&#xa0;</span></p><div>

</div><p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center"><span style="font-family: Arial, Helvetica, Sans-Serif; font-weight: normal">&#xa0;</span></p><div>

</div><p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center"><span style="font-family: Arial, Helvetica, Sans-Serif; font-weight: normal">&#xa0;</span></p><div>

</div><p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center"><span style="font-family: Arial, Helvetica, Sans-Serif; font-weight: normal">&#xa0;</span></p><div>

</div><p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center"><span style="font-family: Arial, Helvetica, Sans-Serif; font-weight: normal">&#xa0;</span></p><div>

</div><p style="font: 12pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 12pt"><b>Important
Notice Regarding the Availability of Proxy Materials for the </b></span></p><div>

</div><p style="font: 12pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 12pt"><b>Joint
Annual Shareholder Meeting to Be Held on June 8, 2023.</b></span></p><div>

</div><p style="font: bold 12pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 12pt"><b>The
Joint Proxy Statement and Proxy Card for this meeting are available at: </b></span></p><div>

</div><p style="font: bold 12pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 12pt; color: Blue"><b><span style="text-decoration: underline">https://www.proxy-direct.com/tkl-33282</span></b></span></p><div>

</div><p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center"><span style="font-family: Arial, Helvetica, Sans-Serif; font-weight: normal">&#xa0;</span></p><div>

</div><p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center"><span style="font-family: Arial, Helvetica, Sans-Serif; font-weight: normal">&#xa0;</span></p><div>

</div><p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center"><span style="font-family: Arial, Helvetica, Sans-Serif; font-weight: normal">&#xa0;</span></p><div>

</div><p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center"><span style="font-family: Arial, Helvetica, Sans-Serif; font-weight: normal">&#xa0;</span></p><div>

</div><p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center"><span style="font-family: Arial, Helvetica, Sans-Serif; font-weight: normal">&#xa0;</span></p><div>

</div><p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center"><span style="font-family: Arial, Helvetica, Sans-Serif; font-weight: normal">&#xa0;</span></p><div>

</div><p style="font: bold 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 12pt"><b>IF
YOU VOTE ON THE INTERNET OR BY TELEPHONE,</b></span></p><div>

</div><p style="font: bold 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 12pt"><b>YOU
NEED NOT RETURN THIS PROXY CARD</b></span></p><div>

</div><p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center"><span style="font-family: Arial, Helvetica, Sans-Serif; font-weight: normal">&#xa0;</span></p><div>

</div><p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center"><span style="font-family: Arial, Helvetica, Sans-Serif; font-weight: normal">&#xa0;</span></p><div>

</div><p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center"><span style="font-family: Arial, Helvetica, Sans-Serif; font-weight: normal">&#xa0;</span></p><div>

</div><p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center"><span style="font-family: Arial, Helvetica, Sans-Serif; font-weight: normal">&#xa0;</span></p><div>

</div><p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center"><span style="font-family: Arial, Helvetica, Sans-Serif; font-weight: normal">&#xa0;</span></p><div>

</div><p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center"><span style="font-family: Arial, Helvetica, Sans-Serif; font-weight: normal">&#xa0;</span></p><div>

</div><p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center"><span style="font-family: Arial, Helvetica, Sans-Serif; font-weight: normal">&#xa0;</span></p><div>

</div><p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center"><span style="font-family: Arial, Helvetica, Sans-Serif; font-weight: normal">&#xa0;</span></p><div>

</div><p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center"><span style="font-family: Arial, Helvetica, Sans-Serif; font-weight: normal">&#xa0;</span></p><div>

</div><p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center"></p><div>

</div><p style="font: bold 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center"><span style="font-family: Arial, Helvetica, Sans-Serif"><b>Please
detach at perforation before mailing.</b></span></p><div>

</div><p style="margin: 0pt 0; font-family: Arial, Helvetica, Sans-Serif"><span style="font-family: Arial, Helvetica, Sans-Serif">&#xa0;</span></p><div>

</div><p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: center"><b>&#xa0;</b></p><div>

</div><p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><b>TO
VOTE MARK BLOCKS BELOW IN BLUE OR BLACK INK AS SHOWN IN THIS EXAMPLE: </b></span><b><span style=" font-size: 8pt">&#x2612;</span></b></p><div>

</div><p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><b>&#xa0;</b></span></p><div>

</div><p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"></p><p style="font: 9pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: bold 10pt Arial, Helvetica, Sans-Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="background-color: Black; width: 3%; text-align: center"><span style="color: white">A</span></td>
                                                                                                                                           <td style="text-align: justify; width: 10%">&#xa0;&#xa0;&#xa0;Proposals</td>
                                                                                                                <td style="text-align: justify; width: 87%">The Board of Trustees recommends a vote FOR all the nominees listed and FOR Proposal 2.</td>
</tr></table><div>

</div><p style="font: bold 9pt Arial, Helvetica, Sans-Serif; margin: 0"><span style="font-size: 5pt">&#xa0;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 9pt Arial, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse">
  <tr style="font-size: 9pt; vertical-align: top">
    <td rowspan="2" style="font-size: 9pt; text-align: center"><span style="font-size: 9pt"><b>1.</b></span></td>
    <td colspan="6" rowspan="2" style="font-size: 9pt; text-align: left"><span style="font-size: 9pt">&#xa0;&#xa0;&#xa0;<span style="color: #231F20"><b>The
    election of two Class C Trustees:</b></span></span></td>
    <td style="font-size: 9pt; text-align: center"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 7pt">FOR</span></td>
    <td style="white-space: nowrap; font-size: 9pt; text-align: center"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 7pt">WITHHOLD
    </span></td>
    <td style="font-size: 9pt; text-align: center"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 7pt">FOR ALL</span></td></tr>
  <tr style="font-size: 9pt; vertical-align: top">
    <td style="font-size: 9pt; text-align: center"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 7pt">ALL </span></td>
    <td style="font-size: 9pt; text-align: center"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 7pt">ALL </span></td>
    <td style="font-size: 9pt; text-align: center"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 7pt">EXCEPT</span></td></tr>
  <tr style="font-size: 9pt">
    <td style="font-size: 9pt; vertical-align: top; width: 3%; text-align: center"><span style="font-size: 9pt">&#xa0;</span></td>
    <td style="font-size: 9pt; width: 4%"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">&#xa0;&#xa0;&#xa0;01.</span></td>
    <td style="font-size: 9pt; width: 22%"><span style="font-size: 9pt">Jeffrey A. Bailey</span></td>
    <td style="font-size: 9pt; width: 3%"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">02.</span></td>
    <td style="font-size: 9pt; width: 22%"><span style="font-size: 9pt">Thomas M. Kent, CPA</span></td>
    <td style="font-size: 9pt; width: 3%"></td>
    <td style="font-size: 9pt; width: 22%"></td>
    <td style="font-size: 9pt; vertical-align: top; width: 7%; text-align: center"><span style="font-size: 9pt">&#x2610;</span></td>
    <td style="font-size: 9pt; vertical-align: top; width: 7%; text-align: center"><span style="font-size: 9pt">&#x2610;</span></td>
    <td style="font-size: 9pt; vertical-align: top; width: 7%; text-align: center"><span style="font-size: 9pt">&#x2610;</span></td></tr>
  </table><div>

</div><p style="font: bold 9pt Arial, Helvetica, Sans-Serif; margin: 0"><span style="font-size: 5pt">&#xa0;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 9pt Arial, Helvetica, Sans-Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="font-size: 9pt; vertical-align: top; text-align: justify">
<td style="font-size: 9pt; width: 3%; text-align: left"></td><td style="font-size: 9pt; text-align: justify; width: 97%"><span style="font-size: 9pt">&#xa0;&#xa0;&#xa0;<b><span style="text-decoration: underline">INSTRUCTIONS:</span>&#xa0;</b>To withhold authority to vote for any individual nominee(s), mark the box</span></td></tr></table><div>

</div><table cellpadding="0" cellspacing="0" style="font: 9pt Arial, Helvetica, Sans-Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="font-size: 9pt; vertical-align: top; text-align: justify">
<td style="font-size: 9pt; width: 3%"></td><td style="font-size: 9pt; text-align: justify; width: 97%"><span style="font-size: 9pt">&#xa0;&#xa0;&#xa0;&#x201c;FOR ALL
                           EXCEPT&#x201d; and write the nominee&#x2019;s number on the line provided below.</span></td>
</tr></table><div>

</div><table cellpadding="0" cellspacing="0" style="font: 9pt Arial, Helvetica, Sans-Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="font-size: 9pt; vertical-align: top; text-align: justify">
<td style="font-size: 9pt; width: 3%"></td><td style="font-size: 9pt; padding-right: 30; padding-left: 10; text-align: justify; width: 60%"><p style="border-bottom: Black 1pt solid; font-size: 9pt; margin-top: 0; margin-bottom: 0"><span style="font-size: 9pt">&#xa0;</span></p>
                                                                    <p style="font-size: 9pt; margin-top: 0; margin-bottom: 0"></p></td><td style="font-size: 9pt; text-align: justify; width: 37%"><span style="font-size: 9pt">&#xa0;</span></td>
</tr></table><div>

</div><p style="font: 9pt Arial, Helvetica, Sans-Serif; margin: 0; text-indent: 0.25in"><span style="font-size: 5pt">&#xa0;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 9pt Arial, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse">
  <tr style="font-size: 9pt; vertical-align: top">
    <td rowspan="2" style="font-size: 9pt; padding-top: 8; width: 3%; text-align: center"><span style="font-size: 9pt"><b>2.</b></span></td>
    <td rowspan="2" style="font-size: 9pt; padding-top: 8; padding-right: 30; padding-left: 10; text-align: justify; width: 76%"><span style="font-size: 9pt">The
    ratification or rejection of the selection of Deloitte &amp; Touche LLP as the independent registered public accountants of the Fund
    for the fiscal year ending September 30, 2023.</span></td>
    <td style="font-size: 9pt; vertical-align: bottom; width: 7%; text-align: center"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 7pt">FOR</span></td>
    <td style="font-size: 9pt; vertical-align: bottom; width: 7%; text-align: center"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 7pt">AGAINST
    </span></td>
    <td style="font-size: 9pt; vertical-align: bottom; width: 7%; text-align: center"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 7pt">ABSTAIN</span></td></tr>
  <tr style="font-size: 9pt; vertical-align: top">
    <td style="font-size: 9pt; text-align: center"><span style="font-size: 9pt">&#x2610;</span></td>
    <td style="font-size: 9pt; text-align: center"><span style="font-size: 9pt">&#x2610;</span></td>
    <td style="font-size: 9pt; text-align: center"><span style="font-size: 9pt">&#x2610;</span></td></tr>
  </table><div>
</div><p style="font: bold 9pt Arial, Helvetica, Sans-Serif; margin: 0"></p><div>

</div><p style="font: bold 9pt Arial, Helvetica, Sans-Serif; margin: 0"><span style="font-size: 5pt">&#xa0;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 9pt Arial, Helvetica, Sans-Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font-size: 9pt; vertical-align: top">
<td style="font-size: 9pt; text-align: center; width: 3%"><span style="font-size: 9pt"><b>3.</b></span></td><td style="font-size: 9pt; padding-right: 30; padding-left: 10; text-align: justify; width: 76%"><span style="font-size: 9pt">The
                                            transaction of such other business as may properly come before the Annual Meeting and any
                                            adjournment(s) or postponement(s) thereof.</span></td>
                                                                  <td style="font-size: 9pt; vertical-align: middle; text-align: center; width: 7%"></td>
                                                                  <td style="font-size: 9pt; vertical-align: middle; text-align: center; width: 7%"></td>
                                                                  <td style="font-size: 9pt; vertical-align: middle; text-align: center; width: 7%"></td></tr></table><div>

</div><p style="font: 9pt Arial, Helvetica, Sans-Serif; margin: 0 99.35pt 0 0.25in; text-align: justify; text-indent: -0.25in"><span style="font-size: 5pt">&#xa0;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 12pt Arial, Helvetica, Sans-Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="vertical-align: middle; background-color: Black; width: 3%; text-align: center"><span style="font-size: 9pt; color: white"><b>B</b></span></td><td style="text-align: justify; width: 97%">&#xa0;&#xa0;<span style="font-size: 10pt"><b>Authorized Signatures &#x2500;
This section must be completed for your vote to be counted. &#x2500; Sign and Date Below</b></span></td>
</tr></table><div>

</div><p style="font: 5pt Arial, Helvetica, Sans-Serif; margin-top: 0; margin-bottom: 0">&#xa0;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 12pt Arial, Helvetica, Sans-Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="text-align: justify; width: 3%"><span style="font-size: 8pt"><b>Note</b>: </span></td>
<td style="padding-left: 5pt; text-align: justify; width: 97%"><span style="font-size: 8pt">Please sign exactly as your name(s) appear(s) on this Proxy Card, and date it. When shares are held jointly,
each holder should sign. When signing as attorney, executor, guardian, administrator, trustee, officer of corporation or other entity
or in another representative capacity, please give the full title under the signature</span><span style="font-size: 7pt">.</span></td>
</tr></table><div>

</div><p style="font: 5pt Arial, Helvetica, Sans-Serif; margin: 0"><b>&#xa0;</b></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 11pt Arial, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="white-space: nowrap; width: 32%"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 8pt"><b>Date (mm/dd/yyyy)  &#x2014;Please print date below</b></span></td>
    <td style="white-space: nowrap; width: 2%">&#xa0;</td>
    <td style="white-space: nowrap; width: 32%"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 8pt"><b>Signature 1 &#x2014; Please keep
    signature within the box</b></span></td>
    <td style="white-space: nowrap; width: 2%">&#xa0;</td>
    <td style="white-space: nowrap; width: 32%"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 8pt"><b>Signature
    2 &#x2014;  Please keep signature within the box</b></span></td></tr>
  <tr style="vertical-align: top">
    <td style="border: Black 1.5pt solid; padding: 3; text-align: center"><span style="font-size: 22"><b>/&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;/</b></span></td>
    <td style="padding: 3"><span style="font-size: 22">&#xa0;</span></td>
    <td style="border: Black 1.5pt solid; padding: 3"><span style="font-size: 22">&#xa0;</span></td>
    <td style="padding: 3"><span style="font-size: 22">&#xa0;</span></td>
    <td style="border: Black 1.5pt solid; padding: 3"><span style="font-size: 22">&#xa0;</span></td></tr>
  </table><div>
</div><p style="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0">&#xa0;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 9pt Arial, Helvetica, Sans-Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="border: Black 1pt solid; padding-top: 3; text-align: center; padding-bottom: 3">Scanner bar code</td>
</tr></table><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; border-collapse: collapse; font-family: Arial, Helvetica, Sans-Serif">
  <tr style="vertical-align: top">
    <td style="text-align: center; width: 34%; font-size: 11pt"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 14pt">xxxxxxxxxxxxxx </span></td>
    <td style="text-align: center; width: 33%; font-size: 11pt"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 14pt">THQ 33282 </span></td>
    <td style="text-align: center; width: 33%; font-size: 11pt"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 14pt">xxxxxxxx</span></td></tr>
  </table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#xa0;</p><div>

</div><p style="margin-top: 0; margin-bottom: 0"></p><div>

</div><!-- Field: Page; Sequence: 4 --><div>
    </div><div style="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="margin: 0pt">&#xa0;</p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#xa0;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="margin: 0">&#xa0;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Arial, Helvetica, Sans-Serif; width: 100%">
  <tr style="font-family: Arial, Helvetica, Sans-Serif; vertical-align: bottom">
    <td style="text-align: left; font-family: Arial, Helvetica, Sans-Serif; vertical-align: bottom"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"><b>TEKLA WORLD HEALTHCARE FUND</b></span></td>
    <td style="font: bold 14pt Arial, Helvetica, Sans-Serif; text-align: left; vertical-align: top">EVERY VOTE IS IMPORTANT</td></tr>
  <tr style="font-family: Arial, Helvetica, Sans-Serif; vertical-align: bottom">
    <td style="text-align: left; font-family: Arial, Helvetica, Sans-Serif; vertical-align: bottom"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"><b>PO
    Box 43131</b></span></td>
    <td style="font: bold 14pt Arial, Helvetica, Sans-Serif; text-align: left; vertical-align: top"><span style="font-size: 10pt">&#xa0;</span></td></tr>
  <tr style="font-family: Arial, Helvetica, Sans-Serif; vertical-align: bottom">
    <td style="text-align: left; font-family: Arial, Helvetica, Sans-Serif; width: 60%; vertical-align: top"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"><b>Providence,
    RI 02940-3131</b></span></td>
    <td style="font: bold 14pt Arial, Helvetica, Sans-Serif; text-align: left; width: 40%; vertical-align: top"><span style="font-family: Arial, Helvetica, Sans-Serif">EASY
    VOTING OPTIONS:</span></td></tr>
  </table><div>


</div><p style="font: bold 14pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 5in"><span style="font-family: Arial, Helvetica, Sans-Serif"><b>&#xa0;</b></span></p><div>

</div><p style="font: bold 14pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 5in"></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Arial, Helvetica, Sans-Serif; width: 100%">
  <tr style="font-family: Arial, Helvetica, Sans-Serif">
    <td style="font-family: Arial, Helvetica, Sans-Serif; width: 60%"><span style="font-family: Arial, Helvetica, Sans-Serif">&#xa0;</span></td>
    <td style="font-family: Arial, Helvetica, Sans-Serif; text-align: left; width: 15%"><span style="font-family: Arial, Helvetica, Sans-Serif"><img alt="" src="tm233915d1_def14aimg06.jpg" style="height: 86px; width: 89px" />&#xa0;</span></td>
    <td style="font: 9pt Arial, Helvetica, Sans-Serif; text-align: center; width: 25%; vertical-align: middle"><p style="font: 9pt Arial, Helvetica, Sans-Serif; margin: 0pt 0"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"><b>VOTE
                                            ON THE INTERNET<br />
                                            Log on to:<br />
                                            <span style="color: Blue"><span style="text-decoration: underline">www.proxy-direct.com</span></span></b></span></p>

<p style="font: 9pt Arial, Helvetica, Sans-Serif; margin: 0pt 0"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"><b>or
scan the QR code<br />
Follow the on-screen instructions<br />
<i>available 24 hours</i></b></span></p></td></tr>
  </table><div>
</div><p style="font: bold 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 5in"><span style="font-family: Arial, Helvetica, Sans-Serif"><b>&#xa0;</b></span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Arial, Helvetica, Sans-Serif; width: 100%">
  <tr style="font-family: Arial, Helvetica, Sans-Serif">
    <td style="font-family: Arial, Helvetica, Sans-Serif; width: 60%"><span style="font-family: Arial, Helvetica, Sans-Serif">&#xa0;</span></td>
    <td style="font-family: Arial, Helvetica, Sans-Serif; text-align: left; width: 15%"><span style="font-family: Arial, Helvetica, Sans-Serif"><img alt="" src="tm233915d1_def14aimg03.jpg" style="height: 100px; width: 75px" />&#xa0;</span></td>
    <td style="font: 9pt Arial, Helvetica, Sans-Serif; text-align: center; width: 25%; vertical-align: middle"><p style="font: 9pt Arial, Helvetica, Sans-Serif; margin: 0pt 0"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"><b>VOTE
                                            BY PHONE<br />
                                            Call 1-800-337-3503<br />
                                            Follow the recorded instructions<br />
                                            <i>available 24 hours</i></b></span></p></td></tr>
  </table><div>
</div><p style="margin: 0pt 0; font-family: Arial, Helvetica, Sans-Serif"><span style="font-family: Arial, Helvetica, Sans-Serif">&#xa0;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Arial, Helvetica, Sans-Serif; width: 100%">
  <tr style="font-family: Arial, Helvetica, Sans-Serif">
    <td style="font-family: Arial, Helvetica, Sans-Serif; width: 60%"><span style="font-family: Arial, Helvetica, Sans-Serif">&#xa0;</span></td>
    <td style="font-family: Arial, Helvetica, Sans-Serif; text-align: left; width: 15%"><span style="font-family: Arial, Helvetica, Sans-Serif"><img alt="" src="tm233915d1_def14aimg04.jpg" /></span></td>
    <td style="font: 9pt Arial, Helvetica, Sans-Serif; text-align: center; width: 25%; vertical-align: middle"><p style="font: 9pt Arial, Helvetica, Sans-Serif; margin: 0pt 0"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"><b>VOTE
                                            BY MAIL<br />
                                            Vote, sign and date this Proxy <br />
                                            Card and return in the <br />
                                            postage-paid envelope</b></span></p></td></tr>
  </table><div>
</div><p style="margin: 0pt 0; font-family: Arial, Helvetica, Sans-Serif"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 12pt">&#xa0;</span></p><div>

</div><p style="margin: 0pt 0; font-family: Arial, Helvetica, Sans-Serif"></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Arial, Helvetica, Sans-Serif; width: 100%">
  <tr style="font-family: Arial, Helvetica, Sans-Serif">
    <td style="font-family: Arial, Helvetica, Sans-Serif; width: 60%"><span style="font-family: Arial, Helvetica, Sans-Serif">&#xa0;</span></td>
    <td style="font-family: Arial, Helvetica, Sans-Serif; text-align: left; width: 15%"><span style="font-family: Arial, Helvetica, Sans-Serif"><img alt="" src="tm233915d1_def14aimg05.jpg" /></span></td>
    <td style="font: 9pt Arial, Helvetica, Sans-Serif; vertical-align: middle; text-align: center; width: 25%"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"><b>VOTE
    IN PERSON <br />
    Attend Shareholder Meeting<br />
    100 Federal Street, 19<sup>th</sup> Floor<br />
    Boston, MA 02110<br />
    on June 8, 2023 <br />
    at 12:00 P.M. Eastern Time</b></span></td></tr>
  </table><div>
</div><p style="margin: 0pt 0; font-family: Times New Roman, Serif"><span style="font-family: Arial, Helvetica, Sans-Serif">&#xa0;</span></p><div>

</div><p style="margin: 0pt 0; font-family: Times New Roman, Serif"><span style="font-family: Arial, Helvetica, Sans-Serif">&#xa0;</span></p><div>

</div><p style="margin: 0pt 0; font-family: Arial, Helvetica, Sans-Serif"><span style="font-family: Arial, Helvetica, Sans-Serif">&#xa0;</span></p><div>

</div><p style="font: bold 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center"><span style="font-family: Arial, Helvetica, Sans-Serif"><b>Please
detach at perforation before mailing.</b></span></p><div>

</div><p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center"><span style="font-family: Arial, Helvetica, Sans-Serif"><b>&#xa0;</b></span></p><div>

</div><p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center"><span style="font-family: Arial, Helvetica, Sans-Serif"><b>&#xa0;</b></span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font-family: Arial, Helvetica, Sans-Serif; border-collapse: collapse; width: 100%">
  <tr style="font-family: Arial, Helvetica, Sans-Serif; vertical-align: bottom">
    <td style="font: normal bold 10pt Arial, Helvetica, Sans-Serif; width: 10%; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">PROXY</span></td>
    <td style="font: normal bold 10pt Arial, Helvetica, Sans-Serif; width: 80%; text-align: center"><span style="font-family: Arial, Helvetica, Sans-Serif">TEKLA WORLD HEALTHCARE FUND</span></td>
    <td style="font: normal bold 10pt Arial, Helvetica, Sans-Serif; width: 10%; text-align: left"><span style="font-family: Arial, Helvetica, Sans-Serif">&#xa0;</span></td></tr>
  </table><div>


</div><p style="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Arial, Helvetica, Sans-Serif"><b>JOINT
ANNUAL MEETING OF SHAREHOLDERS </b></span></p><div>

</div><p style="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Arial, Helvetica, Sans-Serif"><b>TO
BE HELD JUNE 8, 2023</b></span></p><div>

</div><p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center"><span style="font-family: Arial, Helvetica, Sans-Serif"><b>&#xa0;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif"><b>This
Proxy is Being Solicited on Behalf of the Board of Trustees. </b>The undersigned hereby appoints Jeffrey A. Bailey, Thomas M. Kent, CPA
and Daniel R. Omstead, Ph.D. and each of them, proxies of the undersigned, with full powers of substitution, to vote at the Joint Annual
Meeting of Shareholders of TEKLA WORLD HEALTHCARE FUND (the &#x201c;Fund&#x201d;) to be held on June 8, 2023 at 12:00 p.m. at 100 Federal
Street, 19<sup>th</sup> Floor, Boston, Massachusetts 02110, and at any adjournment(s) or postponement(s) thereof, all the shares of the
Fund outstanding in the name of the undersigned as follows on the reverse of this card. We encourage you to check our website: <span style="color: Blue"><span style="text-decoration:underline">www.teklacap.com</span></span>&#xa0;prior
to the Joint Annual Meeting if you plan to attend.</span></p><div>

</div><p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif">&#xa0;</span></p><div>

</div><p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif"><b>THIS
PROXY WILL BE VOTED AS SPECIFIED. IF NO SPECIFICATION IS MADE, THIS PROXY WILL BE VOTED FOR ALL PROPOSALS.</b></span></p><div>

</div><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%">
  <tr style="font-size: 8pt; vertical-align: bottom">
    <td style="font-size: 8pt">&#xa0;</td>
    <td colspan="3" style="font: bold 8pt Arial, Helvetica, Sans-Serif"><span style="font-size: 8pt">VOTE VIA THE INTERNET: www.proxy-direct.com&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;</span></td></tr>
  <tr style="font-size: 8pt; vertical-align: bottom">
    <td style="font-size: 8pt; padding-bottom: 5pt">&#xa0;</td>
    <td colspan="3" style="font: bold 8pt Arial, Helvetica, Sans-Serif; padding-bottom: 5pt"><span style="font-size: 8pt">VOTE VIA THE TELEPHONE: 1-800-337-3503</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-top: 3pt; padding-bottom: 3pt; width: 60%">&#xa0;</td>
    <td style="border: Black 1pt solid; font: bold 10pt Arial, Helvetica, Sans-Serif; background-color: rgb(216,216,216); padding-top: 3pt; padding-bottom: 3pt; width: 20%">&#xa0;</td>
    <td style="border-top: White 1pt solid; font: bold 10pt Arial, Helvetica, Sans-Serif; padding-top: 3pt; padding-bottom: 3pt; width: 5%">&#xa0;</td>
    <td style="border: Black 1pt solid; font: bold 10pt Arial, Helvetica, Sans-Serif; padding-top: 3pt; padding-bottom: 3pt; width: 15%">&#xa0;</td></tr>
  </table><div>



</div><p style="font: bold 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 4.5in; text-align: right"></p><div>

</div><p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 4.5in"><span style="font-family: Arial, Helvetica, Sans-Serif">&#xa0;</span></p><div>

</div><p style="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Arial, Helvetica, Sans-Serif">&#xa0;</span></p><div>

</div><p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center"><span style="font-family: Arial, Helvetica, Sans-Serif">&#xa0;</span></p><div>

</div><p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center"><span style="font-family: Arial, Helvetica, Sans-Serif">&#xa0;</span></p><div>

</div><p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center"><span style="font-family: Arial, Helvetica, Sans-Serif">&#xa0;</span></p><div>

</div><p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center"><span style="font-family: Arial, Helvetica, Sans-Serif">&#xa0;</span></p><div>

</div><p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center"><span style="font-family: Arial, Helvetica, Sans-Serif">&#xa0;</span></p><div>

</div><p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center"><span style="font-family: Arial, Helvetica, Sans-Serif">&#xa0;</span></p><div>

</div><p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center"><span style="font-family: Arial, Helvetica, Sans-Serif">&#xa0;</span></p><div>

</div><p style="font: 8pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center"><span style="font: normal 8pt Arial, Helvetica, Sans-Serif">THW_33282_040523</span></p><div>

</div><p style="font: bold 8pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 8pt"><b>PLEASE
MARK, SIGN, DATE ON THE REVERSE SIDE AND RETURN THIS PROXY PROMPTLY USING THE ENCLOSED ENVELOPE.</b></span></p><div>

</div><p style="font: bold 8pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center"><span style="font-size: 2pt">&#xa0;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font-size: 8pt; border-collapse: collapse; width: 100%">
  <tr style="font-size: 8pt; vertical-align: bottom">
    <td style="font: 8pt Arial, Helvetica, Sans-Serif; padding-top: 1pt; text-align: left; width: 9%; vertical-align: middle; padding-bottom: 1pt"><span style="font-size: 8pt"><b>xxxxxxxxxxxxxx</b></span></td>
    <td style="font: 8pt Arial, Helvetica, Sans-Serif; padding-top: 1pt; text-align: center; width: 2%; vertical-align: middle; padding-bottom: 1pt"><span style="font-size: 8pt">&#xa0;</span></td>
    <td style="border: Black 1pt solid; font: 8pt Arial, Helvetica, Sans-Serif; padding-top: 1pt; vertical-align: middle; text-align: center; width: 6%; padding-bottom: 1pt"><span style="font-size: 8pt">code</span></td>
    <td style="font: 8pt Arial, Helvetica, Sans-Serif; padding-top: 1pt; text-align: center; width: 83%; vertical-align: middle; padding-bottom: 1pt"><span style="font-size: 8pt">&#xa0;</span></td></tr>
  </table><div>


</div><p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&#xa0;</span></p><div>

</div><p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 5 --><div>
    </div><div style="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="margin: 0pt">&#xa0;</p></div><div>
    </div><div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#xa0;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&#xa0;</span></p><div>

</div><p style="font: bold 14pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center"><span style="font-family: Arial, Helvetica, Sans-Serif"><b>EVERY
SHAREHOLDER&#x2019;S VOTE IS IMPORTANT</b></span></p><div>

</div><p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center"><span style="font-family: Arial, Helvetica, Sans-Serif; font-weight: normal">&#xa0;</span></p><div>

</div><p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center"><span style="font-family: Arial, Helvetica, Sans-Serif; font-weight: normal">&#xa0;</span></p><div>

</div><p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center"><span style="font-family: Arial, Helvetica, Sans-Serif; font-weight: normal">&#xa0;</span></p><div>

</div><p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center"><span style="font-family: Arial, Helvetica, Sans-Serif; font-weight: normal">&#xa0;</span></p><div>

</div><p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center"><span style="font-family: Arial, Helvetica, Sans-Serif; font-weight: normal">&#xa0;</span></p><div>

</div><p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center"><span style="font-family: Arial, Helvetica, Sans-Serif; font-weight: normal">&#xa0;</span></p><div>

</div><p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center"><span style="font-family: Arial, Helvetica, Sans-Serif; font-weight: normal">&#xa0;</span></p><div>

</div><p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center"><span style="font-family: Arial, Helvetica, Sans-Serif; font-weight: normal">&#xa0;</span></p><div>

</div><p style="font: 12pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 12pt"><b>Important
Notice Regarding the Availability of Proxy Materials for the </b></span></p><div>

</div><p style="font: 12pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 12pt"><b>Joint
Annual Shareholder Meeting to Be Held on June 8, 2023.</b></span></p><div>

</div><p style="font: bold 12pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 12pt"><b>The
Joint Proxy Statement and Proxy Card for this meeting are available at: </b></span></p><div>

</div><p style="font: bold 12pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 12pt; color: Blue"><b><span style="text-decoration: underline">https://www.proxy-direct.com/tkl-33282</span></b></span></p><div>

</div><p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center"><span style="font-family: Arial, Helvetica, Sans-Serif; font-weight: normal">&#xa0;</span></p><div>

</div><p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center"><span style="font-family: Arial, Helvetica, Sans-Serif; font-weight: normal">&#xa0;</span></p><div>

</div><p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center"><span style="font-family: Arial, Helvetica, Sans-Serif; font-weight: normal">&#xa0;</span></p><div>

</div><p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center"><span style="font-family: Arial, Helvetica, Sans-Serif; font-weight: normal">&#xa0;</span></p><div>

</div><p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center"><span style="font-family: Arial, Helvetica, Sans-Serif; font-weight: normal">&#xa0;</span></p><div>

</div><p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center"><span style="font-family: Arial, Helvetica, Sans-Serif; font-weight: normal">&#xa0;</span></p><div>

</div><p style="font: bold 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 12pt"><b>IF
YOU VOTE ON THE INTERNET OR BY TELEPHONE,</b></span></p><div>

</div><p style="font: bold 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 12pt"><b>YOU
NEED NOT RETURN THIS PROXY CARD</b></span></p><div>

</div><p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center"><span style="font-family: Arial, Helvetica, Sans-Serif; font-weight: normal">&#xa0;</span></p><div>

</div><p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center"><span style="font-family: Arial, Helvetica, Sans-Serif; font-weight: normal">&#xa0;</span></p><div>

</div><p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center"><span style="font-family: Arial, Helvetica, Sans-Serif; font-weight: normal">&#xa0;</span></p><div>

</div><p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center"><span style="font-family: Arial, Helvetica, Sans-Serif; font-weight: normal">&#xa0;</span></p><div>

</div><p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center"><span style="font-family: Arial, Helvetica, Sans-Serif; font-weight: normal">&#xa0;</span></p><div>

</div><p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center"><span style="font-family: Arial, Helvetica, Sans-Serif; font-weight: normal">&#xa0;</span></p><div>

</div><p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center"><span style="font-family: Arial, Helvetica, Sans-Serif; font-weight: normal">&#xa0;</span></p><div>

</div><p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center"><span style="font-family: Arial, Helvetica, Sans-Serif; font-weight: normal">&#xa0;</span></p><div>

</div><p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center"><span style="font-family: Arial, Helvetica, Sans-Serif; font-weight: normal">&#xa0;</span></p><div>

</div><p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center"></p><div>

</div><p style="font: bold 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center"><span style="font-family: Arial, Helvetica, Sans-Serif"><b>Please
detach at perforation before mailing.</b></span></p><div>

</div><p style="margin: 0pt 0; font-family: Arial, Helvetica, Sans-Serif"><span style="font-family: Arial, Helvetica, Sans-Serif">&#xa0;</span></p><div>

</div><p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: center"><b>&#xa0;</b></p><div>

</div><p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><b>TO
VOTE MARK BLOCKS BELOW IN BLUE OR BLACK INK AS SHOWN IN THIS EXAMPLE: </b></span><b><span style=" font-size: 8pt">&#x2612;</span></b></p><div>

</div><p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><b>&#xa0;</b></span></p><div>

</div><p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"></p><p style="font: 9pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: bold 10pt Arial, Helvetica, Sans-Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="background-color: Black; width: 3%; text-align: center"><span style="color: white">A</span></td>
                                                                                                                                           <td style="text-align: justify; width: 10%">&#xa0;&#xa0;&#xa0;Proposals</td>
                                                                                                                <td style="text-align: justify; width: 87%">The  Board of Trustees recommends a vote FOR all the nominees listed and FOR Proposal 2.</td>
</tr></table><div>

</div><p style="font: bold 9pt Arial, Helvetica, Sans-Serif; margin: 0"><span style="font-size: 5pt">&#xa0;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 9pt Arial, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse">
  <tr style="font-size: 9pt; vertical-align: top">
    <td rowspan="2" style="font-size: 9pt; text-align: center"><span style="font-size: 9pt"><b>1.</b></span></td>
    <td colspan="6" rowspan="2" style="font-size: 9pt; text-align: left"><span style="font-size: 9pt">&#xa0;&#xa0;&#xa0;<span style="color: #231F20"><b>The
    election of two Class B Trustees:</b></span></span></td>
    <td style="font-size: 9pt; text-align: center"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 7pt">FOR</span></td>
    <td style="white-space: nowrap; font-size: 9pt; text-align: center"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 7pt">WITHHOLD
    </span></td>
    <td style="font-size: 9pt; text-align: center"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 7pt">FOR ALL</span></td></tr>
  <tr style="font-size: 9pt; vertical-align: top">
    <td style="font-size: 9pt; text-align: center"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 7pt">ALL </span></td>
    <td style="font-size: 9pt; text-align: center"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 7pt">ALL </span></td>
    <td style="font-size: 9pt; text-align: center"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 7pt">EXCEPT</span></td></tr>
  <tr style="font-size: 9pt">
    <td style="font-size: 9pt; vertical-align: top; width: 3%; text-align: center"><span style="font-size: 9pt">&#xa0;</span></td>
    <td style="font-size: 9pt; width: 4%"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">&#xa0;&#xa0;&#xa0;01.</span></td>
    <td style="font-size: 9pt; width: 22%"><span style="font-size: 9pt">Rakesh K. Jain, Ph.D.</span></td>
    <td style="font-size: 9pt; width: 3%"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">02.</span></td>
    <td style="font-size: 9pt; width: 22%"><span style="font-size: 9pt">Daniel R. Omstead, Ph.D.</span></td>
    <td style="font-size: 9pt; width: 3%"></td>
    <td style="font-size: 9pt; width: 22%"></td>
    <td style="font-size: 9pt; vertical-align: top; width: 7%; text-align: center"><span style="font-size: 9pt">&#x2610;</span></td>
    <td style="font-size: 9pt; vertical-align: top; width: 7%; text-align: center"><span style="font-size: 9pt">&#x2610;</span></td>
    <td style="font-size: 9pt; vertical-align: top; width: 7%; text-align: center"><span style="font-size: 9pt">&#x2610;</span></td></tr>
  </table><div>

</div><p style="font: bold 9pt Arial, Helvetica, Sans-Serif; margin: 0"><span style="font-size: 5pt">&#xa0;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 9pt Arial, Helvetica, Sans-Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="font-size: 9pt; vertical-align: top; text-align: justify">
<td style="font-size: 9pt; width: 3%; text-align: left"></td><td style="font-size: 9pt; text-align: justify; width: 97%"><span style="font-size: 9pt">&#xa0;&#xa0;&#xa0;<b><span style="text-decoration: underline">INSTRUCTIONS:</span>&#xa0;</b>To withhold authority to vote for any individual nominee(s), mark the box</span></td></tr></table><div>

</div><table cellpadding="0" cellspacing="0" style="font: 9pt Arial, Helvetica, Sans-Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="font-size: 9pt; vertical-align: top; text-align: justify">
<td style="font-size: 9pt; width: 3%"></td><td style="font-size: 9pt; text-align: justify; width: 97%"><span style="font-size: 9pt">&#xa0;&#xa0;&#xa0;&#x201c;FOR ALL
                           EXCEPT&#x201d; and write the nominee&#x2019;s number on the line provided below.</span></td>
</tr></table><div>

</div><table cellpadding="0" cellspacing="0" style="font: 9pt Arial, Helvetica, Sans-Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="font-size: 9pt; vertical-align: top; text-align: justify">
<td style="font-size: 9pt; width: 3%"></td><td style="font-size: 9pt; padding-right: 30; padding-left: 10; text-align: justify; width: 60%"><p style="border-bottom: Black 1pt solid; font-size: 9pt; margin-top: 0; margin-bottom: 0"><span style="font-size: 9pt">&#xa0;</span></p>
                                                                    <p style="font-size: 9pt; margin-top: 0; margin-bottom: 0"></p></td><td style="font-size: 9pt; text-align: justify; width: 37%"><span style="font-size: 9pt">&#xa0;</span></td>
</tr></table><div>

</div><p style="font: 9pt Arial, Helvetica, Sans-Serif; margin: 0; text-indent: 0.25in"><span style="font-size: 5pt">&#xa0;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 9pt Arial, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse">
  <tr style="font-size: 9pt; vertical-align: top">
    <td rowspan="2" style="font-size: 9pt; padding-top: 8; width: 3%; text-align: center"><span style="font-size: 9pt"><b>2.</b></span></td>
    <td rowspan="2" style="font-size: 9pt; padding-top: 8; padding-right: 30; padding-left: 10; text-align: justify; width: 76%"><span style="font-size: 9pt">The
    ratification or rejection of the selection of Deloitte &amp; Touche LLP as the independent registered public accountants of the Fund
    for the fiscal year ending September 30, 2023.</span></td>
    <td style="font-size: 9pt; vertical-align: bottom; width: 7%; text-align: center"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 7pt">FOR</span></td>
    <td style="font-size: 9pt; vertical-align: bottom; width: 7%; text-align: center"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 7pt">AGAINST
    </span></td>
    <td style="font-size: 9pt; vertical-align: bottom; width: 7%; text-align: center"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 7pt">ABSTAIN</span></td></tr>
  <tr style="font-size: 9pt; vertical-align: top">
    <td style="font-size: 9pt; text-align: center"><span style="font-size: 9pt">&#x2610;</span></td>
    <td style="font-size: 9pt; text-align: center"><span style="font-size: 9pt">&#x2610;</span></td>
    <td style="font-size: 9pt; text-align: center"><span style="font-size: 9pt">&#x2610;</span></td></tr>
  </table><div>
</div><p style="font: bold 9pt Arial, Helvetica, Sans-Serif; margin: 0"></p><div>

</div><p style="font: bold 9pt Arial, Helvetica, Sans-Serif; margin: 0"><span style="font-size: 5pt">&#xa0;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 9pt Arial, Helvetica, Sans-Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font-size: 9pt; vertical-align: top">
<td style="font-size: 9pt; text-align: center; width: 3%"><span style="font-size: 9pt"><b>3.</b></span></td><td style="font-size: 9pt; padding-right: 30; padding-left: 10; text-align: justify; width: 76%"><span style="font-size: 9pt">The
                                            transaction of such other business as may properly come before the Annual Meeting and any
                                            adjournment(s) or postponement(s) thereof.</span></td>
                                                                  <td style="font-size: 9pt; vertical-align: middle; text-align: center; width: 7%"></td>
                                                                  <td style="font-size: 9pt; vertical-align: middle; text-align: center; width: 7%"></td>
                                                                  <td style="font-size: 9pt; vertical-align: middle; text-align: center; width: 7%"></td></tr></table><div>

</div><p style="font: 9pt Arial, Helvetica, Sans-Serif; margin: 0 99.35pt 0 0.25in; text-align: justify; text-indent: -0.25in"><span style="font-size: 5pt">&#xa0;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 12pt Arial, Helvetica, Sans-Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="vertical-align: middle; background-color: Black; width: 3%; text-align: center"><span style="font-size: 9pt; color: white"><b>B</b></span></td><td style="text-align: justify; width: 97%">&#xa0;&#xa0;<span style="font-size: 10pt"><b>Authorized Signatures &#x2500;
This section must be completed for your vote to be counted. &#x2500; Sign and Date Below</b></span></td>
</tr></table><div>

</div><p style="font: 5pt Arial, Helvetica, Sans-Serif; margin-top: 0; margin-bottom: 0">&#xa0;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 12pt Arial, Helvetica, Sans-Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="text-align: justify; width: 3%"><span style="font-size: 8pt"><b>Note</b>: </span></td>
<td style="padding-left: 5pt; text-align: justify; width: 97%"><span style="font-size: 8pt">Please sign exactly as your name(s) appear(s) on this Proxy Card, and date it. When shares are held jointly,
each holder should sign. When signing as attorney, executor, guardian, administrator, trustee, officer of corporation or other entity
or in another representative capacity, please give the full title under the signature</span><span style="font-size: 7pt">.</span></td>
</tr></table><div>

</div><p style="font: 5pt Arial, Helvetica, Sans-Serif; margin: 0"><b>&#xa0;</b></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 11pt Arial, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="white-space: nowrap; width: 32%"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 8pt"><b>Date (mm/dd/yyyy)  &#x2014;Please print date below</b></span></td>
    <td style="white-space: nowrap; width: 2%">&#xa0;</td>
    <td style="white-space: nowrap; width: 32%"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 8pt"><b>Signature 1 &#x2014; Please keep
    signature within the box</b></span></td>
    <td style="white-space: nowrap; width: 2%">&#xa0;</td>
    <td style="white-space: nowrap; width: 32%"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 8pt"><b>Signature
    2 &#x2014;  Please keep signature within the box</b></span></td></tr>
  <tr style="vertical-align: top">
    <td style="border: Black 1.5pt solid; padding: 3; text-align: center"><span style="font-size: 22"><b>/&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;/</b></span></td>
    <td style="padding: 3"><span style="font-size: 22">&#xa0;</span></td>
    <td style="border: Black 1.5pt solid; padding: 3"><span style="font-size: 22">&#xa0;</span></td>
    <td style="padding: 3"><span style="font-size: 22">&#xa0;</span></td>
    <td style="border: Black 1.5pt solid; padding: 3"><span style="font-size: 22">&#xa0;</span></td></tr>
  </table><div>
</div><p style="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0">&#xa0;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 9pt Arial, Helvetica, Sans-Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="border: Black 1pt solid; padding-top: 3; text-align: center; padding-bottom: 3">Scanner bar code</td>
</tr></table><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; border-collapse: collapse; font-family: Arial, Helvetica, Sans-Serif">
  <tr style="vertical-align: top">
    <td style="text-align: center; width: 34%; font-size: 11pt"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 14pt">xxxxxxxxxxxxxx </span></td>
    <td style="text-align: center; width: 33%; font-size: 11pt"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 14pt">THW 33282 </span></td>
    <td style="text-align: center; width: 33%; font-size: 11pt"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 14pt">xxxxxxxx</span></td></tr>
  </table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#xa0;</p><div>

</div><p style="margin-top: 0; margin-bottom: 0"></p><div>

</div><!-- Field: Page; Sequence: 6; Options: Last --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><p style="margin: 0pt">&#xa0;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#xa0;</p><div>

</div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>3
<FILENAME>ck0001635977-20230411.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<schema xmlns:ck0001635977="http://www.teklacap.com/20230411" xmlns="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:negated="http://www.xbrl.org/2009/role/negated" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:deprecated="http://www.xbrl.org/2009/arcrole/fact-explanatoryFact" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:dei="http://xbrl.sec.gov/dei/2022" xmlns:cef="http://xbrl.sec.gov/cef/2022" targetNamespace="http://www.teklacap.com/20230411" elementFormDefault="qualified">
  <!-- INTEGIX by Ez-XBRL -->
  <import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
  <import namespace="http://xbrl.sec.gov/dei/2022" schemaLocation="https://xbrl.sec.gov/dei/2022/dei-2022.xsd"/>
  <import namespace="http://xbrl.sec.gov/cef/2022" schemaLocation="https://xbrl.sec.gov/cef/2022/cef-2022.xsd"/>
  <import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd"/>
  <annotation>
    <appinfo>
      <link:roleType roleURI="http://www.teklacap.com/role/Cover" id="Cover">
        <link:definition>0001 - Document - Cover</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:linkbaseRef xlink:type="simple" xlink:href="ck0001635977-20230411_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase"/>
      <link:linkbaseRef xlink:type="simple" xlink:href="ck0001635977-20230411_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase"/>
    </appinfo>
  </annotation>
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>4
<FILENAME>ck0001635977-20230411_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <!-- INTEGIX by Ez-XBRL -->
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel"/>
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel"/>
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel"/>
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel"/>
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel"/>
  <labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract" xlink:label="loc_dei_CoverAbstract_1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_dei_CoverAbstract_0" xml:lang="en-US">Cover [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract_1" xlink:to="lab_dei_CoverAbstract_0"/>
  </labelLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>5
<FILENAME>ck0001635977-20230411_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<link:linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <!-- INTEGIX by Ez-XBRL -->
  <link:roleRef roleURI="http://xbrl.sec.gov/cef/role/N2" xlink:type="simple" xlink:href="https://xbrl.sec.gov/cef/2022/cef-2022.xsd#N2"/>
  <link:presentationLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/cef/role/N2">
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cef/2022/cef-2022.xsd#cef_AllSecuritiesMember" xlink:label="loc_cef_AllSecuritiesMember_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cef/2022/cef-2022.xsd#cef_AllRisksMember" xlink:label="loc_cef_AllRisksMember_0"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>j2339152_aa001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 j2339152_aa001.jpg
M_]C_X  02D9)1@ ! @  9 !D  #_[  11'5C:WD  0 $    9   _^X #D%D
M;V)E &3      ?_; (0  0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0(" @(" @(" @(" P,# P,# P,# P$! 0$! 0$" 0$"
M @(! @(# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,#
M P,# P,# P,#_\  $0@ "0*L P$1  (1 0,1 ?_$ :(    & @,!
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ME<?(K_[GGW[KW7O^@5O^:;_WL3^ '_I7'R*_^YY]^Z]U[_H%;_FF_P#>Q/X
M?^E<?(K_ .YY]^Z]U[_H%;_FF_\ >Q/X ?\ I7'R*_\ N>??NO=>_P"@5O\
MFF_][$_@!_Z5Q\BO_N>??NO=>_Z!6_YIO_>Q/X ?^E<?(K_[GGW[KW7O^@5O
M^:;_ -[$_@!_Z5Q\BO\ [GGW[KW7O^@5O^:;_P![$_@!_P"E<?(K_P"YY]^Z
M]U[_ *!6_P":;_WL3^ '_I7'R*_^YY]^Z]U[_H%;_FF_][$_@!_Z5Q\BO_N>
M??NO=>_Z!6_YIO\ WL3^ '_I7'R*_P#N>??NO=>_Z!6_YIO_ 'L3^ '_ *5Q
M\BO_ +GGW[KW7O\ H%;_ )IO_>Q/X ?^E<?(K_[GGW[KW7O^@5O^:;_WL3^
M'_I7'R*_^YY]^Z]U[_H%;_FF_P#>Q/X ?^E<?(K_ .YY]^Z]U[_H%;_FF_\
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M?NO=>_Z!6_YIO_>Q/X ?^E<?(K_[GGW[KW7O^@5O^:;_ -[$_@!_Z5Q\BO\
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FU[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>j2339152_aa002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 j2339152_aa002.jpg
M_]C_X  02D9)1@ ! @  9 !D  #_[  11'5C:WD  0 $    9   _^X #D%D
M;V)E &3      ?_; (0  0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0(" @(" @(" @(" P,# P,# P,# P$! 0$! 0$" 0$"
M @(! @(# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,#
M P,# P,# P,#_\  $0@  @*L P$1  (1 0,1 ?_$ :(    & @,!
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MU[_T_P">_=>Z]_Z?\]^Z]U[_ -/^>_=>Z]_Z?\]^Z]U[_P!/^>_=>Z]_Z?\
M/?NO=>_]/^>_=>Z]_P"G_/?NO=>_]/\ GOW7NO?^G_/?NO=>_P#3_GOW7NO?
M^G_/?NO=>_\ 3_GOW7NO?^G_ #W[KW7O_3_GOW7NO?\ I_SW[KW7O_3_ )[]
MU[KW_I_SW[KW7O\ T_Y[]U[KW_I_SW[KW7O_ $_Y[]U[KW_I_P ]^Z]U[_T_
MY[]U[KW_ *?\]^Z]U[_T_P">_=>Z]_Z?\]^Z]U[_ -/^>_=>Z]_Z?\]^Z]U[
M_P!/^>_=>Z]_Z?\ /?NO=>_]/^>_=>Z]_P"G_/?NO=>_]/\ GOW7NO?^G_/?
MNO=>_P#3_GOW7NO?^G_/?NO=>_\ 3_GOW7NO?^G_ #W[KW7O_3_GOW7NO?\
MI_SW[KW7O_3_ )[]U[KW_I_SW[KW7O\ T_Y[]U[KW_I_SW[KW7O_ $_Y[]U[
MKW_I_P ]^Z]U[_T_Y[]U[KW_ *?\]^Z]U[_T_P">_=>Z]_Z?\]^Z]U[_ -/^
M>_=>Z]_Z?\]^Z]U[_P!/^>_=>Z]_Z?\ /?NO=>_]/^>_=>Z]_P"G_/?NO=>_
M]/\ GOW7NO?^G_/?NO=>_P#3_GOW7NO?^G_/?NO=>_\ 3_GOW7NO?^G_ #W[
MKW7O_3_GOW7NO?\ I_SW[KW7O_3_ )[]U[KW_I_SW[KW7O\ T_Y[]U[KW_I_
MSW[KW7O_ $_Y[]U[KW_I_P ]^Z]U[_T_Y[]U[KW_ *?\]^Z]U[_T_P">_=>Z
M]_Z?\]^Z]U[_ -/^>_=>Z]_Z?\]^Z]U[_P!/^>_=>Z]_Z?\ /?NO=>_]/^>_
==>Z]_P"G_/?NO=>_]/\ GOW7NO?^G_/?NO=?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>j2339152_aa004.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 j2339152_aa004.jpg
M_]C_X  02D9)1@ ! @  9 !D  #_[  11'5C:WD  0 $    9   _^X #D%D
M;V)E &3      ?_; (0  0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0(" @(" @(" @(" P,# P,# P,# P$! 0$! 0$" 0$"
M @(! @(# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,#
M P,# P,# P,#_\  $0@ "0*L P$1  (1 0,1 ?_$ :(    & @,!
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M[]U[KW_#F?\ PF"_[U;?/_\ ]+$[^_\ NY??NO=>_P"',_\ A,%_WJV^?_\
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MX<S_ .$P7_>K;Y__ /I8G?W_ -W+[]U[KW_#F?\ PF"_[U;?/_\ ]+$[^_\
MNY??NO=>_P"',_\ A,%_WJV^?_\ Z6)W]_\ =R^_=>Z]_P .9_\ "8+_ +U;
M?/\ _P#2Q._O_NY??NO=>_X<S_X3!?\ >K;Y_P#_ *6)W]_]W+[]U[KW_#F?
M_"8+_O5M\_\ _P!+$[^_^[E]^Z]U[_AS/_A,%_WJV^?_ /Z6)W]_]W+[]U[K
MW_#F?_"8+_O5M\__ /TL3O[_ .[E]^Z]U[_AS/\ X3!?]ZMOG_\ ^EB=_?\
MW<OOW7NO?\.9_P#"8+_O5M\__P#TL3O[_P"[E]^Z]U[_ (<S_P"$P7_>K;Y_
M_P#I8G?W_P!W+[]U[KW_  YG_P )@O\ O5M\_P#_ -+$[^_^[E]^Z]U[_AS/
M_A,%_P!ZMOG_ /\ I8G?W_W<OOW7NO?\.9_\)@O^]6WS_P#_ $L3O[_[N7W[
MKW7O^',_^$P7_>K;Y_\ _I8G?W_W<OOW7NO?\.9_\)@O^]6WS_\ _2Q._O\
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)=>Z][]U[K__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>9
<FILENAME>j2339152_ac006.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 j2339152_ac006.jpg
M_]C_X  02D9)1@ ! @  9 !D  #_[  11'5C:WD  0 $    9   _^X #D%D
M;V)E &3      ?_; (0  0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0(" @(" @(" @(" P,# P,# P,# P$! 0$! 0$" 0$"
M @(! @(# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,#
M P,# P,# P,#_\  $0@ )P"Z P$1  (1 0,1 ?_$ :(    & @,!
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/-%:%IE/NO=#+[]U[K__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>10
<FILENAME>tm233915d1_coverimg001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm233915d1_coverimg001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  I '@# 2(  A$! Q$!_\0
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MN#S]1BFO]\_\!_G1_P M/^!_^RT +VSU[Y'\_K2X/?@>U-/\7^^/Z4?\M/\
M@?\ [+0!B:*[MXA\3!Y&94O(0H+<*/L\1./3G)INC2.WBOQ,I=F5);?:N[('
M[E20!VKQKQI_R7R'_K]LO_04IOQ _P"2XI_UVL?YB@#T.\TF^U?Q;KRV< 6:
H*XMA#?M>.AM<1(3MC PW4G' .<&BNCT/_D:O%/\ U\V__I.E% '_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>tm233915d1_def14aimg03.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm233915d1_def14aimg03.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  (! 0(! 0(" @(" @(" P4# P,#
M P8$! ,%!P8'!P<&!P<("0L)" @*" <'"@T*"@L,# P,!PD.#PT,#@L,# S_
MVP!# 0(" @,# P8# P8," <(# P,# P,# P,# P,# P,# P,# P,# P,# P,
M# P,# P,# P,# P,# P,# P,# P,# S_P  1" !\ & # 2(  A$! Q$!_\0
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M=#7\U?QH^*^H_'7XN>)/&6K,[:AXFU"6_EWG)0.?D3/^R@5?^ T ?M)^R?\
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M_P#L&?LGR?#3X$?"/X2-8YU'Q%*OC;QLI\Q-B. 1#*R#*%80(@<X+-'R,@T
M?;'[%?P^E\"? 73[BYN6NK[Q0YUZY??O4-<*A0#Y0?\ 5K'NSGY]^"1BO6:*
M* "BBHKZ^ATRRFN;F:*WM[=&EEEE<(D2*,EF)X  !))H ^>/V]_CIIWPB\-S
MZKJT8&D^ =,E\77<CK_K9U$D-G$ASRQD\QBI7D(N#UK^;#QUXVU#XE>-M8\1
M:M(9M3UV]EO[IR<_O)'+$#V&<#V K],?^"[?[4EU)\,-%\'+)Y&K_$N^_P"$
MHUJ%6!-OI\.$L;=B N> K!L?,-V>37Y<T %%%% !1110!]"_\$N?V:D_:?\
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7T4*JY.2<  <FK=% !1110 4444 ?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>tm233915d1_def14aimg04.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm233915d1_def14aimg04.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  _ %X# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#U'QQ\1-'\
M BQ.JP7LQO?,\H6L:MC9MSG<R_WQ^M8EK\9=/O;9+BT\)>+IX'&4EBTY75A[
M$/@UA_&R&.X\8?#R&:-9(I+]T=&&0P,D (([BKVI^%O$'PZO)-8\"H]YI$CF
M2\T%CD=,;HNI'T'/ ZC@ &I_PMJ#_H2O&?\ X*Q_\71_PMJ#_H2O&?\ X*Q_
M\774>%_%>D^+M)2_TNX5P !-">'A?'*L.Q_0]JVZ ///^%M0?]"5XS_\%8_^
M+H_X6U!_T)7C/_P5C_XNO0Z* ///^%M0?]"5XS_\%8_^+H_X6U!_T)7C/_P5
MC_XNO0Z* ///^%M0?]"5XS_\%8_^+H_X6U!_T)7C/_P5C_XNO0Z\T\1^.]0U
MO5?^$7\ ^7=WQ&+S4P=T-DI.,YZ%NOK^)Z %>Z^//AVPNUM;_1/$5G,<92XM
M$0@'N09,X_"O4Z\"^)O@/3_"GPZ-X\KZAK5SJ$1NM2N.9)"0V0.NU>!Q^>:]
M]H \=^,W_([_  Y_["+?^C+>O8J\=^,W_([_  Y_["+?^C+>O8J //\ Q7\/
M7DU!O$OA&8:9XD3!RIVPW0[K(N,9/KZXSZBYX/\ B!;Z[<'1=7A;3/$ENN+F
MRF&T.PZF(DG<O?KT/<<UVE<WXP\&:?XNL%28FVU"#YK._BR);9^H8$$$C('&
M?R/- '245Y?H7Q"N/#>MQ^#_ !W-%'J*KF#4U<>5<H3\I;NC'D<CM^?J% !4
M%[>VNFV4MY>W$=O;0KNDEE8*JCW)K*\4^+-(\'Z2VH:O<K$N"(HAR\S ?=4=
MS^@[XK@])T74OBG>6WB+Q+B#PTI\RPT9)0XE(&/,E8=>_'X<#.0!)]3UOXL7
MGV+13=:5X/4[;J_9?+FO.Y6/N%/ S[\_W:]%T#P[I7AC2TT[2+1+:W7D@<LQ
M]6)Y)^M:444<,211(J1HH5448"@= !Z4Z@#RWX^_\DZC_P"PA#_)J]2KRWX^
M_P#).H_^PA#_ ":O4J /'?C-_P CO\.?^PBW_HRWKV*O'?C-_P CO\.?^PBW
M_HRWKUR[N[>PM);N[GC@MX5+R2R,%50.I)- $U><>)_B%=7FHOX8\"QKJ&NE
MMLUSMS!9KW9FZ$]O3/J>#F7^N^(?BE.^F>%?.TSPT'9+G67&&N ."D0ZX/\
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M\X_X9U\(_P#01US_ +_Q?_&J/^&=?"/_ $$=<_[_ ,7_ ,:H ]'_ .$H\/\
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-%6P<X(\OD5ZQ0!__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>tm233915d1_def14aimg05.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm233915d1_def14aimg05.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  (! 0(! 0(" @(" @(" P4# P,#
M P8$! ,%!P8'!P<&!P<("0L)" @*" <'"@T*"@L,# P,!PD.#PT,#@L,# S_
MVP!# 0(" @,# P8# P8," <(# P,# P,# P,# P,# P,# P,# P,# P,# P,
M# P,# P,# P,# P,# P,# P,# P,# S_P  1" !1 %T# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#]_**** &-
M.B2!2P#'H/6L3QY\1]!^&OA>[UOQ!K&FZ)I%A&TMU>WLZPPP(OWBS,0!BKNN
MI*8)/(\I97C95>0%E4X."5')QZ9'?D5^6/Q-3Q!8?!OXG?%#XO>'-1_:$^)O
MP0\3,FK?#VXO5M- T?2O.$D6HV.G(&2[+6$IG#71E/F)*BF-HF  /??BI_P4
MH\1?&30]5N?@GHVEV'@31H)9-7^*OC1FL/#6FP1NZS26J-B6^*^7G<FV$[ES
M*#D5\F_LS?'GX _$_P#;:\%V_BN^U?X[WGCJPO;RT^)?CB6&V\/B:*^_L][;
M2M/D;RE8W"HB[5=R&1@Y!S7QO\9?VW_B'^T'X@L?B?XD\66&L2>%WF\-6PBN
MGLO".M36,\FIP6]W9L\D'V/6=%NS&F]2S7%BB_* :^K/AQ_P37\6_M&>!H_^
M%=:?9>'? EEJFE_&?X*>*M?LX9;+PHFH[9M1T.:UVE@@8-+&J*W1"6CRIH ^
MN_\ @G+=S_L3?M0>-_V5]6N93X>MD;QA\-IYI!F?1IW)GLERQ8FUG++T'RLF
M!C%?=]DVZ,G &3DX]>]?GU^TN#\<_@?IVN?#7X@:+\3/C]^S)/'J-W>Z/&84
MU&01_P"G:<\:/(JFXB0@19)#K'WK[,_9J^.^B_M%_ CPOXYT.3=IGB:PBO8@
M8RC1LP^9&! (96R"" >* ._HI%</G':EH **** &M*%S[>U->[2.0(6PQQ@8
MZUSOQ2^+7A;X*>$[K7O&'B/1?"VB6@W3:AJEY':6\/U>0A<^V<FOAGQ9_P %
MK+_]H/Q?+X;_ &3_ (2^)_CCJ3EHCXJO8Y-%\'V#*VURUW*BO/L.&98QR,;&
M.: /T"N9XMVYI%"XP3G[H[_Y[5\3?MD_'[P!^SE\?O!WQXT;QSX0:S66#P9\
M0K*VU:"2:YT:[N!%;WQB63YI-/O)(Y&9@=EK+?\ !.!7*6__  2E^,O[:2RW
M7[6GQMUG7]!O<.WPW^'\TOA_PN$V@-;7,R_Z7>1DX8>8X((/)S@0?M._\$S?
M@9\"?#$>G> _V#=%^+E^]A(L3Z;!H.GV\;X(59;F\G2=7)Q\ZQR''))(Q0!&
M_P#P2W_9W_X)@>%?C=\2K3P1<^./"'Q)U#3;O5?!E_;Z;=Z%I>+KR[>6**Y5
M(X+>![V266:64K#!E@ %-=1^TOHWQ)^)'@B\^$/C"7X?>&[CQYHPU;P!#H<E
MZ=)2_P!.>.6XT'4)7:);RTF3R@3LA\V"6Z A'D!VH?L<_&#XW:+^Q];_  \^
M,_[*GQ;U2XM[>\T$PVNN>&]=AO-&):*UAN;BXU2!II?LA6*9S&/-96<X+D#S
M;6M ^-_PAEW_  E_9B^*UWXHTKP])::9X\^(&K^']>UJ.00E(M.@A_MA8[&U
MW)"SR1,P;$A-N9',U #OV4;GQ9^S9^T%=?%7XV77@WX+:7XHMAI%IX7MI));
MC7K.UBMK> VVD0-*-/MX&62X+++-Q=R-*L2KD>P?!+Q%I'_!/+]L+6? -W?Z
M+X>^#_Q=2;Q;X+N;F6&SM=-O^'O]/1]JH(V+"= 3G$F%R!7!6?B/XS>"/&OC
MOQ+IW[(7Q&\6ZC\2=!L+768?$&K^&U?[9%$+:9!/_:DA>R,(5A!Y:@R>9RHD
M^7D_VBOV??''[2'_  3ITOX0^*OV<_C1XI\4^&FM]1TG4[Y?#$=D][;OOC69
M#KLKF!ES&X+/N0]. * /T/M/VH_AI&GS?$/P.,MMYUZU^]UQ]^I6_:D^&2 $
M_$3P,H9MH)UVU&3Z??K\J?AA^R-KGC+Q1INF:U_P2;^$/AI9@JW.KZAXVT5;
M.%^-[E+>UFDVGDA A/;-?4'QL_X)W_L/?LL?!VZ\<?%;X+_ [P9I]M$K7C/I
M4+Q>;C_50#RD:5B>%5(]S'M0!]9G]J[X7>0\O_"Q_ GEQL$=AKUKA&)P 3OX
MR3BNK\*>-M&\>:<]WHFK:;K%K%*8'FLKE+B-)  2A9"0& (R.O(]:_%ZV_X)
M)>%_^"M^MQW/A'X!>%OV9_@'%<13G7)?#5O;^,?&$2,&46D3+BPMV49,C#>X
M=?E9<BOKG_@W3^&&C?!C]CWXC^%?#\;PZ/X>^+?B;3+2)Y#))##;SQP1J[GE
MF$<:9;)SUSV !\B_';]@;0/^"L__  < _M)?#?XH^)O&P\'_  \T#0M3T/3]
M/U@Q6]M--IFFB0*C;A'N:1V(4#<23SFOJK0?^"&7@_X1^ [;2[+]HK]HSPOX
M>L$$$<$/CV2SLX5Z* H"HO(XXY->6? I==/_  <;_MP?\(^ZQ:X/ .@OI;F,
M.!.-+TS9E3P<O@8/'-<E^UW\)/VA-8_X(!?&ZU_:/U-9?&FD>;K>GOIL^_RK
M>*5;N/,HPWRLS1E>BK&!DB@#Z2L/^"1?AVZTN6\'[5_[2LUM!CS;@?$V8QQC
MH-S [1^-3Z1_P2&T+7 ?[/\ VJ?VFKT*%+?9OB7<2;=V<9VDXS@_D?0U^#_[
M#_QD\0V'_!!;]M+.N7\DEMK7@Z&U\RY<O$MQ?R),4).1N51GZ"H?V=_VE/%'
M[-?_  ;^?%_5-)U._AU/XO\ Q)L/ LMZMTWVBWM(=/FO)@K]0&0^60#R)FH
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M6L_A7:_ CX<VWQ$L=4UB.PUQ6CF>;3K2+;N=]HP(RIY;[P*\"N!_9M>ZN_\
M@XG^,%Q>_9_M3?!30O-^SDF+>;XYVYYQG.,T ?H;.=ML_P!#7Q#_ ,$$CG]G
M'XN?]EH\7?\ I:*^V[R0?9WY[&OB3_@@@I'[-?Q8?^&7XR^+74^H^VC_  H
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MWJXA8WK$C<IPV#W%5Y_^"VGB=(D1?V(?VRO+B*[5/@;A?3 $G_UO6OENTO\
M]JK]N;_@IAXY\2?"OX2_$S]GOP_\0?"%CX9U3Q5X^T&33[G1+:WE9I6M$*^7
M+,^_"?,<')Z"@#[1_;D_X*@:M8?$[_A1_P"SSHUI\2?C?J/[JX59/^)5X30X
MWW-]*O"E0<JF<L1VY->O?\$P?V*KO]A/]F/_ (175_$;>+/%.NZS>>)O$>JB
M/RX;O4KME>=HEZB/*C;GD]3C. _]@/\ X)V^ _\ @GC\*9O#'@JPFDN]2F^V
MZQKE^[3:GKUV1EY[B4Y))8L<9P-QZDDGZ"MU*18( /? P* )**** "BBB@ H
1HHH **** "BBB@ HHHH _]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>tm233915d1_def14aimg06.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm233915d1_def14aimg06.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  (! 0(! 0(" @(" @(" P4# P,#
M P8$! ,%!P8'!P<&!P<("0L)" @*" <'"@T*"@L,# P,!PD.#PT,#@L,# S_
MVP!# 0(" @,# P8# P8," <(# P,# P,# P,# P,# P,# P,# P,# P,# P,
M# P,# P,# P,# P,# P,# P,# P,# S_P  1" !6 %D# 2(  A$! Q$!_\0
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M%\$]&_:RO/\ @I;\(;KXE?#[X<Z]XN^,YN+&X\4ZM%9PR)!J%S(Y 9@S<8'
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MOC#PQI0U_P"(6A>)=9_MF^O_  O OVJ=+:W;!BF<Q;4F8!0<\C- 'Y>?!?\
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M\5VFNZ]9>%_@7_P1RU/5+ZVL-.T_Q='<75W=W"QPVL2:OIS,[NQ"HBJ"220
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MM\'?AM\%OV6_ /B[X>Z%^RGKW_"VYM-\1W1U"YU^VAN'FFL[1DDE=KN6:4[
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MX%^*GQ;T3XV_#SQI974"^!+6^:*;P- (9F^R3&&0/&Q=%<<H3LQC'4 ^X/\
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MLW:+^T9\"OVG?AC\;OA=^PN\UEX;\)7NFW.I:2TL-K\0A>0X_MB5R25,B'S
MO/\ K2,],>%W7[5WP!_X**^(+[X6:G\%/@7^R7>ZK.]Y<?$J5[J\ETN:V?SV
MMQ'E,O.RF(Y8<.V,G%?JK_P1(^ OC#7_ !7I_P 4(/VM[GXI>#_"^BRVVO\
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MERQQ%;PK)AE7"D<C''=Q?L[>/?\ @DW\#OAM\9/"T>G?MY_!_1-,NKKPS>-
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M3?V9/ OB?PO\;K!?$'Q9\%:O!:CPWX!>*1(HK&"WC;;-"Q<,1A\'!''3Q?\
MX*)_\%4_V5/C'\*_V@_$?@[XI?%CQ?\ %;X@2:;J/@:V\1:)+';_  \O+6]@
MG9M(N#\]B[K&"SHRY,2<YSGF?V#/V//%O_!9/1/ &CZ#^TC\>/$_A*XMTM?C
MC8:YXI:--+FD#R01V$,[$7<9>-=V5?;\IY)P #ZS_P"".7BU/V/OV@O@M=>%
M])TO^S?V\QJ_C;7-.6+[/:>"V@>XFAL=/1  84601_/T"# &<#]MOL8_O/\
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M\+^(M2@'AC3_  C>M&(KRUNU:*)[[)BQ']HD."Y,6$.?MOX0?\&CW[./[/\
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MX+_:JL/@?XA\ ^&7\>W]M+\,'O\ 5+V_70XX&^=+Y7M#MRA?!C\[EN>F244
M?6GPV_8A_P"$^U7X(_$;XSW=IXC^.GPFT1K2?5]#EFM-*EO9X@EVR0DCS$)!
5 9U7=][9'G8OT'_9*^K?G110!__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140220541737600">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>N-2<br></strong></div></th>
<th class="th"><div>Apr. 11, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001635977<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">DEF 14A<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Tekla World Healthcare Fund<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>tm233915d1_def14a_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2022"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="ck0001635977-20230411.xsd" xlink:type="simple"/>
    <context id="C_20230411to20230411">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635977</identifier>
        </entity>
        <period>
            <startDate>2023-04-11</startDate>
            <endDate>2023-04-11</endDate>
        </period>
    </context>
    <dei:EntityCentralIndexKey
      contextRef="C_20230411to20230411"
      id="Fdei_EntityCentralIndexKey20230406134046386">0001635977</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag
      contextRef="C_20230411to20230411"
      id="Fdei_AmendmentFlag20230406134104483">false</dei:AmendmentFlag>
    <dei:DocumentType
      contextRef="C_20230411to20230411"
      id="Fdei_DocumentType20230406134124323">DEF 14A</dei:DocumentType>
    <dei:EntityRegistrantName
      contextRef="C_20230411to20230411"
      id="Fxbrl_20230407002516323">Tekla World Healthcare Fund</dei:EntityRegistrantName>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>17
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M              "  0    !D;V-0<F]P<R]A<' N>&UL4$L! A0#%     @
M5F&+5FY\\B_N    *P(  !$              ( !KP   &1O8U!R;W!S+V-O
M<F4N>&UL4$L! A0#%     @ 5F&+5IE<G",0!@  G"<  !,
M ( !S $  'AL+W1H96UE+W1H96UE,2YX;6Q02P$"% ,4    " !688M66WF'
M_#L"  "N!0  &               @($-"   >&PO=V]R:W-H965T<R]S:&5E
M=#$N>&UL4$L! A0#%     @ 5F&+5I^@&_"Q @  X@P   T
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;72YX;6Q02P4&      D "0 ^ @  T1$

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.23.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>4</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="tm233915d1_def14a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>995470 - Disclosure - N-2</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/cef/role/N2</Role>
      <ShortName>N-2</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="DEF 14A" original="tm233915d1_def14a.htm">tm233915d1_def14a.htm</File>
    <File>ck0001635977-20230411.xsd</File>
    <File>ck0001635977-20230411_lab.xml</File>
    <File>ck0001635977-20230411_pre.xml</File>
  </InputFiles>
  <SupplementalFiles>
    <File>j2339152_aa001.jpg</File>
    <File>j2339152_aa002.jpg</File>
    <File>j2339152_aa004.jpg</File>
    <File>j2339152_ac006.jpg</File>
    <File>tm233915d1_def14aimg03.jpg</File>
    <File>tm233915d1_def14aimg04.jpg</File>
    <File>tm233915d1_def14aimg05.jpg</File>
    <File>tm233915d1_def14aimg06.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="4">http://xbrl.sec.gov/dei/2022</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>22
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "tm233915d1_def14a.htm": {
   "axisCustom": 0,
   "axisStandard": 0,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2022": 4
   },
   "contextCount": 1,
   "dts": {
    "inline": {
     "local": [
      "tm233915d1_def14a.htm"
     ]
    },
    "labelLink": {
     "local": [
      "ck0001635977-20230411_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "ck0001635977-20230411_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "ck0001635977-20230411.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/2006/xbrldi-2006.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.sec.gov/cef/2022/cef-2022.xsd",
      "https://xbrl.sec.gov/dei/2022/dei-2022.xsd",
      "https://xbrl.sec.gov/dei/2022/dei-2022_lab.xsd"
     ]
    }
   },
   "elementCount": 189,
   "entityCount": 1,
   "hidden": {
    "http://xbrl.sec.gov/dei/2022": 3,
    "total": 3
   },
   "keyCustom": 0,
   "keyStandard": 4,
   "memberCustom": 0,
   "memberStandard": 0,
   "nsprefix": "ck0001635977",
   "nsuri": "http://www.teklacap.com/20230411",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "strong",
       "span",
       "p",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tm233915d1_def14a.htm",
      "contextRef": "C_20230411to20230411",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:EntityRegistrantName",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "true",
     "longName": "995470 - Disclosure - N-2",
     "menuCat": "Cover",
     "order": "1",
     "role": "http://xbrl.sec.gov/cef/role/N2",
     "shortName": "N-2",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "strong",
       "span",
       "p",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tm233915d1_def14a.htm",
      "contextRef": "C_20230411to20230411",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:EntityRegistrantName",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 0,
   "tag": {
    "cef_AcquiredFundFeesAndExpensesNoteTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Acquired Fund Fees and Expenses, Note [Text Block]"
       }
      }
     },
     "localname": "AcquiredFundFeesAndExpensesNoteTextBlock",
     "nsuri": "http://xbrl.sec.gov/cef/2022",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "textBlockItemType"
    },
    "cef_AcquiredFundFeesAndExpensesPercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Acquired Fund Fees and Expenses [Percent]"
       }
      }
     },
     "localname": "AcquiredFundFeesAndExpensesPercent",
     "nsuri": "http://xbrl.sec.gov/cef/2022",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "percentItemType"
    },
    "cef_AcquiredFundFeesEstimatedNoteTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Acquired Fund Fees Estimated, Note [Text Block]"
       }
      }
     },
     "localname": "AcquiredFundFeesEstimatedNoteTextBlock",
     "nsuri": "http://xbrl.sec.gov/cef/2022",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "textBlockItemType"
    },
    "cef_AcquiredFundIncentiveAllocationNoteTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Acquired Fund Incentive Allocation, Note [Text Block]"
       }
      }
     },
     "localname": "AcquiredFundIncentiveAllocationNoteTextBlock",
     "nsuri": "http://xbrl.sec.gov/cef/2022",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "textBlockItemType"
    },
    "cef_AcquiredFundTotalAnnualExpensesNoteTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Acquired Fund Total Annual Expenses, Note [Text Block]"
       }
      }
     },
     "localname": "AcquiredFundTotalAnnualExpensesNoteTextBlock",
     "nsuri": "http://xbrl.sec.gov/cef/2022",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "textBlockItemType"
    },
    "cef_AllRisksMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Risks:"
       }
      }
     },
     "localname": "AllRisksMember",
     "nsuri": "http://xbrl.sec.gov/cef/2022",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "domainItemType"
    },
    "cef_AllSecuritiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Securities:"
       }
      }
     },
     "localname": "AllSecuritiesMember",
     "nsuri": "http://xbrl.sec.gov/cef/2022",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "domainItemType"
    },
    "cef_AnnualCoverageReturnRatePercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Annual Coverage Return Rate [Percent]"
       }
      }
     },
     "localname": "AnnualCoverageReturnRatePercent",
     "nsuri": "http://xbrl.sec.gov/cef/2022",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "percentItemType"
    },
    "cef_AnnualDividendPayment": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Annual Dividend Payment"
       }
      }
     },
     "localname": "AnnualDividendPayment",
     "nsuri": "http://xbrl.sec.gov/cef/2022",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "perShareItemType"
    },
    "cef_AnnualDividendPaymentCurrent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Annual Dividend Payment, Current"
       }
      }
     },
     "localname": "AnnualDividendPaymentCurrent",
     "nsuri": "http://xbrl.sec.gov/cef/2022",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "perShareItemType"
    },
    "cef_AnnualDividendPaymentInitial": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Annual Dividend Payment, Initial"
       }
      }
     },
     "localname": "AnnualDividendPaymentInitial",
     "nsuri": "http://xbrl.sec.gov/cef/2022",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "perShareItemType"
    },
    "cef_AnnualExpensesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Annual Expenses [Table Text Block]"
       }
      }
     },
     "localname": "AnnualExpensesTableTextBlock",
     "nsuri": "http://xbrl.sec.gov/cef/2022",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "textBlockItemType"
    },
    "cef_AnnualInterestRateCurrentPercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Annual Interest Rate, Current [Percent]"
       }
      }
     },
     "localname": "AnnualInterestRateCurrentPercent",
     "nsuri": "http://xbrl.sec.gov/cef/2022",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "percentItemType"
    },
    "cef_AnnualInterestRateInitialPercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Annual Interest Rate, Initial [Percent]"
       }
      }
     },
     "localname": "AnnualInterestRateInitialPercent",
     "nsuri": "http://xbrl.sec.gov/cef/2022",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "percentItemType"
    },
    "cef_AnnualInterestRatePercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Annual Interest Rate [Percent]"
       }
      }
     },
     "localname": "AnnualInterestRatePercent",
     "nsuri": "http://xbrl.sec.gov/cef/2022",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "percentItemType"
    },
    "cef_BasisOfTransactionFeesNoteTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Basis of Transaction Fees, Note [Text Block]"
       }
      }
     },
     "localname": "BasisOfTransactionFeesNoteTextBlock",
     "nsuri": "http://xbrl.sec.gov/cef/2022",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "textBlockItemType"
    },
    "cef_BdcFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "BDC File Number"
       }
      }
     },
     "localname": "BdcFileNumber",
     "nsuri": "http://xbrl.sec.gov/cef/2022",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "cef_BusinessDevelopmentCompanyFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Development Company [Flag]"
       }
      }
     },
     "localname": "BusinessDevelopmentCompanyFlag",
     "nsuri": "http://xbrl.sec.gov/cef/2022",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "booleanItemType"
    },
    "cef_CapitalStockLongTermDebtAndOtherSecuritiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Capital Stock, Long-Term Debt, and Other Securities [Abstract]"
       }
      }
     },
     "localname": "CapitalStockLongTermDebtAndOtherSecuritiesAbstract",
     "nsuri": "http://xbrl.sec.gov/cef/2022",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "stringItemType"
    },
    "cef_CapitalStockTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Capital Stock [Table Text Block]"
       }
      }
     },
     "localname": "CapitalStockTableTextBlock",
     "nsuri": "http://xbrl.sec.gov/cef/2022",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "textBlockItemType"
    },
    "cef_DistributionServicingFeesPercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Distribution/Servicing Fees [Percent]"
       }
      }
     },
     "localname": "DistributionServicingFeesPercent",
     "nsuri": "http://xbrl.sec.gov/cef/2022",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "percentItemType"
    },
    "cef_DistributionsMayReducePrincipalTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Distributions May Reduce Principal [Text Block]"
       }
      }
     },
     "localname": "DistributionsMayReducePrincipalTextBlock",
     "nsuri": "http://xbrl.sec.gov/cef/2022",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "textBlockItemType"
    },
    "cef_DividendAndInterestExpensesOnShortSalesPercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Dividend and Interest Expenses on Short Sales [Percent]"
       }
      }
     },
     "localname": "DividendAndInterestExpensesOnShortSalesPercent",
     "nsuri": "http://xbrl.sec.gov/cef/2022",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "percentItemType"
    },
    "cef_DividendExpenseOnPreferredSharesPercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Dividend Expenses on Preferred Shares [Percent]"
       }
      }
     },
     "localname": "DividendExpenseOnPreferredSharesPercent",
     "nsuri": "http://xbrl.sec.gov/cef/2022",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "percentItemType"
    },
    "cef_DividendReinvestmentAndCashPurchaseFees": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Dividend Reinvestment and Cash Purchase Fees"
       }
      }
     },
     "localname": "DividendReinvestmentAndCashPurchaseFees",
     "nsuri": "http://xbrl.sec.gov/cef/2022",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cef_EffectsOfLeveragePurposeTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effects of Leverage, Purpose [Text Block]"
       }
      }
     },
     "localname": "EffectsOfLeveragePurposeTextBlock",
     "nsuri": "http://xbrl.sec.gov/cef/2022",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "textBlockItemType"
    },
    "cef_EffectsOfLeverageTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effects of Leverage [Table Text Block]"
       }
      }
     },
     "localname": "EffectsOfLeverageTableTextBlock",
     "nsuri": "http://xbrl.sec.gov/cef/2022",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "textBlockItemType"
    },
    "cef_EffectsOfLeverageTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effects of Leverage [Text Block]"
       }
      }
     },
     "localname": "EffectsOfLeverageTextBlock",
     "nsuri": "http://xbrl.sec.gov/cef/2022",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "textBlockItemType"
    },
    "cef_ExpenseExampleTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Expense Example [Table Text Block]"
       }
      }
     },
     "localname": "ExpenseExampleTableTextBlock",
     "nsuri": "http://xbrl.sec.gov/cef/2022",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "textBlockItemType"
    },
    "cef_ExpenseExampleYear01": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Expense Example, Year 01"
       }
      }
     },
     "localname": "ExpenseExampleYear01",
     "nsuri": "http://xbrl.sec.gov/cef/2022",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cef_ExpenseExampleYears1to10": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Expense Example, Years 1 to 10"
       }
      }
     },
     "localname": "ExpenseExampleYears1to10",
     "nsuri": "http://xbrl.sec.gov/cef/2022",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cef_ExpenseExampleYears1to3": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Expense Example, Years 1 to 3"
       }
      }
     },
     "localname": "ExpenseExampleYears1to3",
     "nsuri": "http://xbrl.sec.gov/cef/2022",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cef_ExpenseExampleYears1to5": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Expense Example, Years 1 to 5"
       }
      }
     },
     "localname": "ExpenseExampleYears1to5",
     "nsuri": "http://xbrl.sec.gov/cef/2022",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cef_FeeTableAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fee Table [Abstract]"
       }
      }
     },
     "localname": "FeeTableAbstract",
     "nsuri": "http://xbrl.sec.gov/cef/2022",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "stringItemType"
    },
    "cef_FinancialHighlightsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Financial Highlights [Abstract]"
       }
      }
     },
     "localname": "FinancialHighlightsAbstract",
     "nsuri": "http://xbrl.sec.gov/cef/2022",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "stringItemType"
    },
    "cef_GeneralDescriptionOfRegistrantAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "General Description of Registrant [Abstract]"
       }
      }
     },
     "localname": "GeneralDescriptionOfRegistrantAbstract",
     "nsuri": "http://xbrl.sec.gov/cef/2022",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "stringItemType"
    },
    "cef_HighestPriceOrBid": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Highest Price or Bid"
       }
      }
     },
     "localname": "HighestPriceOrBid",
     "nsuri": "http://xbrl.sec.gov/cef/2022",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "perShareItemType"
    },
    "cef_HighestPriceOrBidNav": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Highest Price or Bid, NAV"
       }
      }
     },
     "localname": "HighestPriceOrBidNav",
     "nsuri": "http://xbrl.sec.gov/cef/2022",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "perShareItemType"
    },
    "cef_HighestPriceOrBidPremiumDiscountToNavPercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Highest Price or Bid, Premium (Discount) to NAV [Percent]"
       }
      }
     },
     "localname": "HighestPriceOrBidPremiumDiscountToNavPercent",
     "nsuri": "http://xbrl.sec.gov/cef/2022",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "percentItemType"
    },
    "cef_IncentiveAllocationMaximumPercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Incentive Allocation Maximum [Percent]"
       }
      }
     },
     "localname": "IncentiveAllocationMaximumPercent",
     "nsuri": "http://xbrl.sec.gov/cef/2022",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "percentItemType"
    },
    "cef_IncentiveAllocationMinimumPercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Incentive Allocation Minimum [Percent]"
       }
      }
     },
     "localname": "IncentiveAllocationMinimumPercent",
     "nsuri": "http://xbrl.sec.gov/cef/2022",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "percentItemType"
    },
    "cef_IncentiveAllocationPercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Incentive Allocation [Percent]"
       }
      }
     },
     "localname": "IncentiveAllocationPercent",
     "nsuri": "http://xbrl.sec.gov/cef/2022",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "percentItemType"
    },
    "cef_IncentiveFeesPercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Incentive Fees [Percent]"
       }
      }
     },
     "localname": "IncentiveFeesPercent",
     "nsuri": "http://xbrl.sec.gov/cef/2022",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "percentItemType"
    },
    "cef_InterestExpensesOnBorrowingsPercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Interest Expenses on Borrowings [Percent]"
       }
      }
     },
     "localname": "InterestExpensesOnBorrowingsPercent",
     "nsuri": "http://xbrl.sec.gov/cef/2022",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "percentItemType"
    },
    "cef_IntervalFundFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Interval Fund [Flag]"
       }
      }
     },
     "localname": "IntervalFundFlag",
     "nsuri": "http://xbrl.sec.gov/cef/2022",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "booleanItemType"
    },
    "cef_InvestmentObjectivesAndPracticesTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment Objectives and Practices [Text Block]"
       }
      }
     },
     "localname": "InvestmentObjectivesAndPracticesTextBlock",
     "nsuri": "http://xbrl.sec.gov/cef/2022",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "textBlockItemType"
    },
    "cef_LatestNav": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Latest NAV"
       }
      }
     },
     "localname": "LatestNav",
     "nsuri": "http://xbrl.sec.gov/cef/2022",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "perShareItemType"
    },
    "cef_LatestPremiumDiscountToNavPercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Latest Premium (Discount) to NAV [Percent]"
       }
      }
     },
     "localname": "LatestPremiumDiscountToNavPercent",
     "nsuri": "http://xbrl.sec.gov/cef/2022",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "percentItemType"
    },
    "cef_LatestSharePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Latest Share Price"
       }
      }
     },
     "localname": "LatestSharePrice",
     "nsuri": "http://xbrl.sec.gov/cef/2022",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "perShareItemType"
    },
    "cef_LoanServicingFeesPercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Loan Servicing Fees [Percent]"
       }
      }
     },
     "localname": "LoanServicingFeesPercent",
     "nsuri": "http://xbrl.sec.gov/cef/2022",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "percentItemType"
    },
    "cef_LongTermDebtDividendsAndCovenantsTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long Term Debt, Dividends and Covenants [Text Block]"
       }
      }
     },
     "localname": "LongTermDebtDividendsAndCovenantsTextBlock",
     "nsuri": "http://xbrl.sec.gov/cef/2022",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "textBlockItemType"
    },
    "cef_LongTermDebtIssuanceAndSubstitutionTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long Term Debt, Issuance and Substitution [Text Block]"
       }
      }
     },
     "localname": "LongTermDebtIssuanceAndSubstitutionTextBlock",
     "nsuri": "http://xbrl.sec.gov/cef/2022",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "textBlockItemType"
    },
    "cef_LongTermDebtPrincipal": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long Term Debt, Principal"
       }
      }
     },
     "localname": "LongTermDebtPrincipal",
     "nsuri": "http://xbrl.sec.gov/cef/2022",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cef_LongTermDebtRightsLimitedByOtherSecuritiesTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long Term Debt, Rights Limited by Other Securities [Text Block]"
       }
      }
     },
     "localname": "LongTermDebtRightsLimitedByOtherSecuritiesTextBlock",
     "nsuri": "http://xbrl.sec.gov/cef/2022",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "textBlockItemType"
    },
    "cef_LongTermDebtStructuringTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long Term Debt, Structuring [Text Block]"
       }
      }
     },
     "localname": "LongTermDebtStructuringTextBlock",
     "nsuri": "http://xbrl.sec.gov/cef/2022",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "textBlockItemType"
    },
    "cef_LongTermDebtTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long Term Debt [Table Text Block]"
       }
      }
     },
     "localname": "LongTermDebtTableTextBlock",
     "nsuri": "http://xbrl.sec.gov/cef/2022",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "textBlockItemType"
    },
    "cef_LongTermDebtTitleTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long Term Debt, Title [Text Block]"
       }
      }
     },
     "localname": "LongTermDebtTitleTextBlock",
     "nsuri": "http://xbrl.sec.gov/cef/2022",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "textBlockItemType"
    },
    "cef_LowestPriceOrBid": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lowest Price or Bid"
       }
      }
     },
     "localname": "LowestPriceOrBid",
     "nsuri": "http://xbrl.sec.gov/cef/2022",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "perShareItemType"
    },
    "cef_LowestPriceOrBidNav": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lowest Price or Bid, NAV"
       }
      }
     },
     "localname": "LowestPriceOrBidNav",
     "nsuri": "http://xbrl.sec.gov/cef/2022",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "perShareItemType"
    },
    "cef_LowestPriceOrBidPremiumDiscountToNavPercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lowest Price or Bid, Premium (Discount) to NAV [Percent]"
       }
      }
     },
     "localname": "LowestPriceOrBidPremiumDiscountToNavPercent",
     "nsuri": "http://xbrl.sec.gov/cef/2022",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "percentItemType"
    },
    "cef_ManagementFeeNotBasedOnNetAssetsNoteTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Management Fee not based on Net Assets, Note [Text Block]"
       }
      }
     },
     "localname": "ManagementFeeNotBasedOnNetAssetsNoteTextBlock",
     "nsuri": "http://xbrl.sec.gov/cef/2022",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "textBlockItemType"
    },
    "cef_ManagementFeesPercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Management Fees [Percent]"
       }
      }
     },
     "localname": "ManagementFeesPercent",
     "nsuri": "http://xbrl.sec.gov/cef/2022",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "percentItemType"
    },
    "cef_NetExpenseOverAssetsPercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Expense over Assets [Percent]"
       }
      }
     },
     "localname": "NetExpenseOverAssetsPercent",
     "nsuri": "http://xbrl.sec.gov/cef/2022",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "percentItemType"
    },
    "cef_NewCefOrBdcRegistrantFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "New CEF or BDC Registrant [Flag]"
       }
      }
     },
     "localname": "NewCefOrBdcRegistrantFlag",
     "nsuri": "http://xbrl.sec.gov/cef/2022",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "booleanItemType"
    },
    "cef_NoPublicTradingTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "No Public Trading [Text Block]"
       }
      }
     },
     "localname": "NoPublicTradingTextBlock",
     "nsuri": "http://xbrl.sec.gov/cef/2022",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "textBlockItemType"
    },
    "cef_NoTradingHistoryTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "No Trading History [Text Block]"
       }
      }
     },
     "localname": "NoTradingHistoryTextBlock",
     "nsuri": "http://xbrl.sec.gov/cef/2022",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "textBlockItemType"
    },
    "cef_OtherAnnualExpense1Percent": {
     "auth_ref": [],
     "calculation": {
      "http://xbrl.sec.gov/cef/role/Item3Ae": {
       "order": 1.0,
       "parentTag": "cef_OtherAnnualExpensesPercent",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Annual Expense 1 [Percent]"
       }
      }
     },
     "localname": "OtherAnnualExpense1Percent",
     "nsuri": "http://xbrl.sec.gov/cef/2022",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "percentItemType"
    },
    "cef_OtherAnnualExpense2Percent": {
     "auth_ref": [],
     "calculation": {
      "http://xbrl.sec.gov/cef/role/Item3Ae": {
       "order": 2.0,
       "parentTag": "cef_OtherAnnualExpensesPercent",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Annual Expense 2 [Percent]"
       }
      }
     },
     "localname": "OtherAnnualExpense2Percent",
     "nsuri": "http://xbrl.sec.gov/cef/2022",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "percentItemType"
    },
    "cef_OtherAnnualExpense3Percent": {
     "auth_ref": [],
     "calculation": {
      "http://xbrl.sec.gov/cef/role/Item3Ae": {
       "order": 3.0,
       "parentTag": "cef_OtherAnnualExpensesPercent",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Annual Expense 3 [Percent]"
       }
      }
     },
     "localname": "OtherAnnualExpense3Percent",
     "nsuri": "http://xbrl.sec.gov/cef/2022",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "percentItemType"
    },
    "cef_OtherAnnualExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Annual Expenses [Abstract]"
       }
      }
     },
     "localname": "OtherAnnualExpensesAbstract",
     "nsuri": "http://xbrl.sec.gov/cef/2022",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "stringItemType"
    },
    "cef_OtherAnnualExpensesPercent": {
     "auth_ref": [],
     "calculation": {
      "http://xbrl.sec.gov/cef/role/Item3Ae": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Annual Expenses [Percent]"
       }
      }
     },
     "localname": "OtherAnnualExpensesPercent",
     "nsuri": "http://xbrl.sec.gov/cef/2022",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "percentItemType"
    },
    "cef_OtherExpensesNoteTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Expenses, Note [Text Block]"
       }
      }
     },
     "localname": "OtherExpensesNoteTextBlock",
     "nsuri": "http://xbrl.sec.gov/cef/2022",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "textBlockItemType"
    },
    "cef_OtherFeederFundExpensesPercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Feeder Fund Expenses [Percent]"
       }
      }
     },
     "localname": "OtherFeederFundExpensesPercent",
     "nsuri": "http://xbrl.sec.gov/cef/2022",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "percentItemType"
    },
    "cef_OtherMasterFundExpensesPercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Master Fund Expenses [Percent]"
       }
      }
     },
     "localname": "OtherMasterFundExpensesPercent",
     "nsuri": "http://xbrl.sec.gov/cef/2022",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "percentItemType"
    },
    "cef_OtherSecuritiesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Securities [Table Text Block]"
       }
      }
     },
     "localname": "OtherSecuritiesTableTextBlock",
     "nsuri": "http://xbrl.sec.gov/cef/2022",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "textBlockItemType"
    },
    "cef_OtherSecurityDescriptionTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Security, Description [Text Block]"
       }
      }
     },
     "localname": "OtherSecurityDescriptionTextBlock",
     "nsuri": "http://xbrl.sec.gov/cef/2022",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "textBlockItemType"
    },
    "cef_OtherSecurityTitleTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Security, Title [Text Block]"
       }
      }
     },
     "localname": "OtherSecurityTitleTextBlock",
     "nsuri": "http://xbrl.sec.gov/cef/2022",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "textBlockItemType"
    },
    "cef_OtherTransactionExpense1Percent": {
     "auth_ref": [],
     "calculation": {
      "http://xbrl.sec.gov/cef/role/Item3Te": {
       "order": 1.0,
       "parentTag": "cef_OtherTransactionExpensesPercent",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Transaction Expense 1 [Percent]"
       }
      }
     },
     "localname": "OtherTransactionExpense1Percent",
     "nsuri": "http://xbrl.sec.gov/cef/2022",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "percentItemType"
    },
    "cef_OtherTransactionExpense2Percent": {
     "auth_ref": [],
     "calculation": {
      "http://xbrl.sec.gov/cef/role/Item3Te": {
       "order": 2.0,
       "parentTag": "cef_OtherTransactionExpensesPercent",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Transaction Expense 2 [Percent]"
       }
      }
     },
     "localname": "OtherTransactionExpense2Percent",
     "nsuri": "http://xbrl.sec.gov/cef/2022",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "percentItemType"
    },
    "cef_OtherTransactionExpense3Percent": {
     "auth_ref": [],
     "calculation": {
      "http://xbrl.sec.gov/cef/role/Item3Te": {
       "order": 3.0,
       "parentTag": "cef_OtherTransactionExpensesPercent",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Transaction Expense 3 [Percent]"
       }
      }
     },
     "localname": "OtherTransactionExpense3Percent",
     "nsuri": "http://xbrl.sec.gov/cef/2022",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "percentItemType"
    },
    "cef_OtherTransactionExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Transaction Expenses [Abstract]"
       }
      }
     },
     "localname": "OtherTransactionExpensesAbstract",
     "nsuri": "http://xbrl.sec.gov/cef/2022",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "stringItemType"
    },
    "cef_OtherTransactionExpensesPercent": {
     "auth_ref": [],
     "calculation": {
      "http://xbrl.sec.gov/cef/role/Item3Te": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Transaction Expenses [Percent]"
       }
      }
     },
     "localname": "OtherTransactionExpensesPercent",
     "nsuri": "http://xbrl.sec.gov/cef/2022",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "percentItemType"
    },
    "cef_OtherTransactionFeesBasisMaximum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Transaction Fees Basis, Maximum"
       }
      }
     },
     "localname": "OtherTransactionFeesBasisMaximum",
     "nsuri": "http://xbrl.sec.gov/cef/2022",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cef_OtherTransactionFeesBasisMaximumPercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Transaction Fees Basis, Maximum [Percent]"
       }
      }
     },
     "localname": "OtherTransactionFeesBasisMaximumPercent",
     "nsuri": "http://xbrl.sec.gov/cef/2022",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "percentItemType"
    },
    "cef_OtherTransactionFeesBasisNoteTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Transaction Fees Basis, Note [Text Block]"
       }
      }
     },
     "localname": "OtherTransactionFeesBasisNoteTextBlock",
     "nsuri": "http://xbrl.sec.gov/cef/2022",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "textBlockItemType"
    },
    "cef_OtherTransactionFeesNoteTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Transaction Fees, Note [Text Block]"
       }
      }
     },
     "localname": "OtherTransactionFeesNoteTextBlock",
     "nsuri": "http://xbrl.sec.gov/cef/2022",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "textBlockItemType"
    },
    "cef_OutstandingSecuritiesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Outstanding Securities [Table Text Block]"
       }
      }
     },
     "localname": "OutstandingSecuritiesTableTextBlock",
     "nsuri": "http://xbrl.sec.gov/cef/2022",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "textBlockItemType"
    },
    "cef_OutstandingSecurityAuthorizedShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Outstanding Security, Authorized [Shares]"
       }
      }
     },
     "localname": "OutstandingSecurityAuthorizedShares",
     "nsuri": "http://xbrl.sec.gov/cef/2022",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "sharesItemType"
    },
    "cef_OutstandingSecurityHeldShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Outstanding Security, Held [Shares]"
       }
      }
     },
     "localname": "OutstandingSecurityHeldShares",
     "nsuri": "http://xbrl.sec.gov/cef/2022",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "sharesItemType"
    },
    "cef_OutstandingSecurityNotHeldShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Outstanding Security, Not Held [Shares]"
       }
      }
     },
     "localname": "OutstandingSecurityNotHeldShares",
     "nsuri": "http://xbrl.sec.gov/cef/2022",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "sharesItemType"
    },
    "cef_OutstandingSecurityTitleTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Outstanding Security, Title [Text Block]"
       }
      }
     },
     "localname": "OutstandingSecurityTitleTextBlock",
     "nsuri": "http://xbrl.sec.gov/cef/2022",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "textBlockItemType"
    },
    "cef_PreferredStockRestrictionsArrearageTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred Stock Restrictions, Arrearage [Text Block]"
       }
      }
     },
     "localname": "PreferredStockRestrictionsArrearageTextBlock",
     "nsuri": "http://xbrl.sec.gov/cef/2022",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "textBlockItemType"
    },
    "cef_PreferredStockRestrictionsOtherTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred Stock Restrictions, Other [Text Block]"
       }
      }
     },
     "localname": "PreferredStockRestrictionsOtherTextBlock",
     "nsuri": "http://xbrl.sec.gov/cef/2022",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "textBlockItemType"
    },
    "cef_PrimaryShelfFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Primary Shelf [Flag]"
       }
      }
     },
     "localname": "PrimaryShelfFlag",
     "nsuri": "http://xbrl.sec.gov/cef/2022",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "booleanItemType"
    },
    "cef_PrimaryShelfQualifiedFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Primary Shelf Qualified [Flag]"
       }
      }
     },
     "localname": "PrimaryShelfQualifiedFlag",
     "nsuri": "http://xbrl.sec.gov/cef/2022",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "booleanItemType"
    },
    "cef_ProspectusLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Prospectus [Line Items]"
       }
      }
     },
     "localname": "ProspectusLineItems",
     "nsuri": "http://xbrl.sec.gov/cef/2022",
     "xbrltype": "stringItemType"
    },
    "cef_ProspectusTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Prospectus:"
       }
      }
     },
     "localname": "ProspectusTable",
     "nsuri": "http://xbrl.sec.gov/cef/2022",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "stringItemType"
    },
    "cef_PurposeOfFeeTableNoteTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Purpose of Fee Table , Note [Text Block]"
       }
      }
     },
     "localname": "PurposeOfFeeTableNoteTextBlock",
     "nsuri": "http://xbrl.sec.gov/cef/2022",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "textBlockItemType"
    },
    "cef_RegisteredClosedEndFundFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Registered Closed-End Fund [Flag]"
       }
      }
     },
     "localname": "RegisteredClosedEndFundFlag",
     "nsuri": "http://xbrl.sec.gov/cef/2022",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "booleanItemType"
    },
    "cef_ReturnAtMinusFivePercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Return at Minus Five [Percent]"
       }
      }
     },
     "localname": "ReturnAtMinusFivePercent",
     "nsuri": "http://xbrl.sec.gov/cef/2022",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "percentItemType"
    },
    "cef_ReturnAtMinusTenPercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Return at Minus Ten [Percent]"
       }
      }
     },
     "localname": "ReturnAtMinusTenPercent",
     "nsuri": "http://xbrl.sec.gov/cef/2022",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "percentItemType"
    },
    "cef_ReturnAtPlusFivePercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Return at Plus Five [Percent]"
       }
      }
     },
     "localname": "ReturnAtPlusFivePercent",
     "nsuri": "http://xbrl.sec.gov/cef/2022",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "percentItemType"
    },
    "cef_ReturnAtPlusTenPercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Return at Plus Ten [Percent]"
       }
      }
     },
     "localname": "ReturnAtPlusTenPercent",
     "nsuri": "http://xbrl.sec.gov/cef/2022",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "percentItemType"
    },
    "cef_ReturnAtZeroPercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Return at Zero [Percent]"
       }
      }
     },
     "localname": "ReturnAtZeroPercent",
     "nsuri": "http://xbrl.sec.gov/cef/2022",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "percentItemType"
    },
    "cef_RightsLimitedByOtherSecuritiesTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rights Limited by Other Securities [Text Block]"
       }
      }
     },
     "localname": "RightsLimitedByOtherSecuritiesTextBlock",
     "nsuri": "http://xbrl.sec.gov/cef/2022",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "textBlockItemType"
    },
    "cef_RightsSubjectToOtherThanMajorityVoteTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rights Subject to Other than Majority Vote [Text Block]"
       }
      }
     },
     "localname": "RightsSubjectToOtherThanMajorityVoteTextBlock",
     "nsuri": "http://xbrl.sec.gov/cef/2022",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "textBlockItemType"
    },
    "cef_RiskAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Risk [Axis]"
       }
      }
     },
     "localname": "RiskAxis",
     "nsuri": "http://xbrl.sec.gov/cef/2022",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "stringItemType"
    },
    "cef_RiskFactorsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Risk Factors [Table Text Block]"
       }
      }
     },
     "localname": "RiskFactorsTableTextBlock",
     "nsuri": "http://xbrl.sec.gov/cef/2022",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "textBlockItemType"
    },
    "cef_RiskTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Risk [Text Block]"
       }
      }
     },
     "localname": "RiskTextBlock",
     "nsuri": "http://xbrl.sec.gov/cef/2022",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "textBlockItemType"
    },
    "cef_SalesLoadPercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sales Load [Percent]"
       }
      }
     },
     "localname": "SalesLoadPercent",
     "nsuri": "http://xbrl.sec.gov/cef/2022",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "percentItemType"
    },
    "cef_SecurityAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security [Axis]"
       }
      }
     },
     "localname": "SecurityAxis",
     "nsuri": "http://xbrl.sec.gov/cef/2022",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "stringItemType"
    },
    "cef_SecurityDividendsTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Dividends [Text Block]"
       }
      }
     },
     "localname": "SecurityDividendsTextBlock",
     "nsuri": "http://xbrl.sec.gov/cef/2022",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "textBlockItemType"
    },
    "cef_SecurityLiabilitiesTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Liabilities [Text Block]"
       }
      }
     },
     "localname": "SecurityLiabilitiesTextBlock",
     "nsuri": "http://xbrl.sec.gov/cef/2022",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "textBlockItemType"
    },
    "cef_SecurityLiquidationRightsTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Liquidation Rights [Text Block]"
       }
      }
     },
     "localname": "SecurityLiquidationRightsTextBlock",
     "nsuri": "http://xbrl.sec.gov/cef/2022",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "textBlockItemType"
    },
    "cef_SecurityObligationsOfOwnershipTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Obligations of Ownership [Text Block]"
       }
      }
     },
     "localname": "SecurityObligationsOfOwnershipTextBlock",
     "nsuri": "http://xbrl.sec.gov/cef/2022",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "textBlockItemType"
    },
    "cef_SecurityPreemptiveAndOtherRightsTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Preemptive and Other Rights [Text Block]"
       }
      }
     },
     "localname": "SecurityPreemptiveAndOtherRightsTextBlock",
     "nsuri": "http://xbrl.sec.gov/cef/2022",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "textBlockItemType"
    },
    "cef_SecurityTitleTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Title [Text Block]"
       }
      }
     },
     "localname": "SecurityTitleTextBlock",
     "nsuri": "http://xbrl.sec.gov/cef/2022",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "textBlockItemType"
    },
    "cef_SecurityVotingRightsTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Voting Rights [Text Block]"
       }
      }
     },
     "localname": "SecurityVotingRightsTextBlock",
     "nsuri": "http://xbrl.sec.gov/cef/2022",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "textBlockItemType"
    },
    "cef_SeniorSecuritiesAmount": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Senior Securities Amount"
       }
      }
     },
     "localname": "SeniorSecuritiesAmount",
     "nsuri": "http://xbrl.sec.gov/cef/2022",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cef_SeniorSecuritiesAverageMarketValuePerUnit": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Senior Securities Average Market Value per Unit"
       }
      }
     },
     "localname": "SeniorSecuritiesAverageMarketValuePerUnit",
     "nsuri": "http://xbrl.sec.gov/cef/2022",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "perShareItemType"
    },
    "cef_SeniorSecuritiesAveragingMethodNoteTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Senior Securities Averaging Method, Note [Text Block]"
       }
      }
     },
     "localname": "SeniorSecuritiesAveragingMethodNoteTextBlock",
     "nsuri": "http://xbrl.sec.gov/cef/2022",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "textBlockItemType"
    },
    "cef_SeniorSecuritiesCoveragePerUnit": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Senior Securities Coverage per Unit"
       }
      }
     },
     "localname": "SeniorSecuritiesCoveragePerUnit",
     "nsuri": "http://xbrl.sec.gov/cef/2022",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "perShareItemType"
    },
    "cef_SeniorSecuritiesHeadingsNoteTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Senior Securities Headings, Note [Text Block]"
       }
      }
     },
     "localname": "SeniorSecuritiesHeadingsNoteTextBlock",
     "nsuri": "http://xbrl.sec.gov/cef/2022",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "textBlockItemType"
    },
    "cef_SeniorSecuritiesHighlightsAnnualizedNoteTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Senior Securities Highlights Annualized, Note [Text Block]"
       }
      }
     },
     "localname": "SeniorSecuritiesHighlightsAnnualizedNoteTextBlock",
     "nsuri": "http://xbrl.sec.gov/cef/2022",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "textBlockItemType"
    },
    "cef_SeniorSecuritiesHighlightsAuditedNoteTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Senior Securities Highlights Audited, Note [Text Block]"
       }
      }
     },
     "localname": "SeniorSecuritiesHighlightsAuditedNoteTextBlock",
     "nsuri": "http://xbrl.sec.gov/cef/2022",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "textBlockItemType"
    },
    "cef_SeniorSecuritiesInvoluntaryLiquidatingPreferencePerUnit": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Senior Securities Involuntary Liquidating Preference per Unit"
       }
      }
     },
     "localname": "SeniorSecuritiesInvoluntaryLiquidatingPreferencePerUnit",
     "nsuri": "http://xbrl.sec.gov/cef/2022",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "perShareItemType"
    },
    "cef_SeniorSecuritiesNoteTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Senior Securities, Note [Text Block]"
       }
      }
     },
     "localname": "SeniorSecuritiesNoteTextBlock",
     "nsuri": "http://xbrl.sec.gov/cef/2022",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "textBlockItemType"
    },
    "cef_SeniorSecuritiesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Senior Securities [Table Text Block]"
       }
      }
     },
     "localname": "SeniorSecuritiesTableTextBlock",
     "nsuri": "http://xbrl.sec.gov/cef/2022",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "textBlockItemType"
    },
    "cef_SharePriceTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share Price [Table Text Block]"
       }
      }
     },
     "localname": "SharePriceTableTextBlock",
     "nsuri": "http://xbrl.sec.gov/cef/2022",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "textBlockItemType"
    },
    "cef_SharePricesNotActualTransactionsTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share Prices Not Actual Transactions [Text Block]"
       }
      }
     },
     "localname": "SharePricesNotActualTransactionsTextBlock",
     "nsuri": "http://xbrl.sec.gov/cef/2022",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "textBlockItemType"
    },
    "cef_ShareholderTransactionExpensesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shareholder Transaction Expenses [Table Text Block]"
       }
      }
     },
     "localname": "ShareholderTransactionExpensesTableTextBlock",
     "nsuri": "http://xbrl.sec.gov/cef/2022",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "textBlockItemType"
    },
    "cef_TotalAnnualExpensesPercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Annual Expenses [Percent]"
       }
      }
     },
     "localname": "TotalAnnualExpensesPercent",
     "nsuri": "http://xbrl.sec.gov/cef/2022",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "percentItemType"
    },
    "cef_UnderwritersCompensationPercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Underwriters Compensation [Percent]"
       }
      }
     },
     "localname": "UnderwritersCompensationPercent",
     "nsuri": "http://xbrl.sec.gov/cef/2022",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "percentItemType"
    },
    "cef_WaiversAndReimbursementsOfFeesPercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Waivers and Reimbursements of Fees [Percent]"
       }
      }
     },
     "localname": "WaiversAndReimbursementsOfFeesPercent",
     "nsuri": "http://xbrl.sec.gov/cef/2022",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "percentItemType"
    },
    "cef_WarrantsOrRightsCalledAmount": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants or Rights, Called Amount"
       }
      }
     },
     "localname": "WarrantsOrRightsCalledAmount",
     "nsuri": "http://xbrl.sec.gov/cef/2022",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cef_WarrantsOrRightsCalledPeriodDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants or Rights, Called Period [Date]"
       }
      }
     },
     "localname": "WarrantsOrRightsCalledPeriodDate",
     "nsuri": "http://xbrl.sec.gov/cef/2022",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "dateItemType"
    },
    "cef_WarrantsOrRightsCalledTitleTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants or Rights, Called Title"
       }
      }
     },
     "localname": "WarrantsOrRightsCalledTitleTextBlock",
     "nsuri": "http://xbrl.sec.gov/cef/2022",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "textBlockItemType"
    },
    "cef_WarrantsOrRightsExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants or Rights, Exercise Price"
       }
      }
     },
     "localname": "WarrantsOrRightsExercisePrice",
     "nsuri": "http://xbrl.sec.gov/cef/2022",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "perShareItemType"
    },
    "dei_AdditionalSecurities462b": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional Securities. 462(b)"
       }
      }
     },
     "localname": "AdditionalSecurities462b",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_AdditionalSecurities462bFileNumber": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional Securities, 462(b), File Number"
       }
      }
     },
     "localname": "AdditionalSecurities462bFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_AdditionalSecuritiesEffective413b": {
     "auth_ref": [
      "r13"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional Securities Effective, 413(b)"
       }
      }
     },
     "localname": "AdditionalSecuritiesEffective413b",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_AddressTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "An entity may have several addresses for different purposes and this domain represents all such types.",
        "label": "Address Type [Domain]"
       }
      }
     },
     "localname": "AddressTypeDomain",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_AmendmentDescription": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of changes contained within amended document.",
        "label": "Amendment Description"
       }
      }
     },
     "localname": "AmendmentDescription",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_ApproximateDateOfCommencementOfProposedSaleToThePublic": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The approximate date of a commencement of a proposed sale of securities to the public. This element is disclosed in S-1, S-3, S-4, S-11, F-1, F-3 and F-10 filings.",
        "label": "Approximate Date of Commencement of Proposed Sale to Public"
       }
      }
     },
     "localname": "ApproximateDateOfCommencementOfProposedSaleToThePublic",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "dateOrAsapItemType"
    },
    "dei_BusinessContactMember": {
     "auth_ref": [
      "r2",
      "r3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business contact for the entity",
        "label": "Business Contact [Member]"
       }
      }
     },
     "localname": "BusinessContactMember",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_ContactPersonnelName": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of contact personnel",
        "label": "Contact Personnel Name"
       }
      }
     },
     "localname": "ContactPersonnelName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]",
        "verboseLabel": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_DelayedOrContinuousOffering": {
     "auth_ref": [
      "r4",
      "r5",
      "r9"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Delayed or Continuous Offering"
       }
      }
     },
     "localname": "DelayedOrContinuousOffering",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DividendOrInterestReinvestmentPlanOnly": {
     "auth_ref": [
      "r4",
      "r5",
      "r9"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Dividend or Interest Reinvestment Plan Only"
       }
      }
     },
     "localname": "DividendOrInterestReinvestmentPlanOnly",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentRegistrationStatement": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a registration statement.",
        "label": "Document Registration Statement"
       }
      }
     },
     "localname": "DocumentRegistrationStatement",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EffectiveAfter60Days486a": {
     "auth_ref": [
      "r18"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective after 60 Days, 486(a)"
       }
      }
     },
     "localname": "EffectiveAfter60Days486a",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EffectiveOnDate486a": {
     "auth_ref": [
      "r18"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective on Date, 486(a)"
       }
      }
     },
     "localname": "EffectiveOnDate486a",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_EffectiveOnDate486b": {
     "auth_ref": [
      "r19"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective on Date, 486(b)"
       }
      }
     },
     "localname": "EffectiveOnDate486b",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_EffectiveOnSetDate486a": {
     "auth_ref": [
      "r18"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective on Set Date, 486(a)"
       }
      }
     },
     "localname": "EffectiveOnSetDate486a",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EffectiveOnSetDate486b": {
     "auth_ref": [
      "r19"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective on Set Date, 486(b)"
       }
      }
     },
     "localname": "EffectiveOnSetDate486b",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EffectiveUponFiling462e": {
     "auth_ref": [
      "r17"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Upon Filing, 462(e)"
       }
      }
     },
     "localname": "EffectiveUponFiling462e",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EffectiveUponFiling486b": {
     "auth_ref": [
      "r19"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective upon Filing, 486(b)"
       }
      }
     },
     "localname": "EffectiveUponFiling486b",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EffectiveWhenDeclaredSection8c": {
     "auth_ref": [
      "r21"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective when Declared, Section 8(c)"
       }
      }
     },
     "localname": "EffectiveWhenDeclaredSection8c",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine2": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 2 such as Street or Suite number",
        "label": "Entity Address, Address Line Two"
       }
      }
     },
     "localname": "EntityAddressAddressLine2",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine3": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 3 such as an Office Park",
        "label": "Entity Address, Address Line Three"
       }
      }
     },
     "localname": "EntityAddressAddressLine3",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityAddressesAddressTypeAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the domain members or categories in the table and the line items or concepts that complete the table.",
        "label": "Entity Addresses, Address Type [Axis]"
       }
      }
     },
     "localname": "EntityAddressesAddressTypeAxis",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityExTransitionPeriod": {
     "auth_ref": [
      "r20"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.",
        "label": "Entity Ex Transition Period"
       }
      }
     },
     "localname": "EntityExTransitionPeriod",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Securities Act File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityInvCompanyType": {
     "auth_ref": [
      "r11"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "One of: N-1A (Mutual Fund), N-1 (Open-End Separate Account with No Variable Annuities), N-2 (Closed-End Investment Company), N-3 (Separate Account Registered as Open-End Management Investment Company), N-4 (Variable Annuity UIT Separate Account), N-5 (Small Business Investment Company), N-6 (Variable Life UIT Separate Account), S-1 or S-3 (Face Amount Certificate Company), S-6 (UIT, Non-Insurance Product).",
        "label": "Entity Inv Company Type"
       }
      }
     },
     "localname": "EntityInvCompanyType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "invCompanyType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "auth_ref": [
      "r12"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.",
        "label": "Entity Well-known Seasoned Issuer"
       }
      }
     },
     "localname": "EntityWellKnownSeasonedIssuer",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_ExhibitsOnly462d": {
     "auth_ref": [
      "r16"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exhibits Only, 462(d)"
       }
      }
     },
     "localname": "ExhibitsOnly462d",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_ExhibitsOnly462dFileNumber": {
     "auth_ref": [
      "r16"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exhibits Only, 462(d), File Number"
       }
      }
     },
     "localname": "ExhibitsOnly462dFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_InvestmentCompanyActFileNumber": {
     "auth_ref": [
      "r5",
      "r6",
      "r7",
      "r8"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment Company Act File Number"
       }
      }
     },
     "localname": "InvestmentCompanyActFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_InvestmentCompanyActRegistration": {
     "auth_ref": [
      "r10"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment Company Act Registration"
       }
      }
     },
     "localname": "InvestmentCompanyActRegistration",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_InvestmentCompanyRegistrationAmendment": {
     "auth_ref": [
      "r10"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment Company Registration Amendment"
       }
      }
     },
     "localname": "InvestmentCompanyRegistrationAmendment",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_InvestmentCompanyRegistrationAmendmentNumber": {
     "auth_ref": [
      "r10"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment Company Registration Amendment Number"
       }
      }
     },
     "localname": "InvestmentCompanyRegistrationAmendmentNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "sequenceNumberItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_NewEffectiveDateForPreviousFiling": {
     "auth_ref": [
      "r5",
      "r6",
      "r7",
      "r8"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "New Effective Date for Previous Filing"
       }
      }
     },
     "localname": "NewEffectiveDateForPreviousFiling",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_NoSubstantiveChanges462c": {
     "auth_ref": [
      "r15"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "No Substantive Changes, 462(c)"
       }
      }
     },
     "localname": "NoSubstantiveChanges462c",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_NoSubstantiveChanges462cFileNumber": {
     "auth_ref": [
      "r15"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "No Substantive Changes, 462(c), File Number"
       }
      }
     },
     "localname": "NoSubstantiveChanges462cFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_PostEffectiveAmendment": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Post-Effective Amendment"
       }
      }
     },
     "localname": "PostEffectiveAmendment",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_PostEffectiveAmendmentNumber": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amendment number to registration statement under the Securities Act of 1933 after the registration becomes effective.",
        "label": "Post-Effective Amendment Number"
       }
      }
     },
     "localname": "PostEffectiveAmendmentNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "sequenceNumberItemType"
    },
    "dei_PreEffectiveAmendment": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-Effective Amendment"
       }
      }
     },
     "localname": "PreEffectiveAmendment",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_PreEffectiveAmendmentNumber": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amendment number to registration statement under the Securities Act of 1933 before the registration becomes effective.",
        "label": "Pre-Effective Amendment Number"
       }
      }
     },
     "localname": "PreEffectiveAmendmentNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "xbrltype": "sequenceNumberItemType"
    }
   },
   "unitCount": 0
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r1": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r10": {
   "Name": "Investment Company Act",
   "Number": "270",
   "Publisher": "SEC",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r11": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "313",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r12": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "405",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r13": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "413",
   "Subsection": "b",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r14": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "462",
   "Subsection": "b",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r15": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "462",
   "Subsection": "c",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r16": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "462",
   "Subsection": "d",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r17": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "462",
   "Subsection": "e",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r18": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "486",
   "Subsection": "a",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r19": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "486",
   "Subsection": "b",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r2": {
   "Name": "Form 20-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "220",
   "Subsection": "f",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r20": {
   "Name": "Securities Act",
   "Number": "7A",
   "Publisher": "SEC",
   "Section": "B",
   "Subsection": "2",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r21": {
   "Name": "Securities Act",
   "Publisher": "SEC",
   "Section": "8",
   "Subsection": "c",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r3": {
   "Name": "Form 40-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "240",
   "Subsection": "f",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r4": {
   "Name": "Form F-3",
   "Publisher": "SEC",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r5": {
   "Name": "Form N-2",
   "Publisher": "SEC",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r6": {
   "Name": "Form N-3",
   "Publisher": "SEC",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r7": {
   "Name": "Form N-4",
   "Publisher": "SEC",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r8": {
   "Name": "Form N-6",
   "Publisher": "SEC",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r9": {
   "Name": "Form S-3",
   "Publisher": "SEC",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  }
 },
 "version": "2.2"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>23
<FILENAME>0001104659-23-043909-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001104659-23-043909-xbrl.zip
M4$L#!!0    ( %9ABU9<38+@B@(  # )   9    8VLP,# Q-C,U.3<W+3(P
M,C,P-#$Q+GAS9+55WV_:,!!^[U_AY=UQ FL[$%!I:SM58IW4=1)ODW$N8.'8
M66P*W5\_V\0EM(2"M+W=^;[O?MAWY\'5NA#H"2K-E1Q&:9Q$""13&9>S8;0T
M.?X478W.!IK-H:#(@J7NLT62).E%][QW>3F,YL:4?4)6JU5L8"$HHV7,5$$Z
M2:>;?$S3:,/: :ZZL:IF%I*D9/)M_,-[KX%]P>5B![V>5B+@N\29IU1#@#MK
M9EX(3? YV1A?H.* W\G8.FXZY0? 7&I#)=LF\2;INL2TU^L1;PU0"3-J(&MU
MWB.5$D!J6&!5D+<R+HBU!F &907LG0BT8CY(3IG!L"X%E=2HZOG6ZB^.3(7-
M<PEZOQ]K)L[LWCG!28H[Z38%OOL<&E@\4T_$&AR\$X"L4=0.T!IJH*'5#,P]
M+4"7E,$Q[08""I#F5E7%->1T*6QS_%Y2P7-N[W-TAM#@ \;H[O[QYNO=!$V?
MT<T?//G\,$88>RLO2E49)/<&;>N#S82,E;UZ/TJM%*?AP,/N"*<=W$WCM<XB
M<FH"VVDX+8' .S&!_=-U9.A <#'/CX[VMGGVA=-M<"=@)YP<<-N$1P4,<"<<
M'?#]D6J+_1[3Z[J1 Y52&>_$J>Z@++G,U4:SNFN)OEL+CY:)G/#SX:Y]X/P"
M^:+LWQ$A;I?-1@S>@K\,<BZYC^H^#831M6)+-Y]6])0!>0U\Y6*I(?LN1UZV
MNTU;KB_#[>N:7$,.$+?N3Z(Q*MA2' Y7'X:;V[W/,&</D"/_#?3=NPPC;5M"
MN._#G\W]>F_^JSCLLU^VY-BNRP!U80X,MW^5U[=4)Q!<U-O_\'=EG:@2*L-!
M;Y<,^=?%"3H]M3A+ ?$_JAJ0QD18I3$O [(9P]%?4$L#!!0    ( %9ABU9A
MWZED^ $  $D(   =    8VLP,# Q-C,U.3<W+3(P,C,P-#$Q7VQA8BYX;6R]
MEE%OVC 4A=_[*SSWV3$!:5H04+45FI"R:H)60IHFY#@7B&IL9+LEW:^?;1I*
M!JPJF_+F).><^]TKRT[OJEP)] S:%$KV<1RU, +)55[(11\_V3GY@J\&%SU1
MR,>,&4!.+DT?+ZU==RG=;#91F6D1*;V@[5:K0RLAWBJ[I2EJZDVGTL9T^BV=
M\"6L&"FDL4SR-Y>/.>:+DR2AX:N3FJ)K@C]5G-G0P+M<Z*3"/Y%*1OPK$K=)
M)XY*D^/!!4*]3X2@T=W]\.MHBK(7-/Q%IC?C%!$2OFHE8 QS%.BZ]F4-?6R*
MU5KXKL*[I8;Y<42A-?5^*F'!+.2^?.++QY]]^<O7URG+0&#DE0_CT<ENDUK6
MUD2;8OP.NE#Y4)X'^X>[8>J)9=K^ _>>OS'R>V69.(MYS]D8[1V<-]^=K[FY
MNC,1SIOKF_._TMI#T@\/LS9%X=>IJU\C@]*"S"&OV+SS+P=K" X'LL_TJ8K7
M\H0_G)4^;-6XO)!E@$<+]4QS*%QFN^T7Q"]"E^YA=JO<%76=&:L9MU52P _Y
MLP/-+-[V6'59(])@U)/F\)$.77:F=ANB#L"R(P"M<)<YC;](09*'"1X$!?I1
M:7[V:(C8![W6]>DQS:MR;OD.Z:N"<N7NTK4E8I]VKM7J]+2JHNIT/]M-0W>[
MQOT6[*[5P6]02P,$%     @ 5F&+5M7\C'!C 0  O0,  !T   !C:S P,#$V
M,S4Y-S<M,C R,S T,3%?<')E+GAM;+533V^",!2_^RDZ=BX%O$P#FBTQBPEZ
MP"WQ9@ ?VEA:0JO@/OUH'3HRC=F276C[^OOW'JD_KG.&#E!**GA@N;9C(>"I
M6%.^":R]RO"3-1[U?$;Y;J@_22P!-1PN VNK5#$DI*HJNTY*9HMR0SS'Z9,6
M:)V0AO@+>"UI!UWU6ZQ+EK-PD6XACS'E4L4\O;!^N'SQW,%@0,QM Y5T* T_
M%&FL3--W<Z&;"'W"+0SK$G8]W'?M6JZM40\A_P%C-)V_35ZG2Y0<T>0#+U^B
M$&%L;LU82\$@@@SI]3V:G@,9*PFIO1$'DD)&-(#,O:8+PU/' @)+TKQ@T-:V
M)60G 7E-P7,\3V^PWNB0CXT<N40I2I# E1E,V!0Z3E KX&M8MUXZSOVP6ES+
MB[0CQO3X1?GGW,UA]<S8 M)]214%.8,\@;,>BQ-@QF5U [ER3HW_7[:(RMW=
M6-] ;2*?7/T7S2LDG6<X^@102P,$%     @ 5F&+5D?P(5<  P  = P  !(
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M?=]?^F[O^[O5ZZN_Q[V^-RI $X'_-P%02P,$%     @ 5F&+5D[3+(E5 @
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M7=__S?]\?]?WN/\,E_]5?X][??]7_?FZUW>K1_6/ZJ>C_OC_-P%02P,$%
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MZZVW?__MO=;Y?6?OL[_]G2,:%4T"_F%M864!D-@# /B+/X!H!2![/=KO;BQ
M B % /S3Q0+(7/&'W@D ^/\E]DB(Q@%_ "3^_[;G?TSR;_M7[)]AB7^/_#]-
M]!= ]@! $X"3E) %[)&5D)25$+5+%(D![MLC*0'XV_8?V+=7ZJ#DH3T2@,-B
M][[O?_X[* Y)[M]S0.(@X-#A?P#V2$A*24A*?L>R9]_!:(D]DE*R>W_8=VK_
ML=.  P;'KQBJR1VTORKO>^:\@L/]AXIW7JA?>U>SJG$AXM")MF\7-:<<C1ZM
M919==XJ\86%LZ7?6V<7U9.VGP>EU_\=167\$%-=]'IK1NA2X$:UM8OJKE;6;
MNT=0<$@H+.9!;-R3Q*2GSY)?9N?DOLI[_;ZD%%U67E&/;6AL:L:U=W02N[J_
MD,C#(Z-CE-FY^87%I>7-K6T.E[<C^QWR'BDIR;U24E+[]NV%B"'+2IWZ8:_!
M/L#I8U?L]QOZ'K]_X.I#M1=R#N_NR)\_6'.F[=NUB%6%J4<7U#,=%?VNKQ75
M:EP\X61TPU_S4.3C+(NH[WB= Z)=C/]X\D_ &UHG7[ZO;R?-;F:78#O(<UMG
M+5T#+\$2<TH;.H?GMX-BDG+1C<21!<ZO;L$/GKXJ:^H:7>2:6+F'Q#[+*V_N
M'EOB:9M:>X3&);^NP'VA+.^(* !I<7GVR$K* LP!]!DZCN/#8>%'\'Q,-#N!
M08/_FR/J#Z9>[YBR_G#^P_'=O,)B"CZ&W*(?"9/9H3;O"RCZBZE;F%@UP/H1
M:_'[X.4HQ8J#_MIO6Y8&W]9(BA=Q4O^S5@3XR=B\WVZN9MT/:XR.BB;<18S1
M5$_%2(L LI4QK?/HY;1$KM8(^%CCMN/>87A6=8B4DB>0EM>Z0-T-:6E,F/IR
M31ZLW+3L>?BZHU*:K!T+/]RALCN"XQ"B67@V#8Z!<WP6+S,3J,NL9,9N'X4V
M, HTKXP;"9R9_1*>NM'*V6<<QGRC_L,_BJQ7&CR*7F>::&;G7/*3#B@(<IMQ
M@3F#&+3]!$60BR">ET_:5)Y;2Z^]CZ\A\6X.QT#]&DO5Y)IJ+BVOM%*J+ZW,
MZ>HH%1Y]W-5;+_?E3HB+Y&%<1MJPD?CWG_@<'\;$_P+UMR/9LI?P!JPDW!.=
M>+@IP8Y].;%KU#,EX8XI6_EE!].V[V-%/USK*54II[04 1KLF#=<G=S>'J3$
M>K4Z-'[R+>J<06</E#CC1W 753ON(S=JB2) !X&+$4BC18 4L&"%T(_L( BA
M2)0(H"JNG@-]XR2:E[N6[@_5S]H]M8'^LQ*H!D<\XM8,F2FOY?Z)(\RP'*?)
MZL:Q"-3RK;=980M&PJ-E(2 +MG2.?CCT3:=#L=IS^B@5>SUJ>^]OI6D7Q!O<
M0;CRU''\4+,^\BY[Q'P1.&?N_.#.BK!:J'$>&'1_4KNB(KAA!+:9LQB0SN<-
M*C_;CC [XI.-^32K5OXYH C=_>UF*@O_C?"O0Z4"&QZ=X ]5<3I)#!]BV;+,
M7P/,CP7G@V"I>J/M4/=ME:ERM'\'*XIBPO/]% Z><O;PO^!\ZT\G@'W7/J$X
MK2Z3O_4-3J[6C^>JI_:R3!&W3(^TO?KLNVRTK7H.E9RFN-ZLX[*G[GS3\NH#
MRO)6IMO9N:Z1;MMC51![$\=S<$P44URCBAAA&%F7RH,^+NS!9<LWJF[DSLEH
MWV*U7_;7L)LV[GASF7 *SE'<6AUV)-^9FC@!P6)AV.O))0'OJ9&.B>Z!3_PY
M/DN6M9KE;/T%71KP@V)QQ9BY).C','8ZB1R>2**M;1R-80IW5MX@0+^* !%U
M^P?S[48B%9X_/ Y\]K(NS[J#A2?7BD_.,MJ4/TOL ^?Q"8V1A3(E7"R)+K<S
M@VTDVJU ,W87:EML"!S-!%9!18YW+L7=.V4('T.AJQAXQE3#")'3M?RX]'MD
MJ/98)+*M0EMKK=)ZD^PHSK&Q"*!7F,W'S+%OA$,8^,5MVUL,A@^3^>'A %M8
M5DQ]::9%-?E00 73WHP$1V%![ \]K$MQ'(-7ULEG$BL(9TAYE^,AAL/#EH><
M>L2U^Y/9/\)@/5N>:&<5C%+KX< J'#J =:N-WE+::EJ^= ]H%W(GM"Z6FC7X
M]8ISQH=,E*K%O&E<<&!Y6=;-VYWKIN_$&RUO-42$8G@SN&WCC>.\/JQAGANC
MXC1=]4"K,KNYS'#7?2VE2ONJ<S0FG&W[^ZFROUB%N2C.X=-!M2>>HURMZEQ:
M47(I'A[/$5@'\?[NF>8N:+0QD2B"KO"P _/C\-':!$VF2@H]]C(3DJ!7O)]@
MU/@ XAZS5S>0_C[QUW721<^K./7B+LL+MK+\BA"UEWD>9\5-90PD1/L968SU
MLGK[]&:K.R;+*+B&W. P&GT4^/J!_;=#O@T^;6TL[YFFRH/W0Q'Q>YVO'<[X
M8X\ECG/]:#WA=7H'ZWW%YZ\L7?2&@F9&3]6@$3 , > UYW5-O7T6HJQ)O;3V
M-6KK54!E6K6'5)Y4G7;=Z8SWXJ(O:F&$$?%ZFQ=,S')710!>.2SM_*GTBLK'
MZG^* #FN/>C.W5T5.\V4PCT12ICJAI)C<VJ%2C$/9N,4_^C*=#I3?OF>F*S=
M=^T$]-9 P1->]UA^X]H"#X+\N8#(1=68+IQ?.UF)KLN(@GJ!-.?W>VVK+%'-
M"C\:DRV66$84)<US]9-91^H#?W=UZJH9\+YXL]S^BHPI,IK5H,GMH/(;";B[
MX3 ?P6(XB3OP<=WDR, 3*LV &L6]/M%BIX\U-O(,(_\:H12DE3>.2H$LW#KK
M_S//XV2>5JT;KDS3V_2+/HYS303X;RZL]A0!"LR<[2*VZ2$K/QJ!BB\GZ(L
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M>?#(R<DY6G_XM!_VY$B&Z-:#H= .D:@2C;)N *:_ZWD@=E.P3(H0R8_63SQ
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ME, *"!-2$4B4MSE(<,\#]P85BFO2)GQKZ@!D?""P%4X"-A+N!L9)2&L8X@Q
M]:@9*.CXL<6,XA(;72KT (H M@4J#Q?C:&<]'YL)X.I#5ES@*2H%X.*A..(/
M-\@4,<$OOP-39)([(0!1XKI/+\*?*(!);['!E8M9_%#@V51,)S\X0L)^'^@U
ML9EI@RYSZ,<+XC\I3(O<N0I]', 'PS\.8ZNL(3!U*E&$!5=X??EVS< -\1%I
M/@7XDN9 _YI](0D8B"+.^UQDE'0/M3"85M5/"<1M%']%K$%?PXA U9/X-8HK
MQ= \33(+P9R.+1M!J_H3="8Z41&:KLU R5^107A!AK8/L@I5 LGA6C*$$H[
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MGV[S@CS)Z?W*6A\Q<";[** KA4DVP@-[B##Z$]+?U<Z) =VM56H,&*4XZNW
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MJ3!]&7%5.[PNT7;'=><&P4+]5S_Y[\FXLNR(G][X<XYWBDY1?PU%:4[+N94
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MF.XO*O#BAFREYV%5TE;PI=7IF45KVFT)A"O9YY</8,R3 ?6MI(PW6-\;@$&
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M:7M,:PP4CKJVLA3T<HJGI6./&D,-! R*\?JE7J'2\W@TC:@D%5 6D;Q%^V1
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MHEN.YG[XRLHJI1OO%C?@&V#$,]D&'T@.='!V"2>#NGEUF&=?KU5^H9#M5-B
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ML2,.SF>E[-J-4X?<)E2R?6=_<^_ENW%JK*VQML;:Y3ZU[SY0_'UB[3($ NM
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MA:#&@W7G>]$(@3\+215(EHD+P6.1=$X@"?638C3$42HJ?RL$,?U@*AK1T!L
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M.< L,)L"#FL4W7((F9[AN)(+F@V:^[$2EPV4,' ";I"(%L%S0PG/I?'\;;U
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M1(%"%L+_32@*DL<R'A$#X?DKW[UXN?23"HQI#% BXL\$>V2&34*;<RHQ*@E
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MIP(C G[*QHPS)51*6/TA!SIP]9'B@N'?/YQ8"'$E(@>>W;,+ZD9=ML/#<M)
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M4(.?M>('FDO@LRYE^?;TX=!"ZV'\^-^#X@']&R;?\_X=):B*Z9MY=J,/?X(
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M;#!SXCJNQN$TA"L&RZIB-@+KGA[(2^UX\$VV#F+=$1^&,]>#$U5@7W6FCWM
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M27HJSRGEW=;T9Y#)(&M!]M+)0I!N%(.:98%12#)RK'9BP]+0O-^CS7 +[.M
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MQ&'#2HT_X3F,+:G^E5\3X>&_ %!+ P04    " !688M6F2_QITT2   Z$P
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MSS*D+NY(/UX3]%[VY,J]+OGZV#DAS'R$O;2XP7*'D/6A'9+26%%4HN! ,@G
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MG7S2U3!5.T@Z?,'5Z*O9#9,M\L!J2TN!@G%A"O"ONGCBOP!02P,$%     @
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M/F_H7#UQDY1"V@P%]KGWBZ@$#L5HSGVQ'6LDU'MVLZ/]BFB2^&J&OH'9OS,
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M/Z5\.2 ,H7=O:H>RA#'QQOH?^,EA.PE.>UR]SB03-NZ^NY4:T--R)'L=1W@
MQZFEM+?SF\7Q9+J[A[(0S;M1)6S8]1;']<S=U5[($+6=)^=YWXYK848$N:P2
MZTB^:/[\>DHO0Y&/ARS'^$-<_"2-\[E0A%D[\2_)"5RQ(#&+0%7@-/MC3SI=
MC31_2SAE9I]H-GY8.2HCZ08'D\,&]\L!R/)$(8Y330-/N0C6\]AJ:3H]$>ZT
M]_J]'VJ%V%+SNI75VJ]?!'7DF9CX;&A!5SG];!?'D3ZPE@4#XH"T =Y8_LFS
M#QWP0BJ/'7%H-G;#H:T\TR)5QC\=AE'("HNR5^3M%6QP)ZWD[>R\\.@\+Y6!
M&B[!K:6N)KH(25!<LY'B/G#^<=;@.RU^M]^']A*S3\RUSFJOB/8P-X?@RBE)
M7*7YW7:RX0A5R.K^_+YYS!JG"Y\V^$KP#Y@G!5]\J#O]W/^L=WPIZ!(D9I6\
M1RP;2'1RZ3<VXT#_X?$[$C<H$$3W?S8<E73(+.<^;VQM=J^OK)=VKGLW2:AP
M/M=5VAIEO?[CO>\WY("MQ FJ%-N1GI/!<%PI10=KE3;&E"&KN,.EV>SL19K:
M[.;#,2&/JU(*MIUN UV# M?U:-3\6L3&PYD:P)F&$8WASU!XZ7D0';MMA 9]
MZ611IM#XFOND/T=Z+AFM&MM^*GS;LT=J.^L*7 H.KQL_8YZ^F50-.\'E7I/<
M5(QK]NFM _&%-I5<%P'B)OV"\,7H<G#)GM,AOJMOREZ:C^Y0"35(F57AJ-Y$
MM\%=,I<&AM TX8 'NM=)SHG#&W(JZ3)%H145+!;51":=2+X[>V78K:WBJ]EE
M6EKDP7S PJP%N>V7XE=8X2XR9+^:7I>.,V1J"#),]7KI?8D)LL=_5>@ 6,CT
M]:!IGFW2FVL>?C"G[:63?KE181)=[B>1 ^["L7<T+V+;HAQX;BUS1/Q4),#>
M5=)NF1)IE-**+.Y&$G=+;Q ]N?@BF>M[CYVCY_F58R'8P/#=H[P@]_C:G5K,
MK\%'#%V/,_V#(L7F9'KHXM#SF:PI')^R]G)U9IM+/"71\='?^[>N9C\.D6B5
MBEJE%W&1_D4D(["I#Y-Y3WB;1RA*H#ZX,+'B*S,__OB]PM)-7UH^1__5=7'_
M$=;% S\OM7WXV2Z"CPY96-F&M!.BA^U"%\$*6.22-H!J?D.%8GNU^?/7XQP^
M/;_4NX]Z1[V@17-@QD,CP>VYY4UT(RV>!KG4LD4S<%F*TMIY(<53X(?EW@=L
M1%@,:?7(T=&%A&1;7$B.;HEA_JT2]HL_BKJ3-B4B6*>W2J8+91J3TD<-V0>)
M^R"3'$0&UG3TJ1SXZ%Q@J2@@CS?(5$W$7D1/"!T/#D\1BF4&4%DO68/W5&C?
M.YF@>."]4B>^X%#*=535Q(W7YE<FCET>W.T[]FW-(GZ2(E.M$[;+U*,X"Q-_
M$".%!$8Q_B 4>3=B4.C$?]1DJW.HK:,CHZS!(^4^<7C#6KVSEU1,T"4QM1FF
M$+R+J("S)(/"72"NI_"A!0./[%X_UW:*&#/2Y7,_(B+N_+?RV%3E]W_$ON.7
M#?[%[PC>PA//G4[J9X]/R52E0EAZLCDTUGT&AYQ'5.16"@725IH&S/0#SVCA
M*UT-9_R^7MC1;HE7P6VIF*GW]0+28\%)T7HY<$D<!)D(#:<\/S7DR=R)YF_7
MO$O'[ZB(W[,Q;(*GEC*H9O)R^S9$34CJYPGC%/LWY GK.7:-[CZD?.(_ %!+
M 0(4 Q0    ( %9ABU9<38+@B@(  # )   9              "  0    !C
M:S P,#$V,S4Y-S<M,C R,S T,3$N>'-D4$L! A0#%     @ 5F&+5F'?J63X
M 0  20@  !T              ( !P0(  &-K,# P,38S-3DW-RTR,#(S,#0Q
M,5]L86(N>&UL4$L! A0#%     @ 5F&+5M7\C'!C 0  O0,  !T
M     ( !] 0  &-K,# P,38S-3DW-RTR,#(S,#0Q,5]P<F4N>&UL4$L! A0#
M%     @ 5F&+5D?P(5<  P  = P  !(              ( !D@8  &HR,S,Y
M,34R7V%A,# Q+FIP9U!+ 0(4 Q0    ( %9ABU9.TRR)50(  #8%   2
M          "  <()  !J,C,S.3$U,E]A83 P,BYJ<&=02P$"% ,4    " !6
M88M6;XL@96,#  #>#   $@              @ %'#   :C(S,SDQ-3)?86$P
M,#0N:G!G4$L! A0#%     @ 5F&+5GU  Y2Z%P  JQ@  !(
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M-&%I;6<P-"YJ<&=02P$"% ,4    " !688M6F2_QITT2   Z$P  &@
M        @ %<XP  =&TR,S,Y,35D,5]D968Q-&%I;6<P-2YJ<&=02P$"% ,4
M    " !688M6M=#PS<,;  #I'   &@              @ 'A]0  =&TR,S,Y
J,35D,5]D968Q-&%I;6<P-BYJ<&=02P4&      P # !  P  W!$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
